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1.1 Prostate anatomy
The prostate is a small gland situated in the pelvic cavity and is part of the male repro-
ductive system. It is located between the pelvic bones, below the bladder and in front of
the rectum (Figure 1.1).1 In healthy males, the prostate is about the size of a chestnut and
somewhat conical in shape. Its body is partly glandular and partly muscular. The gland
is perforated by the urethra, originating in the bladder, and the two ejaculatory ducts,
originating at the seminal vesicles. The prostate plays a role in normal sexual functioning.
It secretes an alkaline fluid, which is added to the spermatozoa and the seminal vesicle
fluid, increasing the motility and lifespan of the sperm. Smooth muscles in the prostate
help expel semen during ejaculation.
The prostate can be divided into three different anatomical zones: the peripheral zone,
transition zone, and central zone (Figure 1.2).2 The central zone surrounds the ejaculatory
ducts at the base of the prostate and comprises 25% of glandular tissue in a healthy
prostate. Approximately 2.5% of prostate cancers originate in this zone.3 The transition
zone surrounds the proximal urethra and contains around 5% of the glandular tissue. As
individuals age, the transition zone grows substantially in size as the result of benign
prostatic hyperplasia (BPH). This is a benign enlargement of the prostate and pushes
the central gland away increasing pressure on the urethra. About 10− 20% of cancers
are found here. Lastly, the peripheral zone is located posterolateral and encompasses
the majority of prostatic glandular tissue (up to 70% of tissue in a healthy prostate).
Approximately 70− 80% of all prostate cancers arise in this zone. In addition to these
glandular zones, the prostate usually contains an area of fibromuscular stroma. This area
is usually devoid of glandular components and is composed of only muscle and fibrous
tissue.
Figure 1.1: Anatomical image of the male pelvis showing the position of the prostate, which is located
immediately under the bladder.
1
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Figure 1.2: The zonal anatomy of the prostate. In addition to the three anatomical zones (peripheral
zone, transition zone, and central zone) the prostate contains an area of fibromuscular stroma and a
periurethral gland region (area around the urethra). Image obtained from De Marzo et al. 4
1.2 Prostate cancer epidemiology
On a global level, prostate cancer is the most frequently diagnosed cancer in males, and
one of the leading causes of death from cancer.5–7 Almost 75% of prostate cancer cases
are diagnosed in developed countries.8 The main reasons for this are the higher average
age of the general population in developed countries compared to developing countries,
and secondly, the introduction of prostate specific antigen (PSA) blood tests in developed
countries (Section 1.3).
About one man in six is affected by the disease during his lifetime,7 and about 3%
will die of it.9–11 In the USA, the estimated number of newly diagnosed prostate cancers
is slightly over 230,000 cases and almost 30,000 men will die from it yearly (Figure 1.3).7,12
In the Netherlands, these yearly numbers are approximately 11,000 new cases, and about
2,500 deaths.13 The main reason for this high incidence-to-mortality ratio is that most of
the prostate cancers found are indolent, i.e. will not cause death. This is evidenced by
both the high 10-year survival rate (77%), as well as the incidence of prostate cancer on
autopsy in men who died of other causes.14
Prostate cancer has been known as a disease of elderly men. Autopsy studies have
revealed that about 30% of men at age 50 have prostate cancer, at age 80 this increases
to about 80%.10,11,15 However, only about 30% of the detected cancers are clinically
significant.10,11 Although most prostate cancers diagnosed at an early stage have an
indolent course, local tumor progression and aggressive metastatic disease may develop
in the long term.16
1.3 Prostate cancer diagnosis in current clinical practice
Prostate cancer is generally detected through a combination of PSA blood serum con-
centrations, digital rectum examinations (DREs), and systematic transrectal ultrasound
(TRUS) guided biopsies. PSA tests measure the concentration of PSA in the blood in
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Figure 1.3: Cancer statistics in the United States in 2014. New cancer cases and deaths are estimated
for the ten leading types of cancer, arranged by sex. Image obtained from Siegel et al. 7
nanograms per milliliter (ng/mL). PSA is a biomarker that can be useful for the early
detection of prostate cancer.17 It is a protease produced in the epithelial cells of the
prostate and normally secreted into the glands. In individuals with a healthy prostate, the
PSA level will be low as the PSA will be contained in the prostate gland. In individuals
with prostate cancer or other prostate disorders (e.g. BPH or prostatitis) the PSA level
can increase because of disruption of the glandular structure. The American Cancer
Society guideline for the early detection of prostate cancer recommends that patients with
a PSA level of ≥ 4.0 ng/mL should be referred for further examination.12 To increase
the sensitivity of the test, many other countries (including the Netherlands) lowered the
threshold to 3.0 ng/mL, taking an increase of benign cases into account. The PSA blood
test is also widely used in screening studies (discussed in Section 1.4), but remains a
source of controversy due to its limited specificity.11,12,18
In a DRE, the urologist will use a lubricated, gloved finger to inspect the surface of
the prostate. Healthy prostate tissue is soft and smooth, whereas prostate cancer tends
to feel as a firm, stony, and often asymmetrical lump. As only a small portion of the
prostate gland can be felt, DRE usually tends to miss the more ventrally located cancers.
Additionally, smaller tumors are difficult to detect by DRE. As such, DRE has a limited
sensitivity and specificity for the detection of prostate cancer.19,20
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Figure 1.4: TRUS guided prostate biopsy. The patient is in dorsal or lateral decubitus position. The TRUS
probe is inserted into the rectum to position the needle. Image obtained from Baumann et al. 29
After initial suspicion of prostate cancer has arisen due to either PSA or DRE, a TRUS
guided biopsy is usually performed to make a definite diagnosis. Biopsy specimens are
subsequently evaluated by a pathologist using the Gleason Scoring System. These topics
will be discussed in Sections 1.3.1 and 1.3.2, respectively.
1.3.1 Ultrasound guided biopsy
Transperineal biopsies under finger guidance were the most common means of detecting
prostate cancer until the introduction of transrectal/transperineal biopsies under tran-
srectal ultrasound guidance. Transrectal ultrasound was already introduced in 1968 as
a diagnostic device for prostate cancer.21,22 However, it was not until the early 1980s
when the first TRUS guided biopsies were explored (Figure 1.4). At that time, hypoechoic
nodules were seen as the main representation of prostate cancer, and therefore biopsies
were merely targeted to these nodules.23,24 However, most of these nodules proved to be
benign. With the introduction of the PSA test as indication for prostate biopsy, the need for
‘random’ sampling arose. In 1989, Hodge et al. 25 introduced the systematic sextant biopsy
method. As originally described, six biopsies were obtained in the parasagittal plane
halfway between the lateral border and midline bilaterally, from the base, mid-gland, and
apex (Figure 1.5(a)). The prostate cancer detection rate increased, but still there was a
high false-negative rate.24,26 As it became clear that most cancers originated in the periph-
eral zone, Stamey 27 suggested a ‘modified protocol’ in which the middle biopsies were
moved more laterally to better sample the anterior horns of the peripheral zone (Figure
1.5(b)). Even the modified sextant biopsy scheme showed sampling errors, especially in
enlarged glands, leading to various alternatives being explored.24,26 Extended biopsy
schemes with eight, ten, or twelve cores were reported, which are currently still in use
(Figures 1.5(c)–(e)). No differences were shown between the transrectal and transperineal
approach in terms of cancer detection on initial 12-core prostate biopsy.28
1.3 Prostate cancer diagnosis in current clinical practice 7
(a) (b)
(c) (d) (e)
Figure 1.5: Schematic diagram of the various sampling patterns used. (a) The original sextant biopsy
scheme as described by Hodge et al. 25 The coronal section shows six biopsies obtained in the
parasagittal line (Y-Y), halfway between the lateral border and midline (X-X) on both right and left
sides, from base, mid-gland, and apex. Images (A)-(C) demonstrate the needle trajectory in the axial
plane at points A-C marked on the coronal view. (b) Coronal and axial view illustrating the modified
sextant biopsy protocol. A larger amount of the peripheral is sampled by pointing the needle in an
anterolateral direction. (c)–(e) Coronal representations showing extended 8-, 10-, and 12-core biopsy
schemes, respectively. Image obtained from Raja et al. 24
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Repeat and saturation biopsies
Even with the extended biopsy schemes, the initial biopsy may still be falsely negative.30
Clinical suspicion can persist with e.g. increasing PSA levels. No matter what parameter is
used to determine the need for a repeat biopsy, it is important to first address the adequacy
of the initial biopsy. Number and direction of previous cores should be considered, as
well as the prostate volume. Repeat biopsies should include areas where cancer may have
been missed.24,26,28
To minimise sampling error, more aggressive biopsy approaches have been applied.
These so called ‘saturation’ biopsies involve≥ 20 biopsy cores, evenly distributed through-
out the gland via the transrectal or transperineal route. Using saturation biopsy, Stewart
et al. 31 detected cancer in 77 of 224 patients (34%) after previous negative biopsies.
New ultrasound techniques
Localization of malignant tissue on gray-scale ultrasound remains difficult and system-
atic TRUS guided biopsies are still routinely used in clinical practice. However, new
ultrasound techniques are being explored that might help a targeted approach under
ultrasound guidance. Color Doppler and power Doppler are looking for increased vascu-
larity, which is a sign for prostate cancer. Targeted biopsy studies have been performed
and reported a wide range of sensitivity.23
A second technique is contrast-enhanced TRUS (CEUS), where a microbubble contrast
agent is administered intravascular. Sano et al. 32 reported that targeted biopsy using
CEUS significantly enhanced cancer detection compared to systematic biopsy.
Lastly, elastography is a technique that measures tissue stiffness to distinguish hard
(malignant) from soft (benign) tissue. Sensitivity and specificity have shown to increase
when compared to systematic biopsy.33
Post-prostate biopsy morbidity
Potential biopsy-related complications, including pain, infection, and bleeding, have
implications on patient care. Rosario et al. 34 measured the effect adverse events within 35
days of 10-core TRUS guided biopsies in 1147 men. Pain was reported by 43.6% of men,
fever by 17.5%, and 65.8% reported on haematuria. Anaesthesia can be used for pain
control, which is especially necessary for transperineal biopsies. To minimize infection
rates of transrectal biopsies, patients will commonly receive some antibiotics.24,28
1.3.2 Gleason grading of prostate cancer
The Gleason Scoring System is named after Donald F. Gleason, who developed it with
other colleagues at the Minneapolis Veterans Affairs Hospital during the 1960s.35 This
unique grading system for prostate carcinoma was based solely on the architectural pat-
tern of the tumor. The system was updated in 2005 by International Society of Urological
Pathology (ISUP) consensus conference.36 Gleason grades range from 1− 5, where 5 is
considered the most aggressive pattern (shown in Figure 1.6). The descriptions of the
different patterns are:
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Figure 1.6: Schematic representation of the different Gleason grades assigned to histologic patterns of
prostatic adenocarcinoma. Image obtained from Humphrey 37
1. Very well differentiated, small, closely packed, uniform, glands in essentially cir-
cumscribed masses.
2. Similar (to pattern 1) but with moderate variation in size and shape of glands
and more atypia in the individual cells; cribriform pattern may be present, still
essentially circumscribed, but more loosely arranged.
3. Similar to pattern 2 but marked irregularity in size and shape of glands, with tiny
glands or individual cells invading stroma away from circumscribed masses, or
solid cords and masses with easily identifiable glandular differentiation within most
of them. May be papillary or cribriform, which vary in size and may be quite large,
but the essential feature is the smooth and usually rounded edge around all the
circumscribed masses of tumor.
4. Large clear cells growing in a diffuse pattern resembling hypernephroma; may
show gland formation. Raggedly infiltrating, fused-glandular tumor; glands are
not single and separate, but coalesce and branch.
5. Very poorly differentiated tumors; usually solid masses or diffuse growth with little
or no differentiation into glands. Can resemble comedocarcinoma of the breast;
almost absent gland pattern with few tiny glands or signet cells.
A Gleason score is assigned by the pathologist by summing two numbers; the first
number indicates the grade of the most common tumor pattern in the specimen, the
1
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second number indicates the second most common pattern. If only one pattern is present
in the tissue sample, the corresponding grade is multiplied by two to give the score.
There is a difference in determining the Gleason score from a biopsy sample and radical
prostatectomy specimens. A biopsy sample represents only a small part of tumor. If there
are more than two patterns present in the biopsy specimen, the second number should
refer to the remaining pattern with the highest grade. In a prostatectomy sample, the
pathologist bases the primary and secondary Gleason grades on their prevalence. When
a third pattern contains at least 5% of the total tumor volume, a tertiary grade can be
included in the Gleason score.
The attending physician will use the biopsy Gleason score and other clinical parame-
ters (i.e. PSA level, number of positive biopsy cores) to make a treatment decision.
1.3.3 Treatment options
When diagnosed with prostate cancer, there are several treatments possible. The most
common choices are: active surveillance, radical prostatectomy, radiotherapy, and focal
therapy.
Active surveillance can be provided to men with a low grade, localized, well-differ-
entiated prostate tumor. It involves conservative monitoring of the tumor by repeated
PSA measurements, DREs, TRUS guided biopsies, or even MR imaging (see also Section
1.6). Patients will not be treated immediately, though the urologist can intervene when
the cancer progresses. Several studies have shown that in men with untreated, low-risk
prostate cancer the 10- to 20-year survival rates are similar to an age-matched group
of men without prostate cancer,38–40 showing potential for active surveillance. Initial
results on active surveillance show that mortality rates are low, with moderate rates of
intervention over the first few years.41,42
Radical prostatectomy and radiotherapy are ‘whole gland’ treatment options with
intention to cure. Radical prostatectomy involves the complete surgical removal of the
cancerous prostate. Radiotherapy can either be external beam radiotherapy or internal
brachytherapy. In external beam radiation therapy, the patient receives radiation from an
external source. Internal brachytherapy involves the implantation of radioactive seeds
into the prostate. Cancer recurrence and survival rates are relatively similar. However,
side-effects like urinary leakage and erectile dysfunction are reported and may play a role
in the patients’ decision of treatment.43–46
Recently, minimal invasive focal therapies have been under investigation. Several
options are available: laser interstitial thermotherapy (LITT), cryo-ablation, and high-
intensity focused ultrasound (HIFU). Although initial results are promising, especially for
localized, low-grade prostate cancer, they are currently not yet widely available clinically.
1.4 Prostate cancer screening
The growth and aging of the population are causing an increase in the number of prostate
cancer diagnoses and an increase in men who will require treatment for their malignancy.
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Screening can help find cancer at an early stage when the disease is easily manageable.
However, caution is required for potential overtreatment.
Possible methods used in prostate cancer screening are DRE and PSA blood testing,
usually combined with subsequent TRUS guided biopsy. DRE or PSA testing is essentially
used as a triage test for the more invasive TRUS guided biopsies. PSA testing requires a
predetermined cut-off value, which limits the sensitivity of the screening program. The
PSA cut-off level is a source of discussion.47–49 Lowering the cut-off value will increase
the sensitivity, but reduce the specificity.50
Screening trials in Europe and the USA include respectively the European Random-
ized Study of Screening for Prostate Cancer (ERSPC) and the Prostate, Lung, Colorectal,
and Ovarian (PLCO) Cancer Screening Trial.51–53 Results show that screening helps to
diagnose prostate cancer at an earlier stage and was associated with an increase in in-
cidence.54 The ERSPC trial showed a mortality reduction of 20%,52 and when adjusted
for nonattendance and contamination this reduction increased to approximately 30%.55
However, official statistics tended to overreport prostate cancer as an underlying cause of
death, which would overestimate the true effect in favor of screening.56 Another side-
effect is that screening would cause a large amount of over-diagnosis and over-treatment.
To save one life, 1055 men had to be screened and 37 men had to be treated for prostate
cancer.53
So there is certainly potential for prostate cancer screening, but currently controversy
regarding the effectiveness still exists.54 An alternative technique with higher specificity
for prostate cancer might make screening more feasible. Alternatives are being explored
(e.g. prostate MRI, Section 1.6).
1.5 Drawbacks of current practice
A PSA test followed by systematic (on average 12 core) TRUS guided biopsy is the
currently internationally accepted diagnostic procedure to detect prostate carcinoma
and determine patient management.28 However, this diagnostic procedure is subject to
false-positive as well as false-negative results. First of all, the PSA blood test is often
false-positively elevated due to the fact that elevated PSA levels are also measured at
benign conditions such as prostatitis or BPH. Its specificity is therefore relatively low.50,57
Also, false-negative results can occur if men with prostate cancer do not have elevated
PSA levels. Pelzer et al. 58 showed that more than one third of prostate cancer cases
occurred in the lower PSA ranges (2.0-3.9 ng/mL).
Furthermore, the subsequent TRUS guided biopsies have a relatively poor detection
rate due to sampling errors (some examples are shown in Figure 1.7). Reason for this
is that localization of malignant tissues on ultrasound is difficult. Up to 30% of the
prostate cancer lesions are isoechoic and undetectable by gray-scale ultrasound.23,59
The ultrasound guided approach is thus merely used to guide systematic biopsies in
which specific regions throughout the prostate are sampled without knowing where
tumors are located, rather than targeted biopsy of a palpable nodule or a lesion visible by
1
12 CHAPTER 1: Introduction
(a) (b) (c)
Figure 1.7: Cross sections of the prostate showing the limitations of TRUS guided biopsy. (a) The needle
penetrates next to the tumor or does not reach it. (b) Wrong part of the tumor is biopsied causing
underestimation of aggressiveness. (c) Insignificant (non-aggressive) tumor is biopsied.
imaging. Systematic TRUS guided biopsy misses nearly a quarter of detectable cancers
on the first biopsy session and has a low sensitivity of around 40%.30,60,61 Several studies
have demonstrated discrepancies between the Gleason score of the biopsy tissue and the
subsequent radical prostatectomy specimen.62–65 Significant cancers are missed (Figure
1.7(a)) or underestimated (Figure 1.7(b)), and there is overtreatment due to overdiagnosis
(Figure 1.7(c)).
Combining the results of PSA testing and TRUS guided biopsies, we can conclude
that there is a need for a more accurate method for detecting prostate cancer and correctly
determining the cancer aggressiveness.
1.6 MR imaging of the prostate
Magnetic resonance imaging (MRI) of the prostate made its emergence in the 1980s.66
The zonal anatomy of the prostate could be visualized on T2-weighted imaging due to
high spatial resolution and high tissue contrast. Current state-of-the-art prostate MRI
is characterized by its multiparametric approach. Anatomical T2-weighted imaging
is combined with functional imaging techniques such as dynamic contrast-enhanced
(DCE), diffusion-weighted imaging (DWI), and magnetic resonance spectroscopic imaging
(MRSI). Functional parameters provide additional information on biological properties
of prostatic tissue. Modern prostate MRI is usually acquired on a 1.5 or 3 tesla (T) MRI
scanner. A radiofrequency-emitting coil is placed next to the prostate using either a
(surface) pelvic phased-array coil or an (internal) endo-rectal coil.67
T2-weighted imaging is the best modality for anatomical assessment of the prostate
and its surrounding structures. It has the highest resolution and the best soft tissue
contrast. Usually three orthogonal views are acquired, i.e. transversal, sagittal, and
coronal, with a high in-plane resolution and relatively thick slices (Figures 1.8(a)–(c)). The
central zone, transition zone, and fibromuscular stroma are usually hard to differentiate
radiologically and are grouped together as the central gland.68 The central zone has
usually a dark appearance with a chaotic structure, opposing the bright homogeneous
appearance of the peripheral zone.
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(a) (b) (c)
(d) (e)
(f) (g)
Figure 1.8: Example of a multiparametric MRI. (a) Transversal T2-weighted image. (b) Sagittal T2-
weighted image. (c) Coronal T2-weighted image. (d) DCE image. (e) Curve of the DCE image. (f)
ADC map. (g) DWI with b = 1400.
1
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DCE imaging is based on the permeability of blood vessels and extravasation of
contrast agent into the adjacent tissue.69 A sequential set of T1-weighted images is
acquired over time following the administration of an intravenous contrast agent. Leaky
endothelial cells have an increased permeability causing fast contrast enhancement,
which is a typical feature of prostate cancer. The enhancement pattern can be expressed
in different curve types as illustrated in Figure 1.9. Figure 1.8(d) shows an example of a
DCE image, the corresponding curve is depicted in Figure 1.8(e).
DWI quantifies the random Brownian motion properties of water molecules in tis-
sue.70 The degree of restriction to water molecules in biologic tissue is inversely correlated
to the cellular density. Tumors often show restricted diffusion compared to benign tissue.
The net displacement of molecules is called the apparent diffusion coefficient (ADC),
which can be derived from a series of diffusion images using different parameters (i.e.
b-values). An example of an ADC map and corresponding b1400 image is shown in
Figures 1.8(f),(g) respectively.
MRSI allows to evaluate changes in metabolite concentrations within the prostate.71
The ratio of choline and creatinine relative to citrate is used as marker for prostate cancer.
1.6.1 Prostate cancer diagnosis on MRI
Currently, multiparametric (mp)-MRI is the most sensitive and specific technique for
localizing prostate cancer.72 It has shown great potential in the localization and grading
of prostate cancer.73 A combination of anatomical T2-weighted MRI, dynamic contrast-
enhanced MRI, and diffusion-weighted MRI improves the accuracy of prostate cancer
detection over T2-weighted imaging alone.74–76 Additionally, recent research has investi-
gated the correlation between DWI and tumor aggressiveness. The apparent diffusion
coefficient (ADC) determined at DWI has proven to be inversely correlated to the Gleason
grade in peripheral zone prostate cancer.77–80
Although MRI for prostate cancer certainly has potential, interpretation of mp-MRI
suffers from observer variability81 and requires a high level of experience.82 A major
issue with broad adaptation was the professional disagreement on what parameters
to use and how to interpret them.83,84 A group of prostate MR imaging experts have
developed a set of clinical guidelines with the aim to standardize prostate MRI: the
Prostate Imaging and Reporting Archiving Data System (PI-RADS).85 The PI-RADS
scoring system is summarized in Table 1.1. Bomers and Barentsz 86 provided a detailed
explanation illustrated with examples for every single parameter in mp-MRI. The example
in Figure 1.8 shows a lesion scored as PI-RADS 5 for all three parameters.
The ESUR guidelines recommend to perform mp-MRI consisting of at least T2-
weighted imaging and two functional modalities (DCE and DWI), with MRSI being
an optional parameter. Every modality is scored independently on a 5-point scale. Since
no rules are specified for determining the final lesion score, several studies calculated a
PI-RADS sum score.88–90 An update of the guidelines will prescribe that the ‘dominant’
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Table 1.1: PI-RADS scoring system for multiparametric MR imaging of the prostate, as described by the
ESUR guidelines. 85
Score Criteria
T2-weighted imaging for the peripheral zone (PZ)
1 Uniform high signal intensity (SI)
2 Linear, wedge shaped, or geographic areas of lower SI, usually not well demarcated
3 Intermediate appearances not in categories 1/2 or 4/5
4 Discrete, homogeneous low signal focus/mass confined to the prostate
5 Discrete, homogeneous low signal intensity focus with extra-capsular extension/invasive
behavior or mass effect on the capsule (bulging), or broad (>1.5 cm) contact with the surface
T2-weighted imaging for the transition zone (TZ)
1 Heterogeneous TZ adenoma with well-defined margins: ‘organised chaos’
2 Areas of more homogeneous low SI, however well marginated, originating from the TZ/BPH
3 Intermediate appearances not in categories 1/2 or 4/5
4 Areas of more homogeneous low SI, ill defined: ‘erased charcoal sign’
5 Same as 4, but involving the anterior fibromuscular stroma or the anterior horn of the PZ,
usually lenticular or water-drop shaped.
Diffusion-weighted imaging (DWI)
1 No reduction in ADC compared with normal glandular tissue. No increase in SI on any high
b-value image (≥ b800)
2 Diffuse, hyper SI on ≥ b800 image with low ADC; no focal features, however, linear, triangular
or geographical features are allowed
3 Intermediate appearances not in categories 1/2 or 4/5
4 Focal area(s) of reduced ADC but iso-intense SI on high b-value images (≥ b800)
5 Focal area/mass of hyper SI on the high b-value images (≥ b800) with reduced ADC
Dynamic contrast enhanced (DCE)-MRI∗
1 Type 1 enhancement curve
2 Type 2 enhancement curve
3 Type 3 enhancement curve
+1 For focal enhancing lesion with curve type 2–3
+1 For asymmetric lesion or lesion at an unusual place with curve type 2–3
Magnetic resonance spectroscopic imaging (MRSI)
1 Citrate peak height exceeds choline peak height >2 times
2 Citrate peak height exceeds choline peak height times > 1, < 2 times
3 Choline peak height equals citrate peak height
4 Choline peak height exceeds citrate peak height > 1, < 2 times
5 Choline peak height exceeds citrate peak height >2 times
∗ Different curve types for DCE-MRI are illustrated in Figure 1.9
Figure 1.9: Curve types representing enhancement patterns on DCE-MRI. Type 1 represents progressive
enhancement, type 2 represents rapid enhancement with plateauing, and type 3 represents rapid
enhancement followed by a rapid wash out of the contrast material. Image obtained from Johnson
et al. 87
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Figure 1.10: During the MRI-guided biopsy the worst part of the tumor can be specifically targeted.
parameter should determine the final PI-RADS score, being DWI for peripheral zone and
T2-weighted imaging for central gland.86
Several studies have evaluated the performance of the PI-RADS guidelines. These
show that the PI-RADS score can help to localize possible prostate lesions and indicate
the likelihood of cancer of suspicious lesions.88,89,91
1.6.2 MR guided biopsy
The first MR guided prostate biopsy was done in 1986.92 Since then, MR imaging and
biopsy techniques have improved significantly.
MR guided biopsy uses mp-MRI for accurate prostate cancer localization to direct the
biopsy needle towards (the most aggressive part of) the prostate cancer, as depicted in
Figure 1.10. T2-weighted imaging with additional functional sequences are used to define
targets. Most commonly used techniques in clinical studies are DCE and DWI.93–97 MR
guided biopsies that are targeted to the lowest signal areas on the ADC map within the
tumor determine the Gleason grade in exact concordance with prostatectomy in 88% of
the cases, which is substantially higher than TRUS systematic biopsy (55%).98 MR guided
biopsy has resulted in prostate cancer detection rates ranging from 38− 59% using far
less cores (median 4) compared to systematic TRUS biopsies (8− 12 cores).94,95,99–102
The negative predictive value of mp-MRI for excluding significant prostate cancer
has shown to be around 90%.103,104 This means that mp-MRI can be used to help men
at risk and decide whether they should proceed to prostate biopsy. Parts of the prostate
that were negative at mp-MRI do not require biopsy, leading to a reduction of the total
number of biopsies (up to 50%104). A study on cost-effectiveness showed that total costs
of an MRI strategy are comparable to TRUS guided biopsy, while potential reduction of
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overdiagnosis and overtreatment leads to an improvement in the quality of life.105 MR
guided biopsy can therefore be a more cost-effective solution than the systematic TRUS
guided biopsy.
1.7 MR-TRUS fusion
Despite its versatile capabilities, MRI is not as widely available or as easy to apply to
prostate imaging as is ultrasound (US). Issues of cost, access, scanner time, technical
requirements and radiologists’ acceptance and understanding of the procedure are con-
tinuing challenges.106 By combining advantages of both MR and TRUS imaging, MR
guided TRUS biopsy is a potentially more accessible and practical solution than in-bore
MR guided biopsies. Pre-acquired MR images can be used to enhance TRUS imaging
and improve needle guidance by registration of the two modalities.107 Accurate MR-
TRUS registration requires to take into account prostate deformation and motion inherent
to TRUS probe insertion and prostate scanning. Available methods vary in accuracy,
speed, and user-friendliness. Two strategies can be distinguished: cognitive fusion and
computational fusion.
1.7.1 Cognitive fusion
Cognitive fusion is the first strategy using MR-TRUS registration. It fuses the two
modalities by means of visual or cognitive fusion (sometimes referred to as mental fusion).
It is the simplest MR guided biopsy technique and requires no additional equipment.
With this technique, the physician performing the TRUS guided biopsy reviews the lesion
on MRI and uses this knowledge to aim the biopsy needle at the appropriate prostate area
for a targeted MR guided TRUS biopsy.108–110 The reported results of cognitive fusion
biopsy are contradictory: a study by Puech et al. 111 did not show a significant difference
between computer-assisted MR-TRUS fusion and cognitive fusion, whereas a study by
Delongchamps et al. 112 showed that cognitive fusion biopsies do not perform better than
systematic TRUS guided biopsies. The main disadvantage of this technique is that it
requires experience and training and leads to inaccuracies, subjectivity, variability, and
lack of reproducibility.109 As the accuracy of cognitive fusion depends very much on
the skills of the operating physician, it is likely that this technique is not as effective at
locating lesions for biopsy as direct in-bore MR and computer-assisted MR guided TRUS
biopsies.
1.7.2 Computational fusion
Computational (or computer-assisted) registration of MR and US images is the second MR-
TRUS registration strategy. Compared to cognitive fusion, it is potentially a more accurate
way of image fusion requiring less operator skills but more computation time. MR image
information is very different from information obtained from US images. Therefore,
MR-US registration methods are often surface-based, i.e. the capsule is aligned by
registering a surface representation reconstructed typically from cross-sectional contours.
1
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The main challenge is to compensate for shape differences between MR and US images
due to prostate deformation and motion. Computer-assisted registration methods can be
roughly subdivided into two categories: rigid and non-rigid registration methods.
Computer-assisted rigid registration is a relatively easy and fast computation-based
registration method. Xu et al. 113 describe a method for the real-time rigid registration
of MR and TRUS images during freehand transrectal biopsy. A reconstructed 3D TRUS
volume was manually registered with a 3D MRI volume. Rigid motion compensation
is based on an image registration between the reference 3D US volume and the intra-
operative 2D US images. However, the prostate gland is not a rigid structure. Prostate
motion can arise from a number of causes, of which the most important one is probably
the insertion of the TRUS probe. Significant gland motion can therefore occur between
MR and TRUS imaging.114 The disadvantage of rigid registration is that it does not take
any of these motions into account. To reduce potential errors due to prostate deformation
on TRUS images, Ukimura et al. 115 introduced a plastic outer-frame of the TRUS probe
that was placed in the rectum during MR image acquisition.
Computer-assisted non-rigid registration, on the other hand, is able to compensate
for deformations of the prostate. Singh et al. 116 describe a manual method for the real-
time non-rigid registration of MR and TRUS images. This method, however, requires
significant user interaction. Automatic registration is more challenging and requires
more computation time, but has the advantage of being less dependent on operator
skills. Narayanan et al. 117 propose a non-rigid registration that was achieved by an initial
deformable registration of the prostate surface, segmented from both the MR and TRUS
images, followed by a linear elastic warping of the gland volume using an adaptive
focus deformable model with surface point displacements as boundary conditions. Mitra
et al. 118 present a method to non-rigidly register TRUS and MR images in correspond-
ing 2D slices. The Bhattacharyya distance is used to establish point correspondences
on manually segmented prostate contours. An extended non-linear thin-plate spline
(TPS) algorithm was applied to the corresponding point sets. The performance of the
proposed method was compared against traditional B-splines and TPS-based deformable
registration methods and has a significantly better registration accuracy. A 3D prostate
biopsy tracking system with deformation estimation was published by Baumann et al. 29
A volume-swept 3D US-based tracking system solves the patient motion problem with
an a priori model of rectal probe kinematics. Prostate deformations are estimated with
elastic registration. By incorporating the algorithm proposed by Martin et al. 119 , MR to
3D TRUS registration is performed for clinical applications. They build a mesh from the
MR volume and shape and volume constraints are used to guide surface deformation.
There are many different methods, but in general deformable non-rigid registration
is more accurate than rigid registration.112,120,121 However, many methods are based on
relatively simple volume interpolation that are not always physically plausible.122 Image
volumes can be stretched and moved causing the anatomy to look artificially altered.
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Internal prostate gland motion and deformation can be better predicted by applying
biomechanical modeling using finite element (FE) analysis.123–125 A biomechanical model
of the prostate can be constructed by assigning boundary conditions and elastic properties
to the tissue. The prostate deformation can be simulated and internal gland motion can
then be predicted. Alterovitz et al. 123 use a biomechanical model based registration
algorithm to non-rigidly register MR and MR spectroscopic images. Bharatha et al. 124
apply a 3D FE-based deformable registration algorithm to pre- and intraoperative MR
studies. A biomechanical model of soft-tissue deformation was also used to predict the
actual internal prostate deformation due to a TRUS probe for MR-TRUS registration.125
This method is based on a side-firing TRUS probe and has been applied to transperineal
MR guided TRUS biopsies.
1.7.3 Clinical MR-TRUS fusion systems
Multiple MR-TRUS fusion systems based on different computation registration algorithms
have been developed. The existing systems with published clinical data are summarized
in Table 1.2.109 The general workflow is to acquire pre-biopsy diagnostic MR images used
to identify lesions suspicious for prostate cancer. During the biopsy session, MRI and
real-time TRUS images are superimposed and displayed either side-by-side or as blended
fusion image.
One of the major differences between the different fusion systems is the registration
method. Some clinically available devices are based on a rigid registration method, mostly
using an electro-magnetic (EM-) tracker placed on the TRUS probe to track movements of
the probe. Patient movement or prostate deformation are not taken into account. Other
devices do correct for movement and deformation by tracking the organ itself instead of
the TRUS probe. These incorporate a non-rigid registration algorithm. Another solution
to reduce prostate deformation due to the TRUS probe is by transperineally biopsying
the prostate after MR-TRUS fusion. Some systems have the additional option to archive
the biopsy location.
Another major difference is the amount of manual operator input. Some methods
require manual identification of paired landmarks or manual prostate segmentation.
Others are more automated, with automatic segmentation and the ability to correct for
motion compensation. Some systems require additional manual ‘fine-tuning’. Less human
input increases the reproducibility as there is less room for (manual) errors. Learning
curves may also vary between the different systems.109
The overall results of clinical studies show that targeted prostate biopsy using MR-
TRUS fusion has a significantly higher tumor detection rate compared to conventional
systematic TRUS guided biopsies (Table 1.3).111,112,126–129 These studies use different
commercially available clinical fusion systems, and all of them show a higher detection
rate with MR guided TRUS biopsy of especially clinically significant prostate cancer
when compared to systematic TRUS guided biopsy. Diagnosis of insignificant disease is
avoided. MR guided TRUS biopsy upgrades and detects higher Gleason grade cancer in
1
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24− 32% of patients.111,112,128 However, this does not (yet) reach the performance of in-
bore MR guided biopsy which has shown a 41% reduction of TRUS undergrading.98 For
correct Gleason grading with MR guided TRUS biopsy, an accurate spatial registration of
MR and US images is required. Current MR-US fusion systems may require improvement
to be able to (partly) replace in-bore MR guided biopsies. There certainly is potential for
fusion biopsy but so far, there is no clear consensus on which methodology is optimal for
screening, detection or surveillance, nor on the specific indications.
1.8 Outline of this thesis
Current clinical practice lacks sensitivity for prostate cancer detection. With the increasing
number of PSA tests, or even screening in the future, an alternative technique for prostate
cancer diagnosis is required. MRI has shown to be much better in prostate cancer
detection, but is not ideal for biopsying the increasing number of patients. MR-TRUS
fusion is an upcoming technique for prostate biopsies. Recent studies showed that MR-
TRUS fusion biopsies are better than the systematic TRUS guided biopsies. However,
not much is known about the requirements and whether it is as good as in-bore MR
biopsies. It is not yet clear what role MR-TRUS fusion can potentially play in prostate
cancer diagnosis. The aim of this thesis is to investigate whether MR guided TRUS fusion
biopsy is viable in clinical practice. Both technical requirements and clinical usability are
addressed.
In chapter 2, the viability of MR-TRUS fusion biopsies as alternative to systematic
TRUS guided biopsies is discussed. It includes a short overview of advantages and
disadvantages of MR-TRUS fusion biopsies.
Chapter 3 focuses on the required registration accuracy. Many prostate cancers have
a high-grade focal hotspot. Targeting this highest Gleason grade component solely based
on fusion requires an accurate registration algorithm. Small targets might be missed
with MR guided TRUS biopsies. The goal of this study was to determine the required
registration accuracy, and how this is related to tumor volume. An estimation of the
technical registration accuracy is made by simulating biopsies on a tumor population.
In chapters 4 and 5 the design of a surface-based registration method with biomechan-
ical regularization is presented. Surface-based registration methods have their limitations,
especially with respect to registration accuracy. Biomechanical modeling can better con-
trol internal prostate deformation. The method developed extends a commonly used
non-rigid surface-based registration method with biomechanical modeling. The registra-
tion accuracy of this enhanced method was compared to the regular registration method
to see whether this indeed improves. Chapter 4 evaluates the accuracy for MR-MR
registration. Subsequently, in chapter 5 the method is extended further and applied to
MR-TRUS registration.
Chapter 6 is concerned about the cancer visibility on TRUS images. Prostate cancer
visible on TRUS using prior knowledge of MRI can be targeted under TRUS guidance,
benefitting especially fusion biopsies. The aim of this observer experiment was to de-
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termine the proportion of tumors that are visible when using prior knowledge of MRI
appearance.
In chapter 7, the clinical feasibility of a MR-TRUS fusion biopsy system is tested.
A simple EM-based rigid registration technique can be enhanced with local reference
augmentation, thereby optimizing registration accuracy locally around the lesion. Local
MR-TRUS fusion biopsy may be a viable method providing a definite diagnosis for a
selection of patients. If not, MR guided biopsy will be recommended. Based on the initial
results, an indication of the cancer detection rate and the representativeness is given.
This thesis is concluded with a summary of the main results and a general discussion
in chapter 8. Clinical implications and future perspectives are provided as well.
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Abstract
MRI/ultrasonography (MRI/US)-fusion biopsy outperforms systematic ultrasonography-
guided biopsy, detecting more high-grade prostate tumours while being less able to
detect low-grade cancer, thus preventing overtreatment of indolent tumours. Any of
several MRI-guided biopsy techniques has the potential, therefore, to replace systematic
transrectal ultrasonography-guided prostate biopsies in the future.
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Systematic transrectal ultrasonography (TRUS)-guided biopsy is the current clinical
standard method for diagnosing prostate cancer. However, TRUS-guided biopsy can
miss and undersample aggressive tumours and detect indolent cancers by chance. Multi-
parametric (mp)-MRI has been shown to be highly accurate in detecting and localizing
intermediately aggressive and highly aggressive cancers. Biopsy under direct MRI or
MRI/ultrasonography (MRI/US) guidance is, therefore, rapidly emerging as an alter-
native to TRUS-guided biopsy. Siddiqui et al. 128 are one of the first groups to report
a large prospective study comparing MRI/US-fusion-guided biopsy with systematic
TRUS-guided biopsy. They show that targeted MRI/US-fusion-guided biopsy detects a
higher number of aggressive cancers than TRUS-guided biopsy, and avoids detection of
indolent cancers. These results are in line with other studies.111,112,129
However, caution is required before embarking on immediate large-scale implemen-
tation of MRI-guided biopsy techniques for men with suspected prostate cancer. An
experienced MRI radiologist is crucial for obtaining good biopsy samples, as optimal
acquisition and standardized interpretation of mp-MR images is essential. Acquisition
and interpretation of the mp-MR images requires skills that can only be obtained by good
training and experience. Minimal requirements for prostate mp-MR image acquisition
and standardization for reporting (PI-RADS) have recently been published,85 which will
help to improve the general reliability of the techniques.
Furthermore, any MRI-guided biopsy technique used clinically should be state-of-the-
art. Several MRI-guidance techniques – including direct ‘in-bore’ MRI-guided, MRI/US-
fusion-guided, and cognitive-fusion-guided biopsy – exist,110 but not all are equally
accurate. Direct MRI-guided biopsy95 is likely to be the most accurate technique as it
is less prone to fusion and motion errors. Thus, direct image-guided biopsy is used in
most oncologic applications and can easily locate a lesion detected on a previous MRI
study, enabling very accurate targeting. With this technique, aggressive cancers as small
as 2 mm in diameter can be targeted. Hambrock et al. 98 compared direct MRI-guided
biopsy to TRUS-guided biopsy using prostatectomy as reference standard. Using direct
MRI-guided biopsy resulted in a 41% reduction of TRUS undergrading of intermediately
aggressive and highly aggressive tumours. This result is greater than the 32% reduction
after using MRI/US-fusion-targeted biopsy reported by Siddiqui et al. 128 However, direct
MRI-guided biopsy also has potential disadvantages: it is not yet widely available and can
be relatively expensive compared with TRUS-guided biopsy. However, cost effectiveness
has not been studied for this technique, so it remains unclear what the effects are on the
total cost for health-care systems and the potential improvement in patients’ quality of
life.
The second MRI-guided biopsy method is MRI/US-fusion-guided biopsy. This might
seem an attractive alternative to direct MRI-guided biopsy, because of the limited avail-
ability of the latter technique. However, as it is indirect, it is, therefore, prone to a large
variation in accuracy. Furthermore, collaboration of a skilled MRI radiologist and a urolo-
gist familiar with MRI – which is not available in all centres – is a prerequisite for carrying
2
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out the biopsy procedure. Siddiqui et al. 128 have reported excellent results, as their group
contains two highly skilled prostate MR-radiologists, who were directly involved in the
biopsy procedure. Furthermore, they used an advanced technique compensating as much
as possible for changes in prostate shape between MR and TRUS images. Additionally,
their procedure included motion correction during scanning. Any misregistration will
negatively affect the biopsy outcome. Some MRI/US-fusion techniques provide similar
technologies, but others do not include these advanced solutions – their registration
often does not compensate for difference in prostate shape and motion correction and the
target registration accuracy is, therefore, expected to be less optimal. Thus, each different
MRI/US-fusion technique needs to be validated before its widespread use.
To achieve good results with MRI/US-fusion-guided prostate biopsies, optimal regis-
tration accuracy is critical. Van de Ven et al.130 have shown that a registration accuracy
of 1.9 mm is required for correctly grading 95% of tumours with MRI/US-fusion biopsy.
To our knowledge, only one study125 has reported the actual target registration error of
MRI/US-fusion. That particular technique resulted in a median target registration error
of 2.4 mm. At this accuracy, it is likely that smaller (3–5 mm) lesions are missed. Siddiqui
et al. 128 do not report on their target registration error. To compensate for this potential
error, they sample 2–3 cores per lesion, which is more than usually required with direct
MRI-guided biopsy. However, it remains unclear whether small, highly aggressive focal
tumour ‘hot spots’ were accurately sampled using this approach. A further critical tech-
nological element is the ability to accurately register an MR image to an ultrasonograph
image during biopsy in real-time.
Another drawback of MRI/US-fusion is that it relies on accurate prostate segmenta-
tion. This means that the prostate needs to be outlined – manually or semiautomatically –
on both MR and US images. This segmentation is a time-consuming task and is operator
dependent. Siddiqui et al. 128 do not report the time needed for prostate segmentation,
nor provide details about the used method and its accuracy.
Furthermore, with MRI/US-fusion it is tempting and very easy for the urologist to
take random biopsy samples at the same time and, therefore, find insignificant cancer,
thereby removing one of the advantages of targeted biopsies.
The third MRI-guided prostate biopsy method is cognitive-fusion. With this technique
the physician performing the TRUS-guided biopsy reviews the lesion on mp-MRI and
uses this information to select the appropriate area for a targeted TRUS-guided biopsy.
The reported results of cognitive-fusion biopsy are contradictory: a study by Puech
et al. 111 did not show a significant difference between MRI/US-fusion and cognitive-
fusion, whereas a study by Delongchamps et al. 112 showed that cognitive-fusion biopsies
do not perform better than TRUS-guided biopsies. As the accuracy of the cognitive-fusion
technique depends very much on the skill of the operator, it is likely that this technique is
not as effective at locating lesions for biopsy as direct MRI and MRI/US-fusion biopsy.
Overall, we agree with the conclusion drawn by Siddiqui and colleagues,128 who
assert that MRI-guided biopsy will replace TRUS-guided biopsy. However, good quality
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MR image acquisition and standardized (PI-RADS) interpretation, combined with accu-
rate MRI-guided biopsy, is essential. Advanced targeted MRI/US-fusion guided biopsy
techniques are already more accurate than systematic TRUS-biopsies. However, targeting
lesions relies solely on the accuracy of the fusion method used, so one must keep in mind
that small (3–5 mm) focal hot spots of aggressive cancer are prone to being missed even
with optimal MRI/US-fusion techniques. Thus, small lesions or lesions that are difficult to
reach with MRI/US-fusion biopsy should be biopsied under direct MRI-guidance. Larger
lesions can be targeted using MRI/US-fusion alone. Future studies should be performed
to determine the threshold tumour size and to compare the accuracy of both techniques.
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Abstract
Objectives: To estimate the required spatial alignment accuracy for correctly grading 95%
of peripheral zone (PZ) prostate cancers using a system for multiparametric magnetic
resonance (MR) guided ultrasound (US) biopsies.
Methods: PZ prostate tumours were retrospectively annotated on multiparametric MR
series using prostatectomy specimens as reference standard. Tumours were grouped
based on homogeneous and heterogeneous apparent diffusion coefficient (ADC) values
using an automated ADC texture analysis method. The proportion of heterogeneous
tumours containing a distinct, high Gleason grade tumour focus yielding low ADC values
was determined. Both overall tumour and high-grade focal volumes were calculated.
All high-grade target volumes were then used in a simulated US biopsy system with
adjustable accuracy to determine the hit-rate.
Results: An ADC determined high-grade tumour focus was found in 63% of the PZ
prostate tumours. The focal volumes were significantly smaller than the total tumour
volumes (median volume of 0.3 mL and 1.1 mL respectively). To correctly grade 95% of
the aggressive tumour components the target registration error (TRE) should be smaller
than 1.9 mm.
Conclusions: To enable finding the high Gleason grade component in 95% of PZ prostate
tumours with MR guided US biopsies, a technical registration accuracy of 1.9 mm is
required.
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3.1 Introduction
Prostate cancer is the second most common diagnosed malignancy in men in the Western
World, and one of the leading causes of death from cancer.131 The current routine clinical
standard method for making a definite diagnosis of prostate cancer is transrectal ultra-
sound (TRUS) guided biopsy. As prostate cancer is rarely visible on grey-scale ultrasound,
TRUS is merely used to guide systematic biopsies. This systematic approach misses
nearly a quarter of detectable cancers on the first biopsy.30 Furthermore it substantially
underestimates the true Gleason score compared to radical prostatectomy specimens. In
about 40% of Gleason scores ≥ 7 on prostatectomy, the biopsy revealed a lower Gleason
score.62,64,98 So the number of correctly detected aggressive tumours is rather low with
TRUS guided biopsy. For correct treatment decision and risk stratification, improved
methods for correctly determining the Gleason score on biopsy are needed.
Magnetic resonance (MR) guided MR biopsy is a very promising technique for
prostate biopsies. Firstly, multiparametric MR imaging (MRI) has proven to be an effec-
tive technique to localize prostate cancer.73 A combination of anatomical T2-weighted
MRI, dynamic contrast-enhanced MRI, and diffusion weighted MRI (DWI) improves the
accuracy of prostate cancer detection over T2-weighted imaging alone.75,76 Secondly, it
has been shown that MR guided MR biopsy significantly increases the tumour detec-
tion rate as compared to TRUS systematic biopsy.94 Additionally, recent research has
investigated the correlation between DWI and tumour aggressiveness. The apparent
diffusion coefficient (ADC) determined at DWI has proven to be inversely correlated to
the Gleason grade in peripheral zone (PZ) prostate cancer.77–79 MR guided MR biopsies
are therefore targeted to the lowest signal areas on the ADC map within the tumour. It
has moreover been shown that ADC guided biopsy determines the Gleason grade in exact
concordance with prostatectomy in 88% of the cases, which is substantially higher than
TRUS systematic biopsy (55%).98 However, disadvantages of MR guided MR biopsies are
that such a system is not widely available and is costly.
MR guided TRUS biopsy is potentially a more cost-effective alternative. The question
remains however whether this can also result in a correct sampling of the most aggressive
part of the tumour and thus accurately predict its true aggression. An important aspect
of this method is the correct spatial alignment of the MR and TRUS images using fusion
methods. For merely detecting the tumour, MR-TRUS fusion with reasonable accuracy
may be sufficient. But accurate Gleason grading depends on accurate targeting of biopsies
to the most aggressive tumour component. Many clinically significant tumours show
different Gleason patterns within the same tumour.132,133 These so-called heterogeneous
tumours thus require a more accurate registration method for a correct Gleason grading
as the biopsy needs to be targeted to the smaller high-grade tumour volume component.
Fusion of MR and TRUS images is considered difficult and topic of current research
in image registration. Recent works have investigated several MR to US registration
methods, including rigid as well as nonrigid methods able to compensate for deforma-
tions. Reported mean surface error is 3.3 mm, increasing to up to 12.7 mm in apex and
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base.116 However, this is based on the root mean square distance between TRUS-based
and MRI-based segmentations of the prostate. Reported median target registration er-
rors (TREs) are 5.1 (rigid) and 2.4 mm (nonrigid) in the mid plane, but increase at apex
and base.125 Clinical studies using rigid registration reported a significantly increased
tumour detection rate upon targeted prostate biopsy with MR-US fusion compared to
conventional TRUS guided biopsies.127,134 Accurate Gleason grading depends however
on accurate targeting of biopsies in the most aggressive tumour component.
In this article, we investigate the required accuracy of the registration for a correct
Gleason grading with MR guided US biopsies. The current required accuracy is based on
the widely used cutoff value of 0.5 mL for clinically significant tumour volumes.121,125
We hypothesize that for a correct Gleason grading of heterogeneous tumours, a higher
accuracy is required. This registration accuracy depends on the size of the most aggressive
tumour component, which we define as the high-grade tumour focal spot. Aggressive
tumour components can be distinguished on multiparametric MRI (especially ADC) but
not on US. We therefore used the ADC map to automatically determine the volume of
the focal spot within an annotated tumour region. We first investigate the proportion of
tumours being heterogeneous on ADC. Secondly, we determine the volume distribution
of the most aggressive component of the heterogeneous tumours. Using this volume
distribution, we then estimate the required maximal technical registration error for taking
a representative biopsy of the most aggressive component under MR to US guidance by
using a simulation system.
3.2 Materials and methods
3.2.1 Patients
Between August 2006 and January 2009, 56 consecutive patients with PZ prostate cancer,
scheduled for radical prostatectomy, were referred from the departments of urology at
the Radboud University Nijmegen Medical Centre and Canisius Wilhelmina Hospital in
Nijmegen, The Netherlands, for clinically indicated routine MRI of the prostate. In all
patients, prostatectomy was performed within 6 weeks of MR imaging. The requirement
to obtain institutional review board approval was waived.
Five of the 56 patients were excluded owing to severe motion artifacts (n = 3),
widespread intraprostatic hemorrhage (n = 1), or severe ghosting artefacts on the MR
images (n = 1). The remaining data set contains 51 patients with 62 PZ tumours.
3.2.2 MR imaging protocol
Multiparametric MR imaging was performed on a 3.0-T MR system (Trio Tim; Siemens,
Erlangen, Germany) with the use of both an endorectal coil (Medrad, Pittsburgh, PA, USA)
and a pelvic phased-array coil. The endorectal coil was filled with a 40 mL perfluorocar-
bon preparation (Fomblin; Solvay-Solexis, Milan, Italy). Peristalsis was suppressed with
intramuscular administration of 20 mg butylscopolamine bromide (Buscopan; Boehringer-
3.2 Materials and methods 35
Ingelheim, Ingelheim, Germany) and 1 mg of glucagon (Glucagen; Nordisk, Gentofte,
Denmark).
The imaging protocol included anatomical T2-weighted turbo spin-echo MR imaging
in transverse, coronal, and sagittal planes, covering prostate and seminal vesicles. Axial
DWI was performed using a single-shot echo-planar imaging sequence with diffusion-
module and fat-suppression pulses. Water diffusion was measured in three directions
using b-values of 0, 50, 500, and 800 s/mm2. The ADC maps were automatically calculated
by the imager software using all four b-values and a mono-exponential decay fit.
3.2.3 Histopathology
After radical prostatectomy, prostate specimens were uniformly processed and entirely
submitted for histological investigation. After histological staining, all specimens were
evaluated by one expert urological pathologist with 19 years of experience. The entire
tumour volume was outlined on each step section (Figure 3.1(a)). Each individual tumour
was graded according to the 2005 International Society of Urological Pathology Modified
Gleason Grading System36 and staged according to the 2002 TNM classification. See
Hambrock et al. 78 for a summary of the clinical and pathological tumour characteristics.
3.2.4 MR tumour annotation
Retrospectively, annotations of MR images (Figures 3.1(b)–(c)) were performed in con-
sensus by one radiologist and one urologist. All annotations were performed using an
in-house developed MR viewing and reporting system.135 ADC maps were acquired in
the same orientation and with similar thickness as the histopathology step sections. A pre-
viously described translation technique was used to match the tumour-containing regions
on prostatectomy specimens to ADC maps.78 Using histopathology as reference standard,
a region of interest was placed on the ADC map over the whole tumour-containing region
(Figure 3.1(c)).
3.2.5 Focal volume segmentation
We used an automated method to determine the presence and size of a tumour focal
spot (cluster of low ADC values within annotated tumour region). To summarise, it
was first evaluated if the tumour was heterogeneous on ADC and thus contained a dark
ADC tumour focus. Second, the focal spot was automatically detected and its volume
determined.
Low ADC values within the tumour annotation were considered aggressive compo-
nents for the purpose of this study as aggressiveness showed an inverse relationship with
ADC values and MR guided MR biopsies are targeted to these low signal areas on ADC.
Therefore, we defined the darkest connected tumour region within the annotation on the
ADC map as the aggressive tumour focus.
The segmentation of the high-grade focus was done by means of a 3D region growing
within the tumour annotation, taking the voxel with the lowest ADC value within the
3
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(a) (b)
(c) (d)
Figure 3.1: Patient with a peripheral zone tumour revealing Gleason 4 + 3(+5) on final pathology. (a)
Prostatectomy step section with the tumour delineated in light blue. (b) Anatomical T2-weighted MR
image. A large tumour region corresponding to the step section is seen in the peripheral zone (blue
delineation). (c) On the ADC map, water restriction is clearly visible for the same lesion. Regions of
interest are annotated on the smoothed ADC map in correspondence with the prostatectomy step
section (yellow delineation). (d) The segmentation of the focal finding based on ADC values (orange
region). A seeded region growing was applied to detect a cluster of low ADC values within the tumour
outline.
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annotated tumour region as seed point (Figure 3.1(d)). The upper threshold of the region
growing was set at 1.07 × 10−3mm2/s, which is based on Hambrock et al. 78 At this
setting, most of the high-grade tumour components (primary Gleason grade 4 and any
5) and half of the intermediate-grade tumour components (secondary Gleason grade 4)
can be differentiated from low-grade and normal PZ tissue. To reduce image noise, a 3D
Gaussian smoothing filter (σ = 0.50 voxels) was applied to the ADC map before analysis.
The focal volume was calculated by counting the voxels segmented by the region
growing. An aggressive tumour focus will be detected if the tumour contains a substan-
tial amount of voxels both below and above the threshold of 1.07× 10−3mm2/s. We
recorded a focal spot if its volume was between 5% and 95% of the total tumour volume,
a threshold which is also commonly used for assigning the secondary Gleason grade at
pathology.36,136 When a focal spot was detected, the tumour was assigned to the hetero-
geneous group; if none, then two types of homogeneous tumours can be distinguished: a
tumour with almost all ADC values above the threshold (homogeneous bright, focal spot
< 5%) and a tumour with most values below this threshold (homogeneous dark, focal
spot > 95%).
3.2.6 Registration accuracy and hit-rate
The required registration accuracy depends on the volume to be targeted. To determine
the hit-rate as a function of accuracy we used a simulated image registration method. The
simulation system computes the likelihood of a hit for a given TRE and target volume.
The simulation was performed on the whole tumour population and the outcome allows
determining the required TRE given a requested hit-rate. Simulations were done on the
whole tumour volumes as well as the aggressive target volumes (cluster of low ADC
values and homogeneous low signal intensity tumours on the ADC map).
The simulator is described in Hu et al. 125 The registration error is defined as the
distance between the true centre of the target volume and the projected location as
simulated by the registration method. The x−, y−, and z−components of that error
are assumed to be independently normally distributed with standard deviation σ. The
distance error will then follow a Maxwell-Boltzmann probability density function with a
mean value of:
TRE =
√
3σ. (3.1)
Thus, given a TRE, a probability (or hit-rate) can be computed for the projection to
be within the volume to be targeted, where we assumed a spheroid shape with radius r.
Figure 3.2 shows a graph of the TRE threshold as a function of hit-rate and volume.
3.2.7 Statistical analysis
The proportion of heterogeneous tumours was determined including the 95% confidence
intervals. The Wilcoxon rank-sum test was performed to determine whether there is a
3
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Figure 3.2: The TRE threshold as a function of the hit-rate and the tumour volume.
significant difference between the tumour and target volumes. This non-parametric test
was used because a Shapiro-Wilk normality test proved that both tumour volumes and
target volumes (including focal spots and homogeneous dark tumours) are not from a
normally distributed population (p < 0.001). The Wilcoxon signed-rank test was used to
determine whether there is a significant difference of both population median volumes
with the 0.5 mL level of significant tumours. The required accuracy is based on the TRE
threshold at which 95% of the targets are correctly graded.
Differences were considered to be significant when p < 0.05. Statistical analyses were
performed with Matlab (The Mathworks, Inc., Nattick, MA, version 7.10.0).
3.3 Results
3.3.1 Proportion and volume of tumour foci
Of the 62 PZ tumours, 63% (39/62) were heterogeneous, 27% (17/62) had no focal spot at
all, and 10% (6/62) had homogeneous low signal intensity on the ADC map (Table 3.1).
The focal volumes in heterogeneous tumours are mostly below 0.5 mL, with a median of
0.3 mL (range 0.01− 12.9 mL), and are significantly smaller than whole tumour volumes
(p = 0.006).
A box-and-whisker plot for the two groups of tumour volumes is shown in Figure
3.3. The first group contains the whole tumour volumes. The second group contains
the homogeneous dark tumours and the smaller focal volumes, together forming the
aggressive target volumes. This latter group is important for a correct Gleason grading of
aggressive tumour components. The distributions of the two groups differ significantly
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Table 3.1: Sample size and proportion for each of the tumour groups. For each group, the minimum,
median, and maximum tumour volumes are determined.
All tumours Homogeneous Heterogeneous
Dark Bright Tumour Focal spot
Sample size 62 6 17 39 39
Proportion 100% 10% 27% 63% 63%
(95% CI) (4− 20%) (18− 40%) (50− 74%) (50− 74%)
Minimum volume 0.03 mL 0.05 mL 0.04 mL 0.03 mL 0.01 mL
Median volume 11.04 mL 0.63 mL 0.64 mL 1.48 mL 0.30 mL
Maximum volume 18.35 mL 2.69 mL 4.66 mL 18.35 mL 12.87 mL
(p = 0.008). The tumour volume distribution is significantly different from a population
with median 0.5 mL (p < 0.001); the target volumes are not significantly different from
the 0.5 mL level (p = 0.323).
3.3.2 Required registration accuracy
For the estimation of the registration accuracy, we used the target volumes containing
39 tumour focal volumes and 6 homogeneous dark tumour volumes. The proportion of
targets and tumours detected as a function of the TRE is shown in Figure 3.4. Overall,
for detecting 95% of the high Gleason grade targets, an accuracy of 1.9 mm is required.
Comparing this with the mere detection of tumour volumes, a registration with a TRE of
2.5 mm is sufficient.
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Figure 3.3: Box-and-whisker plot displaying the total tumour volumes (heterogeneous and homoge-
neous tumours) and the target volumes (focal spots and homogeneous dark tumours) on a logarithmic
scale. The 0.5 mL cutoff value for clinically significant tumours is indicated by the dotted line.
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Figure 3.4: The proportion of tumours detected as function of TRE threshold. Two different groups of
tumours are plotted: all tumour volumes and all target volumes.
3.4 Discussion
We have shown that 63% of the PZ tumours in our population were heterogeneous,
containing a high-grade tumour focus. With 0.3 mL, the median focal volume was smaller
than the cutoff value of 0.5 mL for a tumour considered being clinically significant. High-
grade focal spots and homogeneous dark tumours were used for estimating the required
registration accuracy for MR guided US biopsies. By simulation we determined that to
correctly assess the aggressive component in 95% of the PZ tumours in our population, a
technical registration accuracy of 1.9 mm is required.
More than half of the PZ tumours were heterogeneous with a high-grade tumour
focus, which is in line with previous findings.132,133 Although the median target volume
is not significantly different from the 0.5 mL level, still more than half of them are smaller
than 0.5 mL. For a correct Gleason grading of especially these heterogeneous tumours, it
is important to be able to sample the smaller high-grade tumour focus and not a random
spot within the whole tumour volume. These focal spots therefore require a more accurate
registration than a 0.5 mL tumour. Correctly determining the highest Gleason grade on
biopsy is important for correct treatment decision and risk stratification.
The current described required accuracy is based on the cutoff value of 0.5 mL for
a clinically significant tumour volume.121,125 Figure 3.2 shows that a TRE of 3.1 mm is
required to detect 95% of these 0.5 mL tumours. Figure 3.4 shows that for detecting
95% of the PZ tumours in our data set, the required TRE is 2.5 mm. For detecting 95%
of the high-grade targets, a registration accuracy of 1.9 mm is required. Especially the
volume difference between heterogeneous tumours, which constitute more than half of
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the tumours, and their focal volumes lead to a large difference in required accuracy. We
therefore conclude that the 0.5 mL cutoff is insufficient to correctly grade prostate cancer.
The 95% level was chosen arbitrarily. It can be argued that a level of 90% or even
lower is sufficient, thereby also decreasing the required accuracy. TRUS guided biopsies
have a sensitivity of only 54% for high Gleason grades 4 and 5.98 However, the same
study has shown that a sensitivity of 95% for the high Gleason grades can be achieved
with MR guided MR biopsies. MR guided TRUS biopsies have to at least approach this
level to be a potential alternative for MR guided MR biopsies.
Several MR-TRUS registration methods have been published. Most of the described
registration errors have a TRE that is most accurate in the mid plane of the prostate.116,125
The accuracy in that plane is sufficient to find most tumours, explaining the increased
detection rates with MR-TRUS fusion.127,134 However, these systems (especially rigid
registration systems) are not accurate enough to target high-grade focal spots either in
the mid plane itself or especially in the apex and base of the prostate. This may result
in biopsy specimens that undergrade the Gleason scores, as is also the case with regular
systematic TRUS guided biopsies.62,64,98
The patients in this study did not have MR guided TRUS biopsy, but for determining
the required registration accuracy only the volume of the targets is important. The
results of this study are based on the high-grade tumour volumes and only provide a
theoretical measure of accuracy for the registration method itself. An accurate registration
is important for US biopsy as there is no visual feedback like in MR. An initial large
registration inaccuracy will never improve in clinical practice. Therefore, it is important
that the registration is accurate enough to hit the high-grade tumour component. Correct
placement of the biopsy gun and needle deflection are not taken into account. These will
lead to another inaccuracy. So in real clinical practice there will be more limitations to
MR guided TRUS biopsies. A clinical study investigating the Gleason grading with MR
guided TRUS biopsy sessions will provide a better idea of the clinical implications. To
our knowledge, no studies have investigated the Gleason grading with MR guided TRUS
biopsies.
A first limitation of this study may be the bias of the data set in that it only contains
patients who are already scheduled for a prostatectomy. The tumours investigated are
thus relatively large and have a higher proportion of aggressive tumours. If data from a
general population were taken, the mean tumour size would most likely decrease. For
detecting these tumours and correctly grading them, the TRE threshold might thus be
even lower than 1.9 mm.
The second limitation is that transition zone tumours were not included in this study.
We assumed that low ADC values within the tumour correspond with the most aggressive
tumour component. Transition zone tumours are known to have lower ADC values than
PZ tumours;137,138 therefore, a different threshold is needed for their focal detection in
this zone. Although it has been shown that the ADC values for transition and central zone
cancerous tissue are significantly lower than normal prostatic tissue,139,140 no significant
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correlation has been shown between ADC and the Gleason grade in transition zone
tumours.80,138 In addition, the majority of prostate tumours arise in the peripheral zone.
We can conclude that for a correct Gleason grading under MR-US guidance, a technical
registration accuracy of at least 1.9 mm is required throughout the prostate. With this
registration accuracy 95% of the prostate cancers in our population will be correctly
graded.
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Abstract
Adding MR-derived information to standard transrectal ultrasound (TRUS) images for
guiding prostate biopsy is of substantial clinical interest. A tumor visible on MR images
can be projected on ultrasound by using MR-US registration. A common approach is
to use surface-based registration. We hypothesize that biomechanical modeling will
better control deformation inside the prostate than a regular surface-based registration
method. We developed a novel method by extending a surface-based registration with
finite element (FE) simulation to better predict internal deformation of the prostate. For
each of six patients, a tetrahedral mesh was constructed from the manual prostate seg-
mentation. Next, the internal prostate deformation was simulated using the derived
radial surface displacement as boundary condition. The deformation field within the
gland was calculated using the predicted FE node displacements and thin-plate spline
interpolation. We tested our method on MR guided MR biopsy imaging data, as land-
marks can easily be identified on MR images. For evaluation of the registration accuracy
we used 45 anatomical landmarks located in all regions of the prostate. Our results show
that the median target registration error of a surface-based registration with biomechan-
ical regularization is 1.88 mm, which is significantly different from 2.61 mm without
biomechanical regularization. We can conclude that biomechanical FE modeling has the
potential to improve the accuracy of multimodal prostate registration when comparing it
to regular surface-based registration.
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4.1 Introduction
Prostate cancer is the second most common diagnosed malignancy in men in the West-
ern World, and one of the leading causes of death from cancer.131 The current routine
clinical standard method for making a definite diagnosis of prostate cancer is transrec-
tal ultrasound (TRUS) guided biopsy. Localization of malignant tissues on ultrasound
is difficult as most lesions are not visible. Systematic TRUS guided biopsy therefore
substantially underestimates the true Gleason score compared to radical prostatectomy
specimens.62,64,98 Magnetic resonance imaging (MRI) has shown great potential in the
localization and grading of prostate cancer75,76 and MR guided MR biopsy significantly
increases the tumor detection rate when comparing it to TRUS systematic biopsy.94,95
However, disadvantages of MR guided MR biopsies are that such a system is not widely
available and is costly.
MR guided TRUS biopsy is a potentially more cost-effective solution. Pre-acquired
MR images can be used to enhance TRUS imaging and improve needle guidance by
registration of the two modalities.29 Clinical studies have shown that targeted prostate
biopsy using MR-US fusion has a significantly higher tumor detection rate compared to
conventional TRUS guided biopsies.127,134 However, correct Gleason grading with MR
guided TRUS biopsy requires accurate MR-TRUS registration. We have recently shown
that a registration accuracy of 1.9 mm is required for finding the high Gleason grade
component in 95% of the tumors with MR guided TRUS biopsies.130
MR image information is very different from information obtained with US images.
Therefore, MR-US registration methods often use a surface-based registration, i.e. the
capsule is aligned by registering a surface representation reconstructed typically from
cross-sectional contours. Deformable surface-based registration using simple volume
interpolation shows improved accuracy compared to rigid registration, but better accuracy
is still required. An advanced biomechanical model of soft-tissue deformation can be used
to better predict the actual internal prostate deformation.122 In this paper we evaluate a
non-rigid surface-based registration method combined with biomechanical modeling for
MR guided TRUS biopsies. Many anatomical landmarks in the prostate are visible on MR
but not on US. Therefore we developed and tested our novel method on a surface-based
MR to MR registration using MR guided MR biopsy data. The MR biopsy needle guide
had an orientation and dimension comparable to a TRUS probe, therefore causing a
similar deformation of the prostate. Besides, MR-MR registration can be useful for MR
guided interventions.120 The registration accuracy was determined by calculating the
target registration error (TRE) using internal anatomical prostate landmarks in the MR
guided MR biopsy data.
4.2 Methods
An overview indicating the different steps of the method we developed is shown in
Figure 4.1. The additional steps taken for our surface-based registration method with
4
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Figure 4.1: Flowchart showing the steps of our method. The red boxes indicate the additional steps
taken in our method with biomechanical regularization, blue boxes indicate the steps for the regular
non-rigid surface-based registration method.
biomechanical regularization are indicated in red. We compared our method with a
regular surface based method (blue boxes).
4.2.1 Patient data
MR guided MR biopsy imaging data was collected from six consecutive patients who
were scheduled for an MR guided prostate biopsy. MR images were acquired at the
Radboud University Nijmegen Medical Centre on a 3-T MR system (MAGNETOM Skyra;
Siemens, Erlangen, Germany). The dataset included T2-weighted images (slice thickness
of 3 mm, in-plane resolution 0.8× 0.8 mm) before and after insertion of a needle guide
causing deformation of the prostate. The prostate was manually outlined in both images.
The prostates had volumes in the range of 31− 125 cc (Table 4.1).
4.2.2 Biomechanical modeling
A finite element (FE) model comprising 186− 603 tetrahedral elements (Table 4.1) was
constructed of the prostate from the outline before deformation (Figure 4.2). To deform
the biomechanical model the surface nodes were displaced to match the deformed surface.
The prostate surface node displacements were derived by radial projection from the
prostate center of gravity (Figure 4.3).121 These surface node displacements were then
used as a boundary condition in the FE simulation to predict the displacement of the
internal mesh nodes. The initial and final positions of all nodes form a corresponding
Table 4.1: Patient data.
Patient Prostatevolume (cc)
No. of
elements
No. of
nodes
No. of surface
points
No. of
landmarks
1 142 186 161 48 7
2 133 251 174 52 8
3 143 457 126 86 7
4 161 603 150 92 8
5 131 365 101 68 7
6 125 563 138 83 8
4.2 Methods 47
Figure 4.2: An example of a tetrahedral mesh obtained from the prostate contour before deformation
caused by the needle guide.
node coordinate set. In the FE simulation, the prostatic tissue was assumed to behave as
an isotropic, elastic material whose non-linear relationship between applied stress and
strain is described by a neo-Hookean model with a shear and bulk modulus of respectively
7.5 kPa and 35 kPa.141 The simulations of prostate deformation were performed using a
non-linear FE solver, which is implemented using a graphics processing unit (GPU) to
enable parallel computations.142
4.2.3 Surface-based registration
The non-rigid surface-based registration is based on a thin-plate spline (TPS) deformation
algorithm, which aligns corresponding points. The three-dimensional (3D) TPS defor-
mation field is used for non-rigid registration between the two images before and after
deformation of the prostate. The two methods were compared, both of them rely on the
TPS deformation algorithm. The first is the regular surface-based registration method,
which uses only the corresponding prostate surface points for computation of the TPS
(a) Before deformation (b) After deformation
Figure 4.3: Equal angle parameterization to find corresponding surface points on manual prostate
segmentations of images (a) before and (b) after deformation. The spherical coordinates of the
surface point (yellow) were calculated with respect to the center of gravity (red) on the segmentation
before deformation. The corresponding surface point on the image after deformation has the same
angular coordinates (φ and θ) but a different radial distance (r).
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deformation field. The second method uses both surface and internal node coordinates
for computing the TPS and thus receives input from the biomechanical model.
4.2.4 Registration accuracy
A total of 45 patient specific anatomical landmarks (calcifications, cysts, etc.) in all regions
of the prostate were manually annotated in both T2-weighted images to determine the
TRE. These landmarks were equally divided over the six patients (Table 4.1). Nine of the
landmarks were located in either apex or base (within first or last two slices of prostate
visible in MR image). The TRE was defined as the Euclidean distance between registered
(obtained from the deformation field) and real landmark positions (obtained from the
deformed T2-weighted image) in 3D. We compared our method with biomechanical
regularization to a regular surface-based registration method. A significant difference in
TRE was tested with the non-parametric Wilcoxon rank-sum test.
4.3 Results
Figure 4.4 shows an example case with the real position of the anatomical landmarks
before and after deformation of the prostate. The registered position of the landmarks
after applying both methods is indicated as well. This case and others show that the TRE
is smaller when biomechanical regularization was applied.
For each patient, the TREs of the landmarks determined by the surface-based registra-
tion with and without biomechanical regularization are shown in Figure 4.5. The overall
median TRE of the surface-based registration with biomechanical regularization was 1.88
mm (range 0.59− 6.83 mm), at the apex and base of the prostate the median TRE is 2.08
mm (range 1.52− 4.23 mm). The overall median TRE without biomechanical regulariza-
tion was 2.61 mm (range 0.69− 8.18 mm) and was significantly different (p = 0.003). At
apex and base the median TRE without biomechanical regularization was 2.46 mm and
was not significantly different (p = 0.190).
4.4 Conclusion
In this paper we have shown that biomechanical regularization significantly improves
a surface-based prostate registration method. Our method extends a non-rigid surface-
based registration method with a biomechanical FE model which is able to better predict
the internal deformation of the prostate. The median TRE of our method was 1.88 mm,
which was significantly better than a median TRE of 2.61 mm obtained without using
biomechanical regularization. These results are comparable to previous findings on
non-rigid surface-based registration121 and biomechanical modeling based non-rigid
registration.122
In this study we used MR-MR registration for the evaluation of the accuracy. However,
as our method is only based on prostate contour information it can also be applied for
MR-US registration.
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(a) Before deformation (b) After deformation, with
biomechanical regularization
(c) After deformation, without
biomechanical regularization
Figure 4.4: T2-weighted images of the prostate. (a) The left image shows the prostate before deforma-
tion with internal anatomical prostate landmarks in blue. (b)–(c) The middle and right images show
the prostate after deformation with the real positions of the corresponding landmarks indicated in
green and the registered landmarks in red after non-rigid surface-based registration (b) with and (c)
without biomechanical regularization.
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Figure 4.5: Boxplot comparing the TREs on a per patient basis of the non-rigid surface-based registration
with biomechanical regularization (red) and without biomechanical regularization (blue).
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Abstract
Purpose: Adding magnetic resonance (MR)-derived information to standard transrectal
ultrasound (TRUS) images for guiding prostate biopsy is of substantial clinical interest. A
tumor visible on MR images can be projected on ultrasound (US) by using MR-US registra-
tion. A common approach is to use surface-based registration. The authors hypothesize
that biomechanical modeling will better control deformation inside the prostate than
a regular non-rigid surface-based registration method. The authors developed a novel
method by extending a non-rigid surface-based registration algorithm with biomechanical
finite element (FE) modeling to better predict internal deformations of the prostate.
Methods: Data were collected from ten patients and the MR and TRUS images were
rigidly registered to anatomically align prostate orientations. The prostate was manually
segmented in both images and corresponding surface meshes were generated. Next,
a tetrahedral volume mesh was generated from the MR image. Prostate deformations
due to the TRUS probe were simulated using the surface displacements as the boundary
condition. A three-dimensional thin-plate spline deformation field was calculated by reg-
istering the mesh vertices. The target registration errors (TREs) of 35 reference landmarks
determined by surface and volume mesh registrations were compared.
Results: The median TRE of a surface-based registration with biomechanical regulariza-
tion was 2.76 (0.81− 7.96) mm. This was significantly different than the median TRE
of 3.47 (1.05− 7.80) mm for regular surface-based registration without biomechanical
regularization.
Conclusions: Biomechanical FE modeling has the potential to improve the accuracy of
multimodal prostate registration when comparing it to a regular non-rigid surface-based
registration algorithm and can help to improve the effectiveness of MR guided TRUS
biopsy procedures.
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5.1 Introduction
Prostate cancer is a major international health problem. It is the most common diagnosed
noncutaneous malignancy in men in the Western World and one of the leading causes of
death from cancer.143,144 With growing prostate cancer awareness and increasing use of
serum prostate-specific antigen (PSA) tests, the incidence of localized prostate cancer has
grown tremendously. This test is very sensitive but nonspecific to prostate cancer and it
has been shown that PSA-based screening followed by biopsy reduced mortality by 20%,
but was associated with a high risk of overdiagnosis.52
Transrectal ultrasound (TRUS) guided biopsy is currently the routine clinical stan-
dard method for making a definite diagnosis of prostate cancer and determining the
treatment. Localization of malignant tissues on ultrasound (US) is difficult as up to 30% of
prostate cancer lesions are isoechoic and not visible on gray scale US.23,59 This approach
is therefore merely used to guide systematic biopsies in which specific regions throughout
the prostate are sampled without knowing where tumors are located. This systematic
TRUS guided approach may therefore lead to various sampling errors, e.g. missing signif-
icant cancer,30 detecting insignificant cancer by chance,145 or underestimating the cancer
aggressiveness by sampling the less-aggressive tumor part.62,64,98 Underestimation of
Gleason score may lead to incorrect patient risk stratification and suboptimal treatment
choices. Therefore, a more accurate method for detecting prostate cancer and correctly
determining the Gleason score on biopsy is needed.
Magnetic resonance imaging (MRI) has shown great potential in the localization and
grading of prostate cancer.73 A combination of anatomical T2-weighted MRI, dynamic
contrast-enhanced MRI, and diffusion-weighted MRI improves the accuracy of prostate
cancer detection over T2-weighted imaging alone.75,76 Arumainayagam et al. 103 showed
that the negative predictive value of multiparametric (mp)-MRI for excluding significant
prostate cancer was 89%. This means that mp-MRI can be used to help men at risk and
decide if they should proceed to prostate biopsy. Parts of the prostate that were negative
at mp-MRI do not require biopsy, leading to a reduction of the total number of biopsies.
Two targeted MR guided prostate biopsy approaches are under investigation, both
using prebiopsy detection MRI to define potential targets.106 The first is direct in-bore MR
guided MR biopsy. As this technique is performed in-bore, it is less prone to fusion errors
and therefore likely to be the most accurate MR guided technique. It has been shown that
this direct in-bore MR guided MR biopsy significantly increases the tumor detection rate
when comparing it to systematic TRUS guided biopsy.94,95 However, despite its versatile
capabilities, MRI is not as widely available or as easy to apply to prostate imaging as is US.
Issues of cost, access, scanner time, technical requirements, and radiologists’ acceptance
and understanding of the procedure are continuing challenges.106
The second MR guided approach is MR guided TRUS biopsy, which is a potentially
more accessible and practical solution. Preacquired MR images can be used to enhance
TRUS imaging and improve needle guidance by registration of the two modalities.107
Available methods vary in accuracy, speed, and user-friendliness. Registration can either
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be performed mentally or computationally. The accuracy of mental fusion depends very
much on the skills of the operating physician and shows some contradictory results.111,112
Computational registration of MR and TRUS images is potentially a more accurate
way of image fusion requiring less operator skills but more computation time. MR
image information is very different from information obtained with US images. To our
knowledge, current published MR-US registration methods are therefore often surface-
based, i.e. the capsule is aligned by registering a surface representation reconstructed
typically from cross-sectional contours. Computer-assisted registration methods can
be roughly subdivided into two categories: rigid and non-rigid registration methods.
Different registration methods exist,29,113,115–118 but in general, deformable non-rigid
registration is more accurate than rigid registration.112,120,121 However, many methods
are based on relatively simple volume interpolation, which are not always physically
plausible.122
Internal prostate gland motion and deformation can be better predicted by applying
biomechanical modeling using finite element (FE) analysis.123–125 A biomechanical model
of the prostate can be constructed by assigning boundary conditions and elastic properties
to the tissue. The prostate deformation can be simulated and internal gland motion can
then be predicted.
The clinical value of MR guided TRUS biopsies is being investigated in several
studies using different commercially available systems based on different registration
methods.108,109 Overall, the results show that targeted prostate biopsy using MR-US
fusion has a significantly higher tumor detection rate compared to conventional TRUS
guided biopsies, especially for the clinically significant tumors.111,112,126–129 However, for
correct Gleason grading with MR guided TRUS biopsy, an accurate spatial registration
of MR and US images is required.130 Current MR-US fusion systems do not reach this
accuracy and therefore require improvement to be able to (partly) replace in-bore MR
guided biopsies.
In this paper, we evaluate a non-rigid surface-based registration method combined
with biomechanical modeling for transrectal MR guided TRUS biopsies. Regular non-
rigid surface-based registration methods often use simple volume interpolation. We
hypothesize that a biomechanical model of soft-tissue deformation can better predict the
actual internal prostate deformation, resulting in a more accurate registration method. We
therefore extend a non-rigid surface-based registration method121 with the biomechanical
FE model described by Hu et al. 125 The deformation field was calculated by applying a
thin-plate spline (TPS) algorithm to the FE mesh nodes (both internal and surface nodes).
The registration accuracy was determined by calculating the target registration error
(TRE) using internal anatomical prostate landmarks visible in both MR and US images.
This method was also used in our previous work,146 where we applied the biome-
chanical modeling constrained registration algorithm to MR-MR registration. The method
is now adapted so that it can be applied to MR-TRUS registration. Additionally, an initial
rigid alignment is required for MR-TRUS registration. Also, we improved simulation
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Figure 5.1: Flowchart showing the steps of our method. The green boxes indicate the additional steps
taken in our method with biomechanical regularization; blue boxes indicate the steps for the regular
non-rigid surface-based registration method. The gray boxes are common between both methods.
convergence by better conditioning of the mesh model. And, we automated the parameter
settings for meshing and simulation. Compared to our previous work, the registration
process is now fully automated and requires only manual intervention for the prostate
segmentation.
5.2 Materials and methods
5.2.1 Overview
A schematic overview indicating the different steps of the method we developed is shown
in Figure 5.1. The steps involved are summarized as follows:
• Acquire MR and TRUS images (Section 5.2.2).
• Segment the prostate gland in both MR and TRUS images (Section 5.2.3).
• Regularize the shape of the prostate gland by applying a smoothing filter (Section
5.2.4).
• Align the masked prostate images by rigid registration (Section 5.2.5).
• From the rigidly registered MR prostate mask, construct a three-dimensional (3D)
tetrahedral volume mesh of the prostate gland (Section 5.2.6).
• Determine the surface displacements by applying radial surface projection to the
prostate masks (Section 5.2.7).
• The deformation of the prostate due to the TRUS probe is simulated by a biomechan-
ical model. The MR volume mesh will serve as input and the surface displacements
are the boundary conditions. The final mesh will correspond with the prostate on
the TRUS image (Section 5.2.8).
• A TPS based non-rigid registration algorithm is applied to construct the deformation
field (Section 5.2.9).
The green boxes in the schematic overview indicate the additional steps taken for
our surface-based registration method with biomechanical regularization. We compared
our method with a regular surface-based method (blue boxes). The software system
was implemented in MeVisLab147 and automates the entire process of rigid registration,
biomechanical modeling, and non-rigid TPS-based registration. Additionally, we used
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Matlab, TetGen,148 and NiftySim142 for meshing and modeling (Section 5.2.8). Prepro-
cessing and evaluation are done in MeVisLab.
5.2.2 Data collection
Patient selection
Data in this study were collected from the ongoing Prostate Cancer Molecular Medicine
(PCMM) project. The PCMM project is a large multicenter study focusing on prostate
cancer. It addresses two major clinical needs: the need to reduce overdiagnosis and
overtreatment of prostate cancer and the need for better therapy monitoring techniques
for advanced disease. The PCMM study procedure involves the collection of bioma-
terials and an extensive imaging protocol including mp-MRI (T2-weighted, dynamic
contrast-enhanced, and diffusion-weighted MRI) and US (gray scale, Doppler, and
contrast-enhanced imaging) examination. The study was approved by the medical ethical
committee, and all patients gave their written informed consent.
The Radboud University Medical Center in Nijmegen, the Netherlands, is one of the
centers recruiting patients for the PCMM project. Data from ten patients diagnosed with
prostate cancer at our center were collected to validate our registration method.
MR image acquisition
A MR imaging detection or staging protocol was used to acquire mp-MR images of all
patients. A 3-T MR system (MAGNETOM Trio/Skyra; Siemens, Erlangen, Germany)
with either a pelvic phased-array coil (n = 6) or an endorectal coil (n = 4) was used. For
this study, we are only interested in the 3D T2-weighted transversal images. These had
an in-plane resolution of 0.402− 0.625 mm and a slice thickness of 3.0− 3.6 mm.
TRUS image acquisition
TRUS images were acquired on a Toshiba Aplio XG machine (Toshiba Medical Systems,
Japan) using a 4D end-firing transrectal transducer (Toshiba PVT-681MV; Toshiba Medical
Systems, Japan). A 3D gray scale TRUS image of the prostate was made by automatically
sweeping through the prostate with a scanning angle of 90◦ at a rate of 0.1 volumes/s.
The image data were exported from the US machine and converted from a spherical to a
Cartesian representation with an isotropic voxel size of 0.2 mm.
5.2.3 Segmentation
MR images
For the purposes of this study, the diagnostic T2-weighted transversal MR image of
patient i (IiMR, where i = 1 . . . 10) was segmented by manually defining the contour of the
prostate in every slice. The segmentations were made by a researcher (W.J.M.v.d.V.), who
has three years of experience in prostate image analysis.
TRUS images
Due to the high resolution of the Cartesian TRUS images (IiUS), these were downsampled
to an isotropic resolution of 0.8 mm for segmentation purposes only (i.e. limiting the
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amount of slices requiring segmentation). Prostate segmentations were manually made by
the same prostate researcher (W.J.M.v.d.V.) who performed the MR image segmentations.
To improve the segmentation of the prostate in IiUS, three orthogonal projections were
used. In each of the three views, the prostate contour was outlined in every 5-6 slices
and interpolated in the intermediate slices using prior anatomical knowledge of the
smoothness of the prostate gland (i.e. no bumps and pits). To create one image mask
of the prostate contour, the orthogonal segmentations were interpolated by computing
a 3D implicit function that reconstructs a surface as described by Heckel et al. 149 This
3D segmentation algorithm reduces segmentation times compared to slicewise manual
segmentation.
5.2.4 Preprocessing
The MR image masks are resampled to an isotropic voxel size of 0.8 mm, matching the
TRUS image masks. This is required to create a smoother volume mesh without a steplike
surface. To reduce image noise and further regularize the surface shape, we applied a
smoothing filter on masked MR and TRUS images. An isotropic Gaussian smoothing
filter (σ = 5 voxels = 4 mm) using an approximate recursive infinite impulse response
filter to speed up the computation was used.150 Finally, a threshold was applied to create
a binary image.
5.2.5 Rigid registration
The MR and TRUS images have a different world coordinate system. A rigid registration
step aligns the binary prostate masks of both images. The smoothed TRUS image mask
(MiUS) is considered the fixed image and the smoothed MR image mask (M
i
MR) is the
moving image. The objective is to find the rigid transformation (TR) that optimizes the
alignment.
The first step requires an initialization process to align the prostate center of gravity
(CoG) of MiMR with the prostate center of gravity of M
i
US. This step substantially speeds up
the rigid alignment as the prostates are usually far apart in space. Left-right orientation is
matched before initialization. Next, the rigid registration algorithm optimizes translation
and rotation in 3D without changing shape or scale. Image similarity was measured using
sum of squared differences between the two prostate masks.151
5.2.6 Meshing
The rigidly registered MR image I¯iMR = TR(I
i
MR) is now roughly aligned to the cor-
responding TRUS image IiUS, i.e. positional and rotational differences are corrected.
For a more accurate registration, the I¯iMR needs to be deformed so that the segmented
prostate shape (M¯iMR) will fit on the prostate mask in M
i
US. A biomechanical model of
the MR prostate will simulate the deformation due to the TRUS probe by taking surface
displacements into account.
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(a) (b) (c)
Figure 5.2: An example showing a tetrahedral volume mesh of the prostate contour obtained from
the masked MR image: (a) shows the outer prostate surface; (b) shows some of the inner elements by
taking out a quarter of the mesh; and (c) shows a coarser mesh of the same prostate containing less
elements of a larger volume.
Prior to the actual simulation, a volume mesh of the MR prostate needs to be con-
structed. The rigidly registered MR image mask (M¯iMR = TR(M
i
MR)) is used to generate
a volume mesh of the prostate (ViMR) consisting of Delaunay tetrahedra. To obtain the
best quality of the tetrahedral volume mesh, we applied the refinement algorithm of
Shewchuk 152 as implemented by the TetGen mesh generator, which is a tool for gen-
erating tetrahedral meshes from 3D domains.148 The quality of a tetrahedral mesh can
be measured by the radius-edge ratio,153 which we restricted to a maximum of 1.0. An
example of a volume mesh is shown in Figure 5.2.
The number of elements and nodes in a mesh will first of all depend on the prostate
volume. Second, the volume mesh can be further characterized by size requirements for
the tetrahedra in the mesh and for the triangles describing the boundary surface mesh. We
investigated the effect of the number of nodes on the registration accuracy by generating
different volume meshes for each prostate.
5.2.7 Radial surface projection
To correct for the shape differences of the prostate between I¯iMR and I
i
US, we need to
determine the surface displacements. These surface displacements can be derived by sub-
tracting surface node coordinates. Hence, we need to construct meshes with anatomically
corresponding surface vertices of the rigidly aligned prostate masks M¯iMR and M
i
US.
To achieve corresponding prostate surface meshes of M¯iMR and M
i
US, we applied an
algorithm we call radial surface projection. This method is based on the equal angle
parameterization described by Karnik et al. 121 Radial surface projection refers to the
generated MR volume mesh (ViMR) which contains a number of surface nodes, i.e. mesh
nodes located on the prostate surface (SiMR). The spherical coordinates of these surface
mesh nodes can be determined. Hereby, we defined the prostate center of gravity of M¯iMR
as origin of the spherical coordinate system. Every nth surface node of patient i will now
be described by three numbers: the radial distance to the origin (rinMR), its polar angle (θ
in),
and the azimuth angle (φin) (Figure 5.3).
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(rMR,θ,φ)
(a) MR prostate mask
(rUS,θ,φ)
(b) TRUS prostate mask
Figure 5.3: Radial surface projection to find corresponding surface points on manual prostate seg-
mentations of MR images and TRUS images. The spherical coordinates of the surface point (green)
were calculated with respect to the center of gravity (red) on the segmented MR image (a). The
corresponding surface point on the TRUS image (b) has the same angular coordinates (φ and θ) but a
different radial distance (rMR and rUS).
To create a corresponding surface mesh of the prostate from the masked TRUS image
(SiUS), the two angular coordinates (θ
in and φin) are important. The prostate center of
gravity of MiUS is determined and is defined as the origin of the spherical coordinate
system. Rays were shot from the origin at the same angular coordinates as derived from
the MR surface nodes. For each ray, the point of intersection with the TRUS prostate
surface is determined. At this point, a surface node is placed with coordinates (rinUS,θ
in,φin).
All surface nodes together will form the TRUS surface mesh (SiUS), which will correspond
to the MR surface mesh (SiMR).
5.2.8 Biomechanical modeling
A biomechanical model of the prostate can predict the deformation due to the insertion
of a TRUS probe.125 For an accurate registration that can be used during intraoperative
TRUS guided procedures, the MR images need to be deformed to fit on the TRUS images.
The MR volume mesh of the prostate (ViMR) will be used as input. For the biomechanical
FE simulations of prostate deformation, material properties of the prostate and boundary
conditions need to be specified. The simulations were performed using a nonlinear FE
solver (NiftySim), which is implemented using a graphics processing unit (GPU) for
significant solution speed gains.142,154 The simulations were executed on a desktop PC
with a 2.26 GHz Intel® Xeon® dual CPU processor and 24 GB of RAM installed with a
NVIDIA® GeForceTM 570 GTX. Depending on the number of elements, a simulation took
around 5− 60 s.
Material properties
In the FE simulation, the prostatic tissue was assumed to behave as a homogeneous,
isotropic, nonlinear elastic material. Such materials are fully characterized by two out
of four elastic moduli: bulk modulus, shear modulus, Young’s modulus, and Poisson’s
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ratio.154 In our case, we use the shear and bulk moduli to describe the nonlinear relation-
ship between applied stress and strain of the neo-Hookean model of the prostate. These
were set at, respectively, 7.5 and 35 kPa (corresponding to a Poisson ratio of 0.40).141
Boundary conditions
Boundary conditions are required to deform the biomechanical model of the prostate. As
the surface displacements can be determined from the prostate contours in both modali-
ties, these will be used as boundary condition. The MR surface nodes were displaced to
match the deformed TRUS surface of the prostate. The surface node displacements were
derived from the corresponding surface meshes (SiMR and S
i
US) generated by the radial
surface projection algorithm described in Section 5.2.7. The spherical coordinates of the
surface nodes are converted to a Cartesian coordinate system. The nth surface node of
patient i now has the coordinates sinMR = (s
in
MR,x, s
in
MR,y, s
in
MR,z) and s
in
US = (s
in
US,x, s
in
US,y, s
in
US,z)
for SiMR and S
i
US, respectively. Surface displacements are calculated by
∆sin = sinUS − sinMR. (5.1)
These surface node displacements were then used as a boundary condition in the FE
simulation, thereby restricting the movement of the nodes. The simulation predicts the
displacement of the internal mesh nodes of ViMR and gives the locations of corresponding
internal nodes of ViUS.
5.2.9 Non-rigid surface-based registration
The non-rigid surface-based registration is based on a TPS deformation algorithm, which
aligns corresponding point sets. The 3D TPS deformation field is used for non-rigid
registration between the MR and TRUS images of the prostate. A corresponding point set
is formed by all volume mesh nodes, i.e. surface nodes and internal nodes, of the MR
volume mesh (ViMR) and the corresponding TRUS volume mesh (V
i
US). Correspondence
of surface nodes is created by radial surface projection and correspondence of internal
nodes is achieved by the biomechanical model. The resulting transformation (TBM) can be
applied to I¯iMR to achieve biomechanical modeling constrained non-rigid surface-based
registration to IiUS.
Our method was compared to a regular non-rigid surface-based method, which
also relies on the TPS deformation algorithm. In this case, only the corresponding
prostate surface mesh nodes (SiMR and S
i
US) were used for computing the TPS deformation
field, resulting in the non-rigid transformation TNR. This method does not require the
simulation step and therefore does not receive input from the biomechanical model.
5.2.10 Evaluation
Reference landmarks
Patient-specific anatomical landmarks were used as reference landmarks for the esti-
mation of the registration accuracy. These landmarks were identified manually by the
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Figure 5.4: Some examples of anatomical reference landmark points. The three columns show
reference landmarks in the corresponding MR images (top row) and TRUS images (bottom row) of
three different patients.
prostate researcher (W.J.M.v.d.V.) who also performed the segmentations. All landmarks
were checked by an interventional-radiologist (J.J.F.) with expertise in imaging techniques
in prostate cancer. Reference landmarks are anatomical structures visible in both MR and
TRUS images (examples in Figure 5.4). These are, for example, the urethra and the ducts
of the seminal vesicles, but also calcifications and cysts. Calcifications are hyperechoic
on the TRUS images and have a low intensity on the T2-weighted MR images; cysts are
hypoechoic on the US images and appear as high intensity features in the MR images.
The jth sets of 3D coordinates of the landmark points in patient i were recorded in both
I¯iMR and I
i
US as p¯
ij
MR = ( p¯
ij
MR,x, p¯
ij
MR,y, p¯
ij
MR,z) and p
ij
US = (p
ij
US,x, p
ij
US,y, p
ij
US,z), respectively.
A total of 35 reference landmarks in all regions of the prostate were annotated in both
MR and TRUS images to determine the TRE. These landmarks were divided over the ten
patients (Table 5.2). The mean distance (± standard deviation) of the landmarks to the
prostate center of gravity is 12.02± 3.86 mm with a range of 3.80− 19.93 mm.
Registration accuracy
The registration accuracy of the registration methods was evaluated by determining the
TRE. The TRE was defined as the 3D Euclidean distance between registered (obtained
from the deformed MR image I¯iMR) and real positions (obtained from the TRUS image I
i
US)
of corresponding pairs of reference landmarks. The initial TREijR for a given landmark
j of patient i can be calculated after rigid alignment of IiMR and I
i
US. The regular non-
rigid surface-based registration will provide TREijNR, and our biomechanical modeling
constrained non-rigid surface-based registration TREijBM.
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The TREijm for method m being either R for rigid, NR for non-rigid, or BM for biome-
chanical modeling constrained registration is
TREijm = ‖dijm‖ =
√
(dijm,x)2 + (d
ij
m,y)2 + (d
ij
m,z)2, (5.2)
where
dijR = (p
ij
US − p¯ijMR), (5.3)
dijNR = (p
ij
US − TNR(p¯ijMR)), and (5.4)
dijBM = (p
ij
US − TBM(p¯ijMR)). (5.5)
Statistical analysis
Statistical analyses were performed using RStudio155, the R package ‘nlme’ was used
for linear mixed effects modeling.156 Linear mixed effects statistical method can model
both fixed and random effects and handle repeated measurements. These effects can be
statistically evaluated using one test instead of less powerful multiple tests. We used
a linear mixed effect model to evaluate the effect of the number of elements, nodes,
and surface points on the TRE. Significant differences between the different registration
methods were also determined by a linear mixed effect model. For the model, we
considered the number of elements, nodes, and surface points as fixed effects. The
landmarks were considered random effects. The TREs were evaluated against all these
effects in one linear mixed effect model, giving p−values for each of the effects.
5.3 Results
Figure 5.5 shows some example cases with the reference position of the anatomical
landmarks on MR and TRUS images of the prostate. The registered position of the
landmarks after applying both registration methods is indicated in the TRUS image
as well. These cases and others show that the TRE is smaller when biomechanical
regularization was applied.
We evaluated the effect of the number of elements, nodes, and surface points on
the registration accuracy for both the regular surface-based registration method and
our biomechanical constrained registration method. In total, we performed 360 simu-
lations for all ten patients. Some simulations diverged due to inadequate mesh quality
(1706/3600). Also, the more complex meshes with more elements can lead to divergence.
This can be solved by reducing the time step, which we did not do in this study. We were
able to calculate a TRE on reference landmarks 8354 times. For these converging simula-
tions, the number of elements varied between 33 and 3632, the number of nodes between
19 and 681, and the number of surface points between 18 and 218. On a landmark basis,
we determined whether the number of elements, nodes, or surface points had an effect on
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Figure 5.5: Examples from two different patients showing the real and registered positions of reference
landmarks. Each of the two rows contains corresponding MR and TRUS images of the prostate of
one patient. The left column shows the prostate MR image with an internal anatomical prostate
landmark in red. The middle and right images show the corresponding prostate TRUS images of that
patient where the yellow squares indicate the real positions of the reference landmarks and the red
squares indicate the registered positions. The middle column shows the results of the regular non-rigid
surface-based registration method and the right column of the biomechanical constrained registration
method. Both cases show that the biomechanical model decreased the distance between the yellow
and red squares (the TRE) and thus improved the registration accuracy. The example in the top row
has a more accurate registration accuracy than the example in the bottom row for both registration
methods.
the TRE and whether the biomechanical model improved the accuracy of the non-rigid
registration method. A linear mixed effects model showed no significant difference for
either of the mesh variables (p > 0.35), but did show that the biomechanical constrained
registration method was significantly better than the regular non-rigid surface-based
registration method (p < 0.001).
The results with the mesh characteristics in Table 5.1 were used for more in-depth
analysis. For each patient, the TREs of the landmarks determined by the initial rigid and
the non-rigid surface-based registration with and without biomechanical regularization
are shown in Table 5.2. The overall median TRE of the initial rigid registration method
was 3.64 mm (range 0.72− 8.95 mm). The median TRE of the non-rigid surface-based
registration without biomechanical regularization was 3.47 mm (range 1.05-7.80 mm).
The overall median TRE of the non-rigid surface-based registration method extended
with biomechanical regularization was 2.76 mm (range 0.81-7.96 mm). The Bland-Altman
plot in Figure 5.6 shows the differences versus the averages of the non-rigid method with
and without biomechanical modeling on a pairwise basis. The mean difference is −0.31,
indicating that on average, the TRE of the biomechanical modeling is smaller than the
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Table 5.1: Characteristics of the prostate volume meshes obtained with an element volume bound of
0.15 ml and a course surface mesh representation. For each patient, the prostate volumes (determined
by calculating voxels in segmented MR and TRUS images) are shown. Also, the number of elements,
nodes, and surface points are indicated for the tetrahedral meshes of the prostate. The last column
indicates the minimum and maximum displacements of the surface points. MR images of patients 2, 3,
4, and 8 were taken with an endorectal coil.
Patient Prostate volume (cm3) No. of
elements
No. of
nodes
No. of surface
points
Range of surface
displacements (mm)MR TRUS
1 55 54 226 71 54 1.0− 10.1
2 22 26 47 23 22 0.5− 5.01
3 41 48 130 46 38 1.3− 6.41
4 28 22 67 30 28 1.4− 8.41
5 52 48 165 57 47 2.1− 10.5
6 36 34 137 50 42 2.1− 7.21
7 32 40 117 42 34 3.2− 13.9
8 36 36 159 55 46 1.1− 4.51
9 48 53 222 64 44 1.4− 7.41
10 54 54 259 72 50 2.9− 8.41
Table 5.2: Median TREs computed for registrations using the initial rigid registration method (R), the reg-
ular non-rigid surface-based registration method (NR), and the biomechanical modeling constrained
surface-based registration method (BM).
Patient No. of landmarks Initial TRER (mm) Final TRENR (mm) Final TREBM (mm)
1 5 12.87 12.15 12.37
2 2 3.80 3.27 3.35
3 4 2.75 3.26 3.18
4 3 4.78 2.99 3.39
5 2 5.72 5.03 4.52
6 5 4.31 2.43 2.13
7 5 3.09 4.92 2.75
8 2 4.16 3.90 3.87
9 3 2.75 2.73 2.76
10 4 4.61 5.24 3.79
All (range) 35 3.64 (0.72− 8.95) 3.47 (1.05− 7.80) 2.76 (0.81− 7.96)
Mean ± std 4.06± 2.20 3.93± 2.08 3.62± 2.13
regular non-rigid method. Also, the correlation of the TRE with the distance to the center
of gravity is shown (Figure 5.7).
5.4 Discussion
Our biomechanical modeling constrained registration method has a median registration
accuracy of 2.76 mm. The results are comparable with the results reported by Hu et al. 125
In their study, the median TRE is 2.40 mm after a deformable ’model-to-image’ registra-
tion of MR and 3D TRUS images of the prostate. The biomechanical model significantly
improved the regular non-rigid surface-based registration method and was also signifi-
cantly better than the initial rigid registration, especially in strongly deformed shapes.
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Figure 5.6: A Bland-Altman plot showing the differences versus the averages of the non-rigid method
with (BM) and without (NR) biomechanical modeling on a pairwise basis. The points correspond to the
35 landmarks. The middle blue line indicates the mean difference and the top and bottom lines the
95% limits of agreement.
Distance to CoG (mm)
TR
E 
(m
m)
Rigid registration
Non−rigid registration
With biomechanical regularization
0 5 10 15 20
0
2
4
6
8
10
12
Figure 5.7: Scatterplot showing the TRE versus the distance to the prostate CoG of the initial rigid
(orange) and the non-rigid surface-based registration with biomechanical regularization (green) and
without biomechanical regularization (blue). Points corresponding to the same landmark can be
found on one vertical line and are distinguished by the use of different symbols.
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Our method is based on prostate contour information and can thus be applied to MR
images with or without endorectal coil.
We compared our biomechanical modeling constrained method with the non-rigid
surface-based registration algorithm published by Karnik et al. 121 They do not use a
biomechanical model to account for prostate deformations. Karnik et al. 121 applied the
non-rigid surface-based method to US-US registration and compared it to rigid surface-
based registration as well as rigid and non-rigid image-based registration. Images were
obtained at the beginning and end of the biopsy procedure. The mean TRE they found
for the non-rigid surface-based registration was 2.09 mm. This is slightly better than our
method, but this can be explained by the fact that images are from the same modality
(both US) and taken only minutes after each other.
Our registration method extends the regular non-rigid surface-based method of
Karnik et al. 121 with the biomechanical model published by Hu et al. 125 Our method
differs from that of Hu et al. 125 in that the biomechanical model is now applied to the
more common transrectal MR guided TRUS biopsies instead of transperineal biopsies.
Hu et al. 125 performed 500 simulations per patient to create a statistical motion model
which is used for a model-to-image registration. We create a prostate-shape specific
biomechanical model of the prostate for each patient and the results of the modeling step
are used in the final TPS based non-rigid registration step. Our intention is to do only
one simulation per patient and include specific knowledge of surface displacements. Our
purpose was to show that a regular non-rigid method can be easily adapted by adding a
biomechanical FE model which significantly improves the registration accuracy.
The distribution of reference landmarks with respect to the prostate center of gravity
varies between 3.80 and 19.93 mm. The larger TREs correspond to landmarks that are
further away from the center of gravity, probably caused by the prealignment of the
centers (Figure 5.7). In case the prealignment is not optimal, this will cause a larger error
further away from the center. In Table 5.2 it can be seen that for patient 3, the initial
rigid registration performs better than any of the two non-rigid methods. This might be
explained by the small deformation of the prostate in this patient. Also, for patients 7 and
10, the median TRE of the rigid registration is better than that of the regular non-rigid
registration. This is mainly caused by the landmarks in the center of the prostate where
the rigid method outperforms the regular non-rigid method. For the landmarks that are
closer to the surface, the non-rigid method is better. However, for these two patients, the
biomechanical regularization does improve the non-rigid registration and gives smaller
median TREs than the rigid registration method.
The divergence of simulations may be solved by reducing the time step slightly
or changing the meshing parameters. Varying the number of elements, nodes, and
surface points did not have a significant effect on the registration accuracy of either the
regular non-rigid registration or the biomechanical modeling constrained registration
method. This means that the mesh characteristics do not matter and the results are
parameter independent. Regardless the number of elements/nodes/surface points, the
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biomechanical modeling did significantly improve the registration accuracy of the regular
non-rigid surface-based registration method.
We have recently shown that for correctly Gleason grading 95% of the tumors, a
registration accuracy of 1.9 mm is required.130 By taking more than one biopsy from the
same target, the probability of hitting the tumor can be increased. For our method with
an accuracy of 2.76 mm, two or three biopsies would be sufficient for having a reasonable
chance of hitting the tumor. This hit-rate depends on the volume of the target. When
assuming the hotspot volume distribution published in Van de Ven et al.,130 the hit-rate
will be 85.2%, 97.8%, and 99.7% for 1, 2, and 3 biopsies, respectively. The regular non-rigid
registration method has a lower hit-rate, being 75.1%, 93.8%, and 98.5% for 1, 2, and 3
biopsies, respectively. The increased accuracy thus allows for less biopsies to achieve 95%
correct grading.
Clinical implementation of MR guided TRUS biopsy does, however, not only require
accurate segmentation and registration. As is the case for any MR guided biopsy tech-
nique, good quality MR image and image interpretation are essential for carrying out
the biopsy procedure in clinic.157 Minimal requirements for multiparametric prostate
MR image acquisition and standardization for reporting (PI-RADS) have recently been
published,85 which will help to improve the general reliability of the techniques.
A limitation of a surface-based registration method is that it depends on prostate
segmentation, which is time consuming and operator-dependent. Inaccurate segmenta-
tion of either of the two images would negatively affect the registration accuracy. It was
found that the interobserver variability of MR prostate segmentation had a median Dice
similarity coefficient (DSC) of 0.87.158 Automatic segmentation would speed up the pro-
cess of segmentation and also limit the interobserver variability. But, automatic prostate
segmentation is challenging for both MR and TRUS images159. The PROMISE12 challenge
(http://promise12.grand-challenge.org/) compares some recently published meth-
ods in prostate MR segmentation.160 Participating algorithms showed a wide variety in
methods and implementation, and average performance was good. However, automatic
segmentation of the prostate is also not optimal yet and challenges in segmentation still
remain. PROMISE12 showed that a combination of algorithms yielded better results, so
individual segmentation algorithms can still be improved.
Another limitation is that the radial surface projection assumes a similar prostate
orientation between MR and TRUS images. A rigid registration step is crucial for this
aspect. Our rigid registration strategy incorporated both translational and rotational
corrections. It automatically aligns the centers of mass and then optimizes translation
and rotation in 3D using the sum of squared differences. By aligning the centers and
optimizing translation and rotation, we tried to optimize the rigid registration as well
as possible, but small misalignments might still be there. Any misalignment will affect
the further steps taken in our registration method. Including landmark information may
be a possible way to improve the initial rigid registration and is something to explore in
future work.
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The registration accuracy is estimated by determining the TRE of corresponding
reference landmarks in both MR and TRUS images. The correct placement of these
landmarks is therefore crucial. A variability in locating landmarks will exist leading to a
certain localization error. To minimize this effect, the positions of all reference landmarks
were checked by a radiologist. However, a localization error might remain influencing
the registration accuracy.
Biomechanical models can potentially improve the registration accuracy if accurate
mechanical properties and boundary conditions can be obtained, as stated by Chi et al. 161
Obtaining tissue properties is difficult and limited due to technical difficulty in the
calibration of material parameters and the availability of (in-vivo) human tissue for testing.
On top of that, the mechanical properties of one organ can be quite different among
patients. It also is known that the different zones of the prostate (peripheral and transition
zones) have a different stiffness and that tumors are usually stiffer than normal prostatic
tissue.162 We assumed similar uniform elastic properties for the whole prostatic organ
for each patient. The registration accuracy can considerably be affected by the material
uncertainty (around 30%161). Our registration method might be improved by enhancing
the biomechanical model of the prostate and/or expanding the model with more organs.
The model can be made more patient-specific by determining elastic properties on an
individual patient basis, e.g. by means of elastography.
A current development in research focuses on the registration of prostate MR images
with histology step sections from prostatectomy specimens.163,164 We have already shown
before that the biomechanical constrained surface-based registration method can be
applied to MR-MR image registration.146 As our method is only based on prostate
contour information, it may be adapted and applied to MR-histology registration as well.
5.5 Conclusions
In this paper, we have shown that biomechanical regularization significantly improves
a surface-based prostate registration method. Our method extends a non-rigid surface-
based registration method with a biomechanical FE model which is able to better predict
the internal deformation of the prostate. The median TRE of our method was 2.76 mm,
which was significantly better than a median TRE of 3.47 mm obtained without using
biomechanical regularization. These results are comparable to the previous findings on
non-rigid surface-based registration121 and biomechanical modeling based non-rigid
registration.122
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Abstract
Objectives: To determine TRUS visibility of MR lesions.
Methods: Data from 34 patients with 56 MR lesions and prostatectomy was used. Five
observers localized and determined TRUS visibility during retrospective fusion. Visibility
was correlated to PIRADS and Gleason scores.
Results: TRUS visibility occurred in 43% of all MR lesions and 62% of PIRADS 5 lesions.
Visible lesions had a significantly lower localization variability. On prostatectomy, 58% of
the TRUS visible lesions had a Gleason 4 or 5 component.
Conclusions: Almost half of the MR lesions were visible on TRUS. TRUS visible lesions
were more aggressive than TRUS invisible lesions.
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6.1 Introduction
Currently, the most commonly used method to diagnose prostate cancer is transrectal
ultrasound (TRUS) guided biopsy. Localization of malignant tissue on TRUS is, however,
difficult because most lesions are not visible.23 TRUS guided biopsy is therefore at
random and can miss or undersample aggressive tumours and detect indolent cancers by
chance.60,61
Multiparametric (mp)-MR imaging has shown to be highly accurate in detecting and
localizing intermediate and highly aggressive cancers.73,75,76 Recently, a standardized
Prostate Imaging-Reporting and Data System (PIRADS) to detect intermediate and high-
grade cancers on mp-MR imaging was introduced,85 which showed to improve diagnostic
accuracy.88,89
Targeted MR image guided biopsy techniques are a very promising alternative to
systematic TRUS guided biopsy. In this respect, many different techniques are rapidly
emerging, including direct in-bore MR, computer-assisted MR-TRUS fusion, and cognitive
MR-TRUS fusion guidance. All of these techniques use prebiopsy MR imaging to define
potential lesions for targeted biopsy. However, not all of them are equally accurate.110
The first technique is in-bore MR targeted biopsy, which has been shown to signifi-
cantly increase the tumour detection rate compared to systematic TRUS guided biopsy
especially for the clinically significant tumours94 and reduces TRUS undergrading of
aggressive tumours.98 The second and potentially more accessible and practical solution
is computer-assisted MR guided TRUS fusion biopsy.108 Clinical studies show that tar-
geted prostate biopsy using MR-TRUS fusion has an increased tumour detection rate
especially for clinically significant tumours.111,112,126–129,165–167 The third technique is
cognitive targeting. Reported results are contradictory.111,112 As the accuracy of cognitive
fusion strongly depends on the skills of the operating physician, it is likely that this
technique is only effective in the hands of a TRUS and MR expert.
We noted that some MR detected lesions are retrospectively visible on TRUS. These le-
sions may, therefore, be more accurately targeted on both computer-assisted and cognitive
MR-TRUS fusion biopsies. These TRUS visible lesions may even be successfully targeted
solely on TRUS, thereby providing more representative biopsy cores. A recent study by
Ukimura et al. 168 showed that TRUS visibility may indeed facilitate targeted biopsies.
However, they did not look at the visibility of lesions on TRUS with prior knowledge
of MR appearance and PIRADS score. They also did not investigate correlation with
Gleason scores. Knowledge on correlation of TRUS visibility with PIRADS and Gleason
scores will help to predict whether the lesion requires a biopsy and to predict if a lesion
will be visible on TRUS images. Our study is a first step to gather knowledge on TRUS
lesion visibility.
The aim of this retrospective observer study was to determine the proportion of MR
suspicious lesions that are visible on TRUS.
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6.2 Patients and methods
6.2.1 Patient selection
Data in this study was collected retrospectively from the data of the Radboudumc within
the ongoing Prostate Cancer Molecular Medicine (PCMM) project. The PCMM project is
a multi-center study focusing on prostate cancer detection. The inclusion criteria for the
PCMM study were patients with localized prostate cancer confirmed by biopsy who were
scheduled for radical prostatectomy in our institution. The Institutional Review Board
approved the study, and all patients gave their written informed consent.
Between December 2010 and August 2013, 48 consecutive PCMM patients diagnosed
with prostate cancer at our centre were included. Fourteen patients did not have a TRUS
or prostatectomy. In the remaining 34 patients, a total of 56 lesions were prospectively
detected on mp-MR imaging. For those 56 lesions, prostatectomy results were available.
6.2.2 MR imaging
In all patients mp-MR imaging was performed according to the ESUR guidelines85 using
a 3T MR-scanner (MAGNETOM Trio or Skyra; Siemens, Erlangen, Germany) either with
a pelvic phased-array coil or a combination of an endorectal and pelvic phased-array coil.
The mp-MR imaging protocol included anatomical T2-weighted images in axial,
coronal, and sagittal planes. Axial DWI was acquired and apparent diffusion coefficient
(ADC) maps were automatically calculated. Dynamic contrast-enhanced (DCE)-MR
images were obtained using a gadolinium-based contrast agent.
One expert radiologist with 20 years of experience in prostate MR image interpretation
evaluated the images, using structured PIRADS reporting.85,169,170 To assess the final
score a ‘dominant sequence weighting’ was used, being DWI for peripheral zone and
T2-weighted imaging for transition zone.
6.2.3 TRUS imaging
The PCMM project involved collecting TRUS images for study purposes. TRUS images
were collected after MR imaging and the performing physician was aware of the MR
results. The TRUS images were acquired on a Toshiba Aplio XG/Aplio 500 machine
(Toshiba Medical Systems, Japan) using a 4D end-firing transrectal transducer (Toshiba
PVT-681MV; Toshiba Medical Systems, Japan) containing an internal, automatically
tiltable convex element producing wedge shaped 3D volumes. The 3D grey-scale TRUS
images of the prostate were acquired with a scanning angle of 70°/90°and an acquisition
rate of 0.1/0.2 volumes per second. The 3D raw image data was exported from the US
machine and converted from a polar to a Cartesian representation with an isotropic voxel
size of 0.2 mm.
6.2.4 Histopathology
After radical prostatectomy, prostate specimens were uniformly processed and entirely
submitted for histological investigations. After histological staining, all specimens were
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evaluated by one of two expert urological pathologists, one with 20 years of experience
and one with 8 years of experience. The entire tumour volume was outlined on each step
section. Each individual tumour was graded according to the 2005 International Society
of Urological Pathology Modified Gleason Grading System36 and staged according to the
2002 TNM classification.
6.2.5 Observer experiment
The anonymized mp-MR images and grey-scale TRUS images were shown retrospectively
in identical order to 5 observers, who analysed the images independently. The PIRADS
scores of all MR lesions were visible. Observers were aware that patients were scheduled
for radical prostatectomy, but did not have knowledge of the pathology outcomes. The
observers varied in expertise: 2 observers were researchers with experience in prostate
image analysis and MR-TRUS fusion biopsies; 1 observer was a urologist performing
MR-TRUS fusion biopsies; and 2 observers were radiologists experienced in prostate
MR imaging, one performing MR-TRUS fusion biopsies, the other radiologist had no
experience in prostate ultrasound.
All observers were asked to determine the visibility of prostate lesions on pre-recorded
3D TRUS images using an interactive in-house developed tool installed on a desktop
in a lit office. Each of them had to perform cognitive fusion of MR and TRUS images.
Three orthogonal views of the TRUS images were presented, and the observers had
the possibility to translate and rotate the TRUS images around the three axes to allow
cognitive fusion. Scrolling, zooming, and window levelling could be adjusted manually
to optimize visibility.
The observers were asked to mark the centre of the location of all 56 lesions on TRUS
(example shown in Figure 6.1). All readers assigned a 5-point visibility score to each of
the lesions (1: definitely not visible; 2: probably not visible; 3: uncertain; 4: probably
visible; 5: definitely visible). If the prostate could not be fully displayed due to restrictions
of the TRUS probe, the observer could pick a sixth option ‘out of view’.
6.2.6 Data analysis
Statistical proportion analysis was performed to determine the amount of lesions visible,
subdivided into PIRADS score and index lesions (i.e. most aggressive lesions) only.
The proportion of visible lesions for different PIRADS assessments was determined
including the 95% confidence intervals. A lesion was considered visible if at least three of
the five observers scored a 4 or 5 on the 5-point visibility scale.
The observer variability of the tumour location on TRUS was determined by calculat-
ing the distance to the mean location as pointed out by the observers. A small distance is
likely to be an indication for a good localization of the lesion on TRUS during biopsy.
The averaged localization distances are grouped according to PIRADS and visibility
score. An analysis of variance (ANOVA) is performed to determine significance.
6
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(a)
(b)
Figure 6.1: (a) Multiparametric MR images showing a PIRADS 5 lesion (indicated by the blue arrow).
(b) Corresponding ultrasound image. Visibility score of the lesion was 5 for all observers.
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Table 6.1: Summary of patient demographics.
Parameter Value
No. of patients 34
Median age (y) 63 (50− 70)
Median PSA (ng/mL) 8.0 (2.5− 30.0)
Median Gleason score 7 (4− 9)
Clinical stage
- T2 22
- T3 12
Each MR lesion was correlated to the pathology outcomes by means of visual in-
spection of the corresponding prostatectomy specimen and Gleason scores were noted.
The pathology outcomes were grouped by visibility of the lesion on TRUS images to
investigate whether TRUS visibility correlates with Gleason score.
Differences were considered to be significant when p < 0.05. Statistical analyses were
performed with Matlab (The Mathworks, Inc., Nattick, MA, version 7.14.0).
6.3 Results
MR and TRUS images were collected in 34 patients. They had a median age of 63 years
and a median PSA of 8.0 ng/mL (Table 6.1). In total, 56 lesions were detected on the
mp-MR images. PIRADS 5 was present in 61%, PIRADS 4 in 14%, PIRADS 3 in 5% and
PIRADS 2 in 20% (Table 6.2). Of the PIRADS 2 lesions, 55% was not the most suspicious
(index) lesion.
Of all lesions, 43% (24/56) were assessed as visible (score 4 or 5) on TRUS by at least
3 observers. When only index lesions were taken into account, 56% (19/34) were visible.
Of the PIRADS 4 and 5 lesions, 55% (23/42) were visible on TRUS. For PIRADS 5 lesions
this was 62% (21/34). One of the PIRADS 4 lesions was ‘out of view’ according to 4 of
the 5 observers, and therefore also considered ‘invisible’. The results and 95% confidence
intervals are provided in Table 6.2 and Figure 6.2.
The MR detected lesions were predominantly located in the peripheral zone (47/56).
Of these lesions 47% (22/47) were visible on TRUS. Of the remaining nine transition zone
lesions two (22%) were visible on TRUS.
The overall localization variability of lesions, expressed as the distance to the mean
location, on TRUS varied from 0.4 − 18.7 mm (mean 4.9 ± 3.2 mm), when averaged
between the observers the range was 0.4− 8.6 mm. Larger distances corresponded to a
lesion considered not visible by one or more observers, the localization variability for
the visible lesions was 2.1 mm. Boxplots showing the averaged distances per lesion
grouped according to their PIRADS classification and mean visibility score are shown in
Figure 6.3. Visibility score shows a strong correlation with the distance, i.e. visible lesions
have a lower variability. An ANOVA showed a significant difference (p = 0.016) for the
localization variability grouped according to mean visibility score, but not for PIRADS
classification (p = 0.378).
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Table 6.2: Distribution of PIRADS scores for MR lesions and visibility per PIRADS score.
PI-RADS Amount Number visible Visibility (95% CI)
1 10 10 -
2 11 11 9.1%(1.6− 37.7%)
3 13 10 0.0%(0.0− 56.2%)
4 18 12 25.0%(7.2− 59.1%)
5 34 21 61.8%(45.0− 76.1%)
Index lesion 34 19 55.9%(39.5− 71.1%)
All 56 24 42.9%(30.1− 55.9%)
Figure 6.2: Tumour visibility on TRUS according to PIRADS score, with additional categories for index
and all lesions. Proportion (%) including 95% confidence intervals is shown as error bars.
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Figure 6.3: Mean distances of the tumour location on ultrasound grouped according to (a) PIRADS
classification and (b) mean visibility score.
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Table 6.3: Distribution of Gleason scores (GS) grouped according to the visibility of the tumour on TRUS.
Negative GS 4 GS 5 GS 6 GS 7 GS 8 GS 9
3 + 4 4 + 3
Visible 12 0 2 16 17 5 0 2
Invisible 12 1 4 14 14 3 2 2
Total 14 1 6 10 11 8 2 4
The distribution of Gleason scores for visible and invisible tumours is shown in
Table 6.3 and summarized in Figure 6.4. Of the TRUS visible tumours, 58% (14/24) were
Gleason 7 or higher on prostatectomy and 83% (20/24) had a Gleason 6 or higher (see
Figure 6.4). Of the lesions that were not visible on TRUS, this was 34% (11/32) and
47% (15/32), respectively. Of the TRUS invisible lesions, 38% (12/32) were negative on
prostatectomy specimen, for the visible tumours this was only 8% (2/24).
6.4 Discussion
In our study we found that 43% of the MR detected lesions were considered visible on
TRUS. In PIRADS 4 and 5 lesions this was the case in 55%. For the PIRADS 5 lesions the
TRUS visibility increased to 62%. Thus more than half of the potential biopsy targets can
be visible on TRUS when using the information from mp-MR imaging. For these cases
and especially the PIRADS 5 cases, any targeted TRUS guided biopsy method will benefit
from TRUS lesion visibility, increasing the chance of obtaining a representative biopsy.
To our knowledge, our study is the first to investigate the visibility of prostate lesions
on TRUS with prior knowledge of mp-MR images. There are publications on the incidence
of hypo-, hyper-, and isoechoic lesions in TRUS guided biopsies, and also on targeted
biopsies based on ultrasound appearance.59,171–173 Hypoechoic areas have a 17− 57%
Figure 6.4: Distribution of the pathology outcomes for lesions that were visible and not visible on TRUS
images.
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chance of being cancer.23 Targeting all hypoechoic nodules will therefore result in a
relatively low cancer detection rate, so it is important to know which are suspicious.
Our results show that it may be possible to use prior knowledge of mp-MR imaging for
selecting the hypoechoic lesions that require biopsy while indicating other hypoechoic
areas that may be ignored. However, further research is required to determine if this is
indeed possible. Also, more radiologists with different levels of expertise should then be
included to investigate how this affects the results.
The location of the tumour on TRUS was well reproducible between observers. When
averaged between observers, distances to the mean location per lesion varied between
0.4− 8.6 mm. Most of the distances were well below the clinically significant tumour
size (diameter of 10 mm). Larger distances were seen if an observer scored a 1 or 2 for
visibility on TRUS. The observers agreed significantly better on the location of the visible
lesions. The visible lesions may thus be accurately targeted with MR-TRUS fusion biopsy.
More than half of the TRUS visible tumours corresponded to Gleason 7 or higher,
indicating that these contain a Gleason 4 or 5 component. Only one third of the invisible
lesions had Gleason 7 or higher, and the remaining one third was negative on prostatec-
tomy. Therefore, we can conclude that intermediate- and high-grade prostate cancer is
better visible on TRUS images compared to low-grade prostate cancer. Our data included
two Gleason 8 lesions, which were not visible on TRUS. A potential explanation for this
TRUS invisibility might be that both lesions were Gleason 3 + 5 = 8. Also, one of them
was not suspicious on mp-MR imaging (PIRADS 2), the other one was scored as PIRADS
5.
The ability to predict the TRUS visibility from MR suspiciousness would allow these
lesions to be targeted with regular TRUS devices without fusion, or enhance the accuracy
of cognitive or computer-assisted fusion systems. The visible lesions may be targeted
under (direct) TRUS guidance and thus are less dependent on the registration accuracy.
For the lesions that are not visible on TRUS, one can consider an in-bore MR guided
biopsy or a computer-assisted MR-TRUS fusion system (depending on the size of the
lesion130).
Our results are in line with a recent study where fusion biopsy is investigated includ-
ing TRUS suspicion.168 In that study it was shown that TRUS visibility facilitates targeted
biopsies leading to a higher detection rate of significant cancer compared to systematic
TRUS guided biopsies. MR and TRUS images were assessed independently from each
other and cancer suspiciousness was determined on a 3-point scale. MR suspicion corre-
lated with TRUS suspicion and combining both will help to select the most suspicious
lesions. Ukimura et al. 168 did not look at the distribution among Gleason scores, for
which we show that TRUS visible lesions are also more aggressive than TRUS invisible
lesions.
A limitation of our study is that it has a selection bias; the data only contains patients
who are scheduled for a prostatectomy. This thus does not represent the patient pop-
ulation with elevated PSA referred to detect their significant cancer. We can therefore
6.4 Discussion 79
not draw a conclusion on overall US visibility for a regular clinical biopsy cohort, which
may include smaller, lower-grade tumours and benign conditions. The number of lesions
visible on TRUS may in this population be slightly lower. Also, the observers were aware
of patients being scheduled for prostatectomy and had knowledge of the PIRADS scores.
Another limitation is the small number of patients, thus this study needs to be confirmed
by other studies with higher number of patients. Nonetheless, the results are promising
and significant.
The observers were provided with pre-recorded 3D TRUS images. Although they
were able to scroll through the prostate volume, they could not handle the probe them-
selves and assess ‘live’ images. The TRUS images of the prostate often contain artefacts
around urethra and bladder, which might be reduced when moving the probe during
TRUS examination. In some cases a lesion might not be visible due to TRUS artefacts,
especially if it is located in the anterior part of the prostate. A lesion that is not visible on
the pre-recorded images may be visualized better during ‘live’ TRUS. The proportion of
visible tumours might then slightly increase.
In conclusion, we have shown that more than half of the lesions detected on mp-MR
imaging were visible on TRUS, for PIRADS 5 this was almost two thirds. TRUS lesion
visibility may help to improve finding the correct target location during MR guided TRUS
biopsy (both cognitive and computational fusion). Also, TRUS visible lesions appeared to
be more aggressive than invisible lesions; more than half of the visible lesions contain a
Gleason 4 component or higher.
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Abstract
Purpose: To evaluate MR targeted TRUS prostate biopsy using a novel local reference
augmentation method.
Patients and methods: Tracker based MR-TRUS fusion was applied using local reference
augmentation. In contrast to conventional whole gland fusion, local reference augmen-
tation focuses the highest registration accuracy to the region surrounding the lesion to
be biopsied. Pre-acquired multi-parametric MR images (mpMRI) were evaluated using
PIRADS classification. T2-weighted MR images were imported on an ultrasound machine
to allow for MR-TRUS fusion. Biopsies were targeted to the most suspicious lesion area
identified on mpMRI. Each target was biopsied 1− 5 times. For each biopsied lesion the
diameter, PIRADS and Gleason scores, visibility during fusion, and representativeness
were recorded.
Results: Included were 23 consecutive patients with 25 MR suspicious lesions, of which
11 patients had a previous negative TRUS guided biopsy and 12 were biopsy naïve. The
cancer detection rate was 64% (Gleason score ≥ 6). Biopsy was negative (i.e. no Gleason
score) in 7 patients confirmed by follow-up in all of them (up to 18 months). After MR-
TRUS fusion, 88% of the lesions could be visualized on TRUS. The cancer detection rate
increases with increasing lesion size, being 73% for lesions larger than 10 mm.
Conclusion: Tracker based MR-TRUS fusion biopsy with local reference augmentation
is feasible, especially for lesions with an MR maximum diameter of at least 10 mm or
PIRADS 5 lesions. If this is not the case, we recommend in-bore MR guided biopsy.
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7.1 Introduction
A PSA test followed by systematic (on average 12 core) transrectal ultrasound (TRUS)
guided biopsy (USgBx) is the currently internationally accepted diagnostic procedure
to detect prostate cancer and determine patient management.28 TRUS cannot localize
malignant tissue and is merely used to guide systematic biopsies. USgBx has a low
sensitivity (40%),30,60,61 causing three problems: 1) significant cancers can be missed
or underestimated; 2) there is unnecessary overtreatment due to overdiagnosis;62,64,98
and 3) it may lead to repeat biopsies inducing increased infection rates.174 Therefore,
multi-parametric MR imaging and MR guided biopsy might be a better alternative.
Multi-parametric MR imaging (mpMRI) has recently emerged as a diagnostic tech-
nique that can accurately localize significant cancer in the prostate.75,76 In-bore MR
guided MR biopsy (MRgMRBx) has been shown to 1) reduce the detection of low-risk
cancer; and 2) increase the detection rate of intermediate and high-risk cancer, while using
fewer cores.104 However, the associated cost, relative complexity, and inconvenience of
MRgMRBx may prevent widespread adaption in clinical practice. An alternative biopsy
method for MR guided biopsy would be welcome.
MR guided TRUS fusion biopsy (MRgUSBx) has recently emerged.107,115,125 This
allows to combine the high accuracy of mpMRI with the ease and accessibility of TRUS.
However, for 95% correct Gleason grading, a 1.9 mm accurate spatial registration of MR
and US is required.130 Most MRgUSBx devices do not achieve this accuracy in practice
(3− 6 mm116,125). Accuracy can be slightly increased by taking one or more additional
cores.175
Two MRgUSBx strategies can be distinguished: cognitive and computational fusion.
The fastest and simplest form of computational fusion is tracker based rigid registration,
using an electro-magnetic (EM)-tracker.111,112 An EM-tracker attached to a TRUS probe
tracks its position and orientation allowing to link a live TRUS image to a prerecorded
MR image. We previously performed a phantom study on EM-tracker registration and
estimated the registration accuracy in 3D to be 5− 7 mm.176 Current rigid MR-TRUS
fusion protocols focus on optimizing accuracy for the entire gland volume. Due to
prostate deformation, the registration accuracy can never be optimal within the whole
gland. By restricting the registration to the partial gland volume surrounding the lesion,
a more consistent and possibly better registration accuracy can be achieved within this
partial volume containing the lesion. The EM-tracker approach we use in our study
allows to do this quickly, which, combined with visual feedback, can lead in a few
iterations to an augmented, focal match of TRUS and MR imaging. We propose a novel
protocol to augment the accuracy locally by selecting reference landmarks on both MR
and TRUS images that are close to the biopsy target,177 which we refer to as local reference
augmentation in analogy to all-weather aircraft landing systems.
The aim of this study is to evaluate our novel EM-tracker MR-TRUS fusion biopsy
protocol using local reference augmentation in regular clinical practice. To our knowledge,
this is the first report on a locally optimized MR-TRUS fusion biopsy method. We will
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explore the capability of sampling mpMRI suspicious lesions and get insight into the
representativeness of the biopsy result. Additionally, we will determine the proportion of
tumors confidently visible on TRUS after fusion.
7.2 Patients and methods
7.2.1 Patient population
Inclusion criteria for our study were patients scheduled for MRgUSBx who had an mpMRI
showing a lesion scored as PIRADS ≥ 4, or PIRADS 3 lesion with additional clinical
suspicion (e.g. unusually high PSA, persistent rising PSA). Biopsy was performed at the
Radboudumc (Nijmegen, The Netherlands) or at the ZGT (Hengelo, The Netherlands).
The study was approved by the Institutional Review Board of the Radboudumc for MR
lesions > 9 mm, and all included Radboudumc patients gave their written informed
consent. The requirement to obtain Institutional Review Board approval was waived at
ZGT as MRgUSBx was their regular clinical procedure in prostate cancer diagnosis. Our
data set contains all patients included at the Radboudumc and ZGT between September
2013 and October 2014.
7.2.2 Multi-parametric magnetic resonance imaging
Prostate imaging mpMRI sequences were compliant to the ESUR guidelines85 and in-
cluded three orthogonal T2-weighted, diffusion weighted, and dynamic contrast en-
hanced (DCE) series. Apparent diffusion coefficient (ADC) maps were calculated by the
scanner. DCE used a gadolinium-based contrast agent. Preferentially, we also added a
3D T2-weighted sequence with an isotropic resolution of 1 mm for MRgUSBx. Images
of the entire prostate gland and seminal vesicles were obtained using a 3 Tesla MRI
scanner (MAGNETOM Trio or Skyra; Siemens, Erlangen, Germany) with either a pelvic
phased-array coil or a combination of an endorectal and pelvic phased-array coil.
Several prostate radiologists prospectively evaluated the mpMRI in a regular clinical
setting, using structured reporting with the ESUR standardized PIRADS classification.85
The location of each lesion was stored on an in-house developed mpMRI analysis, viewing
and reporting workstation (ProCAD).135 All mpMRI evaluations were discussed in a
consensus meeting and adapted if necessary.
7.2.3 Biopsy procedure
An Aplio 500 (Toshiba Medical Systems, Japan) ultrasound device with an end-firing
transrectal transducer (PVT-781VT; Toshiba Medical Systems, Japan) was used for the
MRgUSBx. Previously obtained T2-weighted MR images were uploaded to the ultrasound
device. The original mpMRI including PIRADS scores were displayed on our mpMRI
workstation, available during the fusion procedure. For a peripheral zone lesion, the
biopsy target was the darkest lesion region on ADC, for the transition zone it was the most
suspicious area on the T2-weighted series. The MR target location was first identified on
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the workstation displaying the mpMRI and then re-located on the uploaded T2-weighted
image.
Patients were positioned in the left lateral position for biopsy, similar to USgBx.
The TRUS probe was inserted rectally with gel. A needle guide was placed onto the
transducer. The ultrasound machine had a SmartFusion option that includes an EM
position sensor attached to the TRUS transducer to spatially correlate imported 3D
MR images and US in real-time. The SmartFusion EM-tracker based fusion is a two-
step process. First, the US scanning orientation is matched to a variable MR image
reformatted orientation by manually selecting the best matching reformatting angle.
Secondly, the correct anatomical 3D position is linked by selecting the same reference
anatomical landmark in both images. During the biopsy procedure, the live US and the
pre-acquired transversal T2-weighted images were shown simultaneously, allowing MR
image guidance (example shown in Figure 7.1). The accuracy of the EM-based method
was enhanced by our novel local reference augmentation, i.e. the reference landmark
used for synchronizing 3D position was selected close to the target location as identified
on MR. The MR identified lesion location is then re-located on ultrasound using the fused
image display. Visible mismatch was minimized by repeating the landmark selection,
compensating for landmark localization errors or patient movement. In case the lesion
was visible on TRUS after initial fusion, the biopsy was targeted to the TRUS location.
Note that visibility in this respect means that lesions become visible on ultrasound only
during the MR targeting fusion procedure. They are much less visible on ultrasound as
such without the aid of fusion. Each mpMRI detected target was biopsied 1− 5 times.
MR-TRUS fusion screenshots were stored during the biopsy to record the exact needle
core location as part of the procedure to assess the representativeness.
7.2.4 Histopathology
Similar to all prostate biopsy procedures, all biopsy core specimens were examined by one
of two specialized urogenital pathologists and graded according to the 2005 International
Society of Urological Pathology Modified Gleason Grading System.36 For stratification of
biopsy data into significant and insignificant cancer we applied the criteria for MRgMRBx
as published by Pokorny et al. 104 In short, lesions with a Gleason score ≥ 7 in at least one
of the MRgUSBx cores were defined as being clinically significant, as well as high-volume
Gleason 3 + 3 (i.e. tumor length > 6 mm or more than 2 positive cores). Low-volume
Gleason 3 + 3 or Gleason scores < 6 were considered clinically insignificant, and lesions
for which no Gleason score could be determined were considered negative. The cancer
detection rate was based on lesions with Gleason score ≥ 6. The pathology results were
correlated to the MR-TRUS fusion biopsy images and the original mpMRI study.
7.2.5 Biopsy evaluation
A urologist in consultation with a radiologist evaluated the biopsy. The biopsy was
considered representative if the patient was not scheduled for an immediate MRgMRBx
7
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(a)
(b)
Figure 7.1: (a) Screenshot of the Toshiba Aplio 500 during MRgUSBx. The green circle indicates the
target as reported on mpMRI, projected on the US image after fusion. The dotted green line indicates
trajectory along which the needle will shoot in the prostate (to be moved slightly for correct targeting
in this screenshot). (b) The corresponding mpMRI with from left to right the transversal T2-weighted
image, ADC map, and DCE image. These images were displayed using ProCAD and were available
during the fusion procedure.
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Table 7.1: Summary of patient characteristics.
All patients, n = 23
Parameter Mean SD Median Range
Age (y) 63 6.4 65 51− 75
PSA (ng/mL) 10.3 6.2 8.9 2.9− 29.3
re-biopsy. As part of the radiological quality control procedure, all mpMRI studies that
did not have significant cancer after MRgUSBx were re-evaluated by two expert prostate
radiologists in consensus. Furthermore, follow-up results of patients were collected.
7.2.6 Data analysis
As an indication of feasibility, the cancer detection rate and number of non-representative
biopsies were analyzed. Earlier research indicated that PIRADS and Gleason score, as
well as visibility and lesion size had an effect upon the detection rate, and therefore we
also performed subgroup analyses. Statistical proportion analysis was performed to
determine the cancer detection rate for each (sub)group. Three different size groups were
created (0− 10 mm, 11− 20 mm, and ≥ 20 mm). Finally, the mean number of cores taken
per lesion was determined for each size group.
7.3 Results
Between September 2013 and October 2014, 23 consecutive patients with 25 mpMRI sus-
picious lesions underwent MRgUSBx and were included (two patients had two lesions).
Table 7.1 summarizes the general characteristics of the included patients. Eleven patients
had at least one previous negative TRUS biopsy session, one patient had a previous
negative MRgMRBx one week before MRgUSBx (but representativeness of MRgMRBx
was uncertain), and the other 11 patients were biopsy naïve. The prospective mpMRI
scores were: 3 PIRADS 3 lesions, 9 PIRADS 4 lesions, and 13 PIRADS 5 lesions. Most of
the mpMRI suspicious lesions were located in the peripheral zone (20/25).
All MRgUSBx were considered representative, none needed an immediate re-biopsy.
Table 7.2 shows the results of the prostate biopsies. In summary, the median number
of targeted cores taken per lesion was 2 (range 1− 5). Cancer (Gleason score ≥ 6) was
detected in 16 of the 25 lesions (64%), and 16 of 23 patients (70%). Two patients had
a second lesion with Gleason score ≥ 6. MRgUSBx was negative in 7 patients: 2 had
a PIRADS 5 lesion, 4 had a PIRADS 4 lesion, and 1 had a PIRADS 3 lesion. Patients
with negative MRgUSBx were referred to active surveillance based on PSA or follow-up
mpMRI after 3− 6 months.
The cancer detection rates per PIRADS score are shown in Table 7.3. The cancer
detection rate of the PIRADS 5 lesions was 77%, of PIRADS 4 this was 44%, and of the
PIRADS 3 lesions 67%. Pathological biopsy outcomes per PIRADS score are shown in
7
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Table 7.2: Results of prostate biopsies.
Parameter Value
No. of patients/lesions 23/25
No. of patients/lesions with cancer (GS ≥ 6) 16/16
Total no. of cores 64
No. of positive cores (GS ≥ 6) 28
Mean primary Gleason grade 3.19± 0.39
Mean secondary Gleason grade 3.25± 0.43
Mean Gleason score (GS) 6.43± 0.50
No. of GS 3 + 3 9 (of which 4 were clinically significant)
No. of GS 3 + 4 4
No. of GS 4 + 3 3
Table 7.3: Cancer detection rates per PIRADS score and TRUS lesion visibility, including 95% confidence
intervals (CI).
Category No. of No. of Proportion No. of lesions Proportion
lesions lesions with (95% CI) with signifi- (95% CI) sig-
any cancer any cancer cant cancer nificant cancer
PIRADS 3 13 12 67% (20− 94%) 12 67% (20− 94%)
PIRADS 4 19 14 44% (19− 73%) 13 33% (12− 65%)
PIRADS 5 13 10 77% (49− 93%) 16 46% (23− 71%)
TRUS visible 22 14 64% (43− 80%) 10 45% (27− 65%)
TRUS invisible 13 12 67% (20− 94%) 11 33% (6− 80%)
All 25 16 64% (44− 80%) 11 44% (27− 68%)
(a) (b)
Figure 7.2: The number of lesions detected with targeted MRgUSBx according to (a) the PIRADS score
on mpMRI, and (b) the visibility of the lesion on TRUS.
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Table 7.4: Biopsy outcomes grouped according to lesion size on mpMRI.
Largest No. of Mean no. of cores Cancer (GS ≥ 6) detection Cancer (GS ≥ 6) detection
diameter lesions (range) rate per lesion (95% CI) rate per core (95% CI)
0− 10 mm 10 2.4 (2− 3) 50% (24− 76%) 33% (18− 53%)
11− 20 mm 11 2.5 (1− 5) 64% (35− 85%) 44% (28− 63%)
> 20 mm 14 2.8 (2− 4) 100% (45− 100%) 73% (43− 91%)
Figure 7.2(a). Clinically significant lesions were present in 46%, 33%, and 67% of the
PIRADS 5, 4, and 3 lesions, respectively.
During the biopsy procedure, 23 of the lesions (88%) could be visualized on TRUS
after image registration. For TRUS visible lesions, biopsies were targeted to the location
as visible on TRUS. The cancer detection rate of the TRUS visible lesions was 64% and
that of the TRUS invisible lesions 67% (see Table 7.3). For clinically significant cancer
this changes to 45% and 33% for TRUS visible and invisible lesions, respectively. The
pathological outcomes for TRUS visibility are shown in Figure 7.2(b).
In Table 7.4 the lesions are grouped according to their size. The cancer detection rate
is higher for the larger lesions, on both lesion and core basis. For lesions larger than 10
mm, the cancer detection rate is 73% (Gleason score ≥ 6). Also, slightly more cores are
taken for larger lesions.
The follow-up of the mpMRI suspicious patients with a negative or insignificant
MRgUSBx outcome was collected and results are shown in Table 7.5. In summary, follow-
up results showed that 3 of 7 patients with negative MRgUSBx had stable or decreasing
PSA after 6− 18 months and one patient is in active surveillance. For the remaining three:
one had negative USgBx after 12 months, one had negative MRgMRBx after 12 months,
and one showed a PIRADS 2 lesion on follow-up mpMRI. For the five patients with
insignificant MRgUSBx: one patient was lost to follow-up, one patient has decreasing
PSA, one patient is scheduled for biopsy, and two are still in active surveillance.
7.4 Discussion
Prostate cancer (Gleason score ≥ 6) was detected in 64% of the lesions biopsied, and
in 70% of the patients. All biopsies were representative showing that our novel local
reference augmented method is feasible in clinical practice. During MR-TRUS fusion,
88% of the lesions could be visualized on TRUS alone, allowing targeted biopsies to be
optimized using live TRUS guidance. The cancer detection rate increases with increasing
tumor size.
The representativeness of the mpMRI suspicious, but negative MRgUSBx was con-
firmed by follow-up; i.e. none of the seven negative MRgUSBx patients revealed clinically
significant pathology. The detection rate for clinically significant cancer (44%) was lower
than the 65% shown by Pokorny et al. 104 for MRgMRBx. Three reasons can be pointed
out for this difference: 1) different patient population between studies; 2) difference in
biopsy technique; and 3) difference in expertise of the radiologist(s). In Pokorny et al. 104
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Table 7.5: Re-evaluation of original mpMRI and follow-up results for negative and clinically insignificant
GS 3 + 3 outcomes.
Biopsy PSA Original PZ/TZ Re-evaluated Re-evaluation Follow-up results
outcome (ng/mL) PIRADS PIRADS comments
Negative
23 5 PZ 2∗ Negative MRgMRBx Still in active surveillance.
one month earlier.
16 5 PZ 5∗ Biopsy may not have Stable PSA after 6 months
been representative. and mpMRI is unchanged.
6 4 TZ 4∗ Biopsy results were Increasing PSA to 8.4 and
considered acceptable now PIRADS 5 lesion on
during re-evaluation mpMRI after 12 months;
of mpMRI. MRgMRBx was negative.
9.7 4 PZ 4∗ Biopsy may not have Stable PSA after 6 months.
been representative.
3.9 4 PZ 4∗ Negative biopsy out- PSA increased to 5.1, but
come is acceptable. USgBx was negative after
12 months.
6.1 4 TZ 3∗ Biopsy outcome pro- PSA decreased to 3.9 after
statitis is acceptable. 6 months.
7.3 3 PZ 2∗ Negative biopsy out- After 12 months, mpMRI
come is acceptable. showed a PIRADS 2 lesion
corresponding to prostatitis.
GS 3+ 3
13 5 PZ 4∗ Biopsy was represen- Lost to follow-up.
tative.
6.4 5 PZ 5∗ Tumor volume in biop- PSA increased to 7.7 after
sy is small regarding 18 months, patient in active
the significant tumor surveillance.
visible on mpMRI.
9 4 PZ/TZ 3∗ Biopsy was represen- Decreasing PSA to 8.1 after
tative. 12 months.
GS 3+ 3 and negative (patients with more than one lesion)
11 5 PZ 5∗ Biopsy was represen- Patient scheduled for
tative. biopsy.
5 PZ 5∗ Biopsy may not have
been representative,
difficult location to
target.
6.3 5 PZ 4∗ Biopsy was represen- Still in active surveillance.
tative.
4 PZ 4∗ Small lesion, biopsy
outcome may not have
been representative.
∗ Lesions that have been downgraded in re-evaluation of the original mpMRI
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three expert radiologists in consensus evaluated the mpMRI, which in our study was
done by the attending prostate radiologist. To investigate the third point, two expert
radiologists in consensus re-evaluated the original mpMRIs with negative and clinically
insignificant MRgUSBx. Table 7.5 shows that the original mpMRI assessment may indeed
have overestimated tumor aggression: 43% (6/14) of the lesions were downgraded during
retrospective re-evaluation by experts. This confirms that expertise is important. In case
subsequent biopsy reveals no clinically significant cancer in PIRADS 4 and 5 lesions it is
very important to re-evaluate the quality of the mpMRI, the reading, and the subsequent
biopsy technique.
The original results of our locally optimized EM-based registration method are well in
line with results of other EM-based systems, which have a cancer detection rate between
49− 69%.111,112 Clinical studies with other MR-TRUS fusion systems, also show similar
detection rates.111,112,128,129 However, patient populations differ quite a bit between the
different studies, e.g. regarding the amount of patients with a previous negative biopsy
or patients that were biopsy naïve.
We know from previous phantom studies that our EM-based registration method has
a registration accuracy of about 5 mm.176 Yet we were still able to achieve reasonable
detection rates in the 0− 10 mm category. The following items played a role. First, we
enhanced the EM-based registration technique by locally optimizing fusion through the
iterative selection of anatomical landmarks close to the target. Secondly, the number of
biopsy cores was increased in case the performing physician was not certain about the
biopsy taken. By taking more cores per target, the tumor hit-rate increases.175 Thirdly,
during the MRgUSBx we noticed that 88% of the targets became visible on TRUS images
during MR-TRUS fusion. In case the targets become visible on TRUS, these can be more
accurately targeted even if the registration is not optimal.168 The TRUS visibility is often
subtle and may very well depend on the quality of the ultrasound images.
The cancer detection rate increases with increasing lesion size, which might be an
indication that the smaller lesions are harder to hit with MRgUSBx and might better be
biopsied with MRgMRBx. For lesions larger than 10 mm diameter, our results show a
cancer detection rate of 73%, approaching the results of MRgMRBx.
The main limitation of our study is the small number of patients. But sufficient to
indicate that MR-TRUS fusion with local reference augmentation is feasible for targeting
prostate biopsies. To make a good comparison with MRgMRBx more patients should be
included in a non-inferiority trial setting. Then, similar patient groups can be compared
and it can be determined whether MRgUSBx is non-inferior to MRgMRBx.
To summarize, MR-TRUS fusion biopsy using local reference augmentation seems
a viable clinical alternative to MR guided biopsy for lesions with an mpMRI maximum
diameter of at least 10 mm, or PIRADS 5 lesions. Smaller lesions may still require in-bore
MR guided biopsy.
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In this thesis, both clinical and technical requirements regarding MR-TRUS fusion for
prostate biopsies have been investigated. This chapter provides a summary of the main
results and conclusions, followed by a general discussion of these conclusions and some
suggestions for further research, and finally a view on future perspectives.
8.1 Summary
In chapter 2, the results of a large clinical trial on MR guided TRUS fusion biopsy were
discussed. This discussion is based on the recently published paper by Siddiqui et al. 128
They compared the results of MR-TRUS fusion biopsy with systematic TRUS guided
biopsy. Its main findings are that MR-TRUS fusion biopsy outperforms systematic TRUS
guided biopsy regarding the cancer detection rate of especially the aggressive cancers,
avoiding detection of indolent cancers. However, implementation of MR-TRUS fusion
biopsy techniques requires caution: good quality MR images and image interpretation is
required; accurate segmentation and registration is essential for targeting tumor suspi-
cious regions with MR-TRUS fusion guidance; and small lesions have a chance of being
missed using this technique. The results show that any of several MR guided biopsy
techniques has the potential to replace systematic TRUS guided prostate biopsies in the
future. However, we conclude that further research is required to determine the threshold
tumor size and to compare the accuracy of MR-TRUS fusion biopsy with that of direct
in-bore MR guided biopsy.
The registration accuracy that is required for targeting the most aggressive tumor
part with MR guided TRUS biopsy is assessed in chapter 3. This registration accuracy
depends on the size of the most aggressive part, the tumor focal spot. Our population
included 51 patients with 62 peripheral zone tumors. More than half of those tumors were
heterogeneous, thus containing a high-grade tumor focal spot. A simulation experiment
performed on the whole tumor population allowed to determine the required target regis-
tration error (TRE) given a requested hit-rate. The results of this simulation experiment
showed that a technical registration accuracy of 1.9 mm is required for finding the highest
Gleason grade component in 95% of the tumors in our population with MR guided TRUS
biopsies. This is only a theoretical measure of accuracy, in clinical practice other factors
like the correct placement of the biopsy gun and needle deflection will possibly lead to
additional inaccuracies.
Chapter 4 describes a registration method with biomechanical regularization. A
common approach for the registration of MR and TRUS images is the alignment of
cross-sectional prostate contours. This surface-based registration does not control in-
ternal prostate deformation. By extending such a surface-based registration method
with biomechanical modeling, internal deformation of the prostate can be simulated.
Initial evaluation of the registration accuracy of the biomechanical regularized method
compared to a regular surface-based registration method is done for MR-MR registration.
MR images before and after insertion of a needle guide were collected from six patients
scheduled for in-bore MR guided biopsy. Manual segmentation was followed by a mesh-
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ing step and subsequently the biomechanical modeling of prostate deformation. The
registration accuracy was determined by calculating the TRE for 45 anatomical landmarks.
The median TRE of a surface-based registration with biomechanical regularization was
1.88 mm, which was significantly better than 2.61 mm without biomechanical regular-
ization. Therefore, biomechanical modeling has the potential to improve the accuracy of
multimodal prostate registration when comparing it to regular surface-based registration.
In chapter 5, the biomechanical modeling constrained surface-based registration
method was developed further. To be able to apply the method presented in chapter
4 to MR-TRUS registration, some adaptations had to be made. First of all, an initial
rigid alignment of MR and TRUS images is required. Simulation convergence was also
improved by better conditioning of the mesh model, and the parameter settings for
meshing and simulation were automated. Manual intervention is only required for
prostate segmentation. MR and TRUS images were collected from ten patients. Again,
anatomical landmarks were used for determining the registration accuracy. The median
TRE of a surface-based registration with biomechanical regularization was 2.76 mm.
This was significantly better than the median TRE of 3.47 mm for regular surface-based
registration without biomechanical regularization. Biomechanical finite element modeling
has the potential to improve the accuracy of multimodal prostate registration and can
help to improve the effectiveness of MR guided TRUS biopsy procedures.
MR guided TRUS fusion biopsies can benefit from the visibility of potential prostate
lesions. Visible lesions can be targeted under TRUS guidance. For biopsying ‘invisible’
lesions an accurate registration algorithm is required. To have a better understanding of
the visibility of prostate cancer on TRUS images using prior knowledge of MRI, we deter-
mined the proportion of lesions that are visible on TRUS in chapter 6. Multiparametric
(mp)-MR images from 34 patients were collected and assessed according to the PI-RADS
guidelines. In total, 56 lesions were detected and scored on mp-MRI. Five observers were
asked to determine the visibility of each of the prostate lesions on 3D TRUS images and
assign a visibility score on a 5-point scale. Our results showed that 43% of all MR lesions
were considered visible by the majority of the observers. Of the PI-RADS 4 and 5 lesions,
55% were visible on TRUS and for merely PI-RADS 5 this increased to 62%. For clinical
application, this means that more than half of the potential biopsy targets are visible on
TRUS images when using the information from mp-MRI. For these cases and especially
the PI-RADS 5 cases (of which almost two thirds were visible) MR guided TRUS fusion
biopsy will benefit from TRUS lesion visibility. For the lesions that are not visible during
fusion biopsy, an accurate registration algorithm or an in-bore MR biopsy is required to
target the lesion.
In chapter 7, the clinical feasibility of a MR-TRUS fusion biopsy system was tested.
Toshiba’s Smart Fusion algorithm is based on electro-magnetic (EM)-tracking of the TRUS
probe. It is a two-step process: first the image plane orientation is matched, then the in-
plane position is linked by selecting the same reference landmark in both images. Because
this is a rigid registration technique which does not correct for prostate deformations,
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it is estimated to have a registration accuracy of 5 mm. The accuracy can be optimized
locally by enhancing the method with local reference augmentation, i.e. the reference
landmark is selected close to the biopsy target. Initial results are based on 23 patients
with 25 MR suspicious lesions. The cancer detection rate is 64%. The cancer detection rate
increases with increasing lesion size, being 73% for lesions larger than 10 mm. Biopsy
was negative in 7 patients and follow-up remained negative in all of them. Our results
show that MR-TRUS fusion biopsy with local reference augmentation is feasible in clinical
practice, especially for the larger lesions.
8.2 General discussion
The optimal prostate cancer diagnostic strategy would involve low morbidity and low
cost to reliably identify cancers that present potential harm to the patient. It would
also minimize unnecessary biopsies or other invasive procedures in patients who do
not have harmful cancers, decreasing invasiveness and the number of biopsy cores in
particular. Furthermore, it is important to correctly determine the cancer aggressiveness
and reduce overtreatment. If an indolent cancer exists that requires no immediate treat-
ment, diagnosing cancer would cause potential psychological harm and unnecessary
treatments with their associated costs and morbidity. The current diagnostic pathway
needs improvements to approach this ideal.
At the moment, a PSA test will be followed by a systematic TRUS guided biopsy to
make a definite diagnosis of prostate cancer. However, a PSA test has limited specificity
and sensitivity, and a systematic TRUS biopsy can miss the tumor or wrongly diagnose
the aggressiveness. In this era, where many men receive a PSA test, diagnostics need
to be improved. Also, if screening becomes applicable, an effective diagnostic pathway
needs to be established.
An MR guided approach has proven to be able to solve many of the issues of system-
atic TRUS guided biopsies as currently used in clinical practice. MRI can help to detect
and localize tumors requiring treatment. Guidelines have been developed to standardize
prostate MRI. In-bore MR guided MR biopsies can accurately target potential lesions
with less cores. The cancer detection rate of MR guided MR biopsies is much higher than
systematic TRUS guided biopsies, especially for the clinically significant tumors. MRI has
a high negative predictive value and the number of biopsies can be reduced significantly.
Furthermore, an MR guided approach is a potentially more cost-effective than TRUS
guided biopsies. A drawback is that clinical use of MR guided MR biopsies is restricted
by its limited availability and relative complexity. MR guided TRUS biopsy is potentially
a more accessible and practical solution and can help to reduce the increasing workload
of MRI and thus provide a faster diagnostic path to the patient.
The work described in this thesis tries to provide an answer on whether MR guided
TRUS biopsy is a viable alternative. Several groups already compared MR guided TRUS
biopsies to systematic TRUS biopsies. Different commercially available systems have been
explored as well as different study populations. Although the numbers may be slightly
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different, all of them show an increased detection rate of especially significant tumors
compared to systematic TRUS biopsies. There are many advantages of MR guided TRUS
biopsies over the systematic TRUS biopsies. Among these are the targeted approach,
reduction of biopsy cores, and more accurate Gleason grading. So yes, MR guided TRUS
biopsy certainly is a viable alternative to systematic TRUS guided biopsies. However, the
remaining question is whether it is also a viable alternative to direct in-bore MR guided
biopsies. Several challenges exist though, and some of them have been addressed in this
thesis.
First of all, caution is required before embarking on immediate large-scale imple-
mentation of MRI-guided biopsy techniques for men with suspected prostate cancer. An
experienced MRI radiologist is crucial for obtaining good biopsy samples, as optimal
acquisition and standardized interpretation of mp-MR images is essential. Acquisition
and interpretation of the mp-MR images requires skills that can only be obtained by good
training and experience. Minimal requirements for prostate mp-MR image acquisition
and standardization for reporting (PI-RADS) have recently been published. This will
help to improve the general reliability of the techniques. However, this holds for both
MR-TRUS fusion biopsies as well as in-bore MR guided biopsies.
The success-rate of MR guided TRUS biopsies is highly depending on the registration
accuracy. We have shown that for correctly grading 95% of the tumors, a technical
registration accuracy of 1.9 mm is required. This is the theoretical threshold on the TRE
to actually hit the most aggressive part of the tumor by taking only one biopsy core. The
probability of hitting the tumor will increase when 2 or 3 cores will be taken, which is also
usually done with in-bore MR guided biopsies. The volume of (the most aggressive part
of) the tumor plays an important role in the hit-rate as well. Larger tumors have a higher
probability of being hit and could therefore be successfully targeted with a less accurate
registration method. This is the case with in-bore MR guided biopsies as well. However,
in clinical practice there are more factors than just the registration accuracy that influence
the success-rate of the fusion biopsy. These are for instance the correct placement of the
biopsy gun and needle deflection, which both have a role in the success-rate of in-bore
MR guided biopsies as well.
Many different registration methods have been described, some of them are imple-
mented in clinical systems. However, most of them are likely to not reach the accuracy
of 1.9 mm. The major challenge in MR-TRUS registration is compensating for prostate
deformation. Rigid registration methods are relatively easy and fast, but ignore shape
differences and are therefore not very accurate in general. Non-rigid methods do correct
for differences in prostate shapes between the two modalities. These methods are more
complex, but also more accurate. However, the outcomes are not always physically
plausible. We explored the possibility of extending a non-rigid surface-based method
with biomechanical modeling. Soft-tissue properties are incorporated and prostate de-
formation is simulated. The results show that biomechanical modeling can improve the
registration accuracy of a non-rigid registration method. The possibilities need to be
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explored further, but improvements to the current systems should be feasible. A possible
suggestion for future work is to consider elastography as enhancement for the biome-
chanical model. This may provide non-uniform elastic properties that better characterize
the prostate.
The current clinically available MR guided TRUS biopsy systems not only differ in
implemented registration algorithms, but also in clinical usability and required manual
input. The relatively easy-to-use systems are usually less accurate than the more advanced
systems. However, the complex methods require a longer time for computing the regis-
tration results. Some systems require manual segmentation, which is a time-consuming
task, while other systems are more automated and less operator-dependent. The different
systems may have different learning curves, so experience of the operating physician
plays an important role as well.
In clinical practice, it will be convenient if the registration procedure is easy and fast to
use. This may be accompanied with a lack in accuracy. However, this does not necessarily
mean that these systems cannot be successful in clinical practice. It is important that
the operating physician is aware of the accuracy of the system. In case the system is not
able to accurately register the smaller lesions, one should consider to proceed to in-bore
biopsies immediately. The larger lesions, on the other hand, may be successfully targeted
with an easy and fast MR guided TRUS biopsy system.
A lack in registration accuracy may be partly resolved by tumor visibility on TRUS
images. More than half of the tumors are actually visible on TRUS images if one knows
where to look based on prior knowledge of MRI. The visible lesions can be accurately tar-
geted under TRUS guidance, thereby less depending on the registration accuracy. Visible
lesions may even be targeted using cognitive fusion, where the physician performing the
biopsy reviews the lesion on MRI and aims the biopsy needle at the appropriate prostate
area on TRUS. We correlated TRUS visibility to PI-RADS, but more research is required
for better identification of TRUS visible lesions. MR characteristics of the lesions that
can be visualized on TRUS should be determined. The PI-RADS scores of the different
modalities of mp-MRI can be addressed separately, peripheral and transition zone tumors
may behave differently on TRUS images, Gleason grades could be taken as ground truth,
lesion size might play an important role, etc. Knowing what type of lesions are visible
will help decide which technique can be used best for targeted prostate biopsies.
In our study, we looked at tumor visibility on common grey-scale TRUS images. Other
ultrasound modalities are emerging and may have potential in prostate cancer imaging.
Contrast-enhanced, Doppler, and/or elastography have shown to be able to increase
the cancer detection rate when compared to non-targeted systematic biopsies. When
combining several modalities and thus using multiparametric TRUS imaging, prostate
cancer image visibility might be improved. Potentially, computer-aided detection (CAD)
might also help to enhance possible prostate lesions on TRUS. These are some suggestions
for future research, which is required to find out if there may be a potential role for any of
these techniques.
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Finally, we explored the feasibility of a clinical MR-TRUS fusion biopsy system.
The implemented EM-based rigid registration method has an accuracy of about 5 mm.
This makes the method fast and relatively easy to use, which is very convenient in
regular clinical practice. By enhancing the method with local reference augmentation,
the accuracy around the target can be optimized. We started off with biopsying only the
relatively large and aggressive tumors, to be sure to take representative biopsies. We
noticed that quite some tumors are visible after fusion. Combining computational with
cognitive fusion seems to work well in clinical practice, especially if tumors are visible on
TRUS images. Also the larger lesions may very well be targeted using fusion biopsies.
The patient group we studied is relatively small, but our results show that the system is
feasible in clinical practice. More data should be collected to give a clear indication of the
success-rate of MR-TRUS fusion biopsy and compare this with in-bore MR guided biopsy.
The correlation between success-rate and tumor size should be determined.
Some other systems work similarly as the one we tested, but there are also systems
that are much more complex. Although the registration method will then be much
more accurate, the system itself is less user friendly. Cumbersome devices and manual
segmentation make these systems less suitable in clinical practice. Each fusion system has
its own advantages and disadvantages, which should be considered carefully. One should
be aware of possible shortcomings, e.g. less accurate fusion systems may lead to a lower
cancer detection rate compared to more accurate systems. Future studies should provide
more data and compare the different biopsy methods. It should be figured out how fusion
biopsies can be used best and what methodology is optimal for clinical practice.
To summarize, MR guided TRUS biopsy may certainly be a viable alternative to
systematic TRUS guided biopsy. But can it be a viable alternative to in-bore MR guided
biopsy as well? In this work, several technical and clinical issues have been addressed.
From our results, it can be concluded that MR guided TRUS biopsy has the potential to be
a viable alternative to in-bore MR guided biopsy. Among other studies, we have shown
that the cancer detection rate of MR guided TRUS biopsies correlates to PI-RADS score,
and that PI-RADS 5 lesions may very well be biopsied using fusion. Also, the relatively
large tumors (diameter ≥ 10 mm) can be successfully targeted with MR guided TRUS
biopsy. Besides, aggressive tumors have a higher chance of being visible on TRUS images
using prior knowledge of MR appearance, thereby facilitating targeted biopsy. Of course,
the characteristics of lesions that may be successfully biopsied with fusion depend on the
accuracy of the fusion system. Therefore, further research is required to determine the
exact lesion characteristics for each fusion system to allow successful biopsy.
8.3 Future perspectives
Any of several MR guided biopsy techniques can be a viable alternative to the current
systematic TRUS guided biopsies. This will certainly happen in the near future, thereby
changing the current diagnostic pathway for prostate cancer diagnosis. Current clinically
available MR-TRUS fusion biopsy systems can still be improved and more tools may
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become available. Ideally, MRI will get an important role in clinical practice, making
screening for prostate cancer more feasible.
How would all of this change the diagnostic pathway? If prostate cancer screening
would be introduced, an initial selection will probably still be based on a PSA test. A
pre-biopsy MRI will then subsequently follow for the men with an elevated PSA level.
The MRI scans need to be assessed according to the PI-RADS guidelines, ideally in a
double reading setting. As the number of scans will increase dramatically, CAD may
potentially assist the radiologist. The results of MRI will then help to decide whether the
patient should proceed to prostate biopsy. Based on the lesion characteristics, a certain
targeted biopsy technique will be advised. Larger and visible lesions, in particular, will
be suitable for MR guided TRUS biopsy. A large part of the lesions requiring biopsy can
therefore be successfully targeted with MR guided TRUS biopsy, the remaining lesions
need to be biopsied directly in the MR scanner. Radiologists and urologists should work
together to determine whether biopsy results are representative. Lesions that have been
unsuccessfully biopsied using either biopsy technique, but are still suspicious for being
cancer, should be re-biopsied in the MR scanner. The biopsy results will then help the
attending physician to make a treatment decision.
The combination of MR guided TRUS biopsies and direct in-bore MR guided MR
biopsies may be a more cost-effective solution than the systematic TRUS guided biopsies,
or an MR only approach. Advantages of both TRUS and MRI will be combined. The
targeted strategy will improve cancer detection and correctly determining the cancer
aggressiveness, providing patients with a clear answer. Overdiagnosis and overtreatment
will be reduced, improving quality of life.
8.4 Closing remarks
In my opinion, the clinical pathway as described above would be a great improvement
to current clinical practice. Of course, there are several challenges still remaining and
further research should provide more solutions. The work described in this thesis is a
good basis for future studies, and will thereby contribute to incorporation of MR guided
TRUS prostate biopsies into clinical practice, with the final goal of improved patient care.
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In dit proefschrift zijn zowel klinische als technische aspecten beschreven die betrekking
hebben op MR-echo fusie voor prostaat biopten. Hieronder volgt een samenvatting van
de belangrijkste resultaten en conclusies.
In hoofdstuk 2 zijn de bevindingen van een grootschalige klinische studie van Sid-
diqui et al. 128 naar MR-echo fusie biopten besproken. Daarin zijn de resultaten van
MR-echo fusie biopsie vergeleken met systematische echo geleide biopsie. De belangrijk-
ste bevindingen zijn dat MR-echo fusie biopsie beter is dan systematische echo geleide
biopsie wat betreft kanker detectie van met name agressieve tumoren, waarbij detectie
van indolente tumoren wordt vermeden. Men dient echter voorzichtig te zijn met de
toepassing van MR-echo fusie biopsie: ten eerste is een goede kwaliteit MRI noodzakelijk,
alsmede een juiste beoordeling van de beelden. Nauwkeurige segmentatie en registratie
is essentieel voor het gericht biopteren van de tumor onder MR-echo geleide. Met name
kleine tumoren hebben een kans om te worden gemist met deze techniek. De resultaten
laten zien dat verschillende MR-echo fusie biopsie technieken de potentie hebben om
systematische echo geleide biopten in de toekomst te vervangen. Verder onderzoek is
nodig om te bepalen wat de minimale tumor grootte is waarbij fusie biopsie mogelijk is.
Ook moet de nauwkeurigheid van MR-echo fusie biopsie worden vergeleken met die van
in-bore MR geleide biopsie.
De registratie nauwkeurigheid die vereist is om het meest agressieve tumor gedeelte
te raken met MR geleide echo biopsie is beschreven in hoofdstuk 3. Deze registratie
nauwkeurigheid is afhankelijk van de grootte van het meest agressieve deel van de tumor.
Onze populatie bestond uit 51 patiënten met 62 perifere zone tumoren. Meer dan de helft
van deze tumoren waren heterogeen, wat wil zeggen dat deze een hoog-gradig tumor
gedeelte bevatten. Een simulatie-experiment is uitgevoerd op de gehele tumor populatie
om de minimaal vereiste registratie nauwkeurigheid in te schatten voor een bepaalde
hit-rate. Voor het vinden van de hoogste Gleason graad in 95% van de tumoren met
MR-echo fusie biopten, is een registratie nauwkeurigheid van 1,9 mm nodig. Dit is slechts
de theoretische mate van nauwkeurigheid. In de kliniek spelen ook andere factoren een
rol. De plaatsing van de naaldgeleider en de afbuiging van de naald kunnen bijvoorbeeld
leiden tot extra onnauwkeurigheden.
Hoofdstuk 4 beschrijft een registratiemethode gebaseerd op biomechanische modelle-
ring. Een veel voorkomende aanpak voor de registratie van MR en echo beelden is het
zo goed mogelijk op elkaar passen van prostaat contouren. Deze contour-gebaseerde
registratie methode houdt geen rekening met interne vervormingen van de prostaat.
Door deze methode uit te breiden met biomechanische modellering, kunnen interne ver-
vormingen van de prostaat worden gesimuleerd. Een eerste schatting van de registratie
nauwkeurigheid van deze biomechanisch-geregulariseerde methode wordt gedaan met
MR-MR registratie. Dit wordt vergeleken met een reguliere contour-gebaseerde registratie
methode. MR beelden zijn gemaakt voorafgaand en na inbrenging van een naaldgeleider
en zijn verzameld van zes patiënten die gepland waren voor een MR-geleide biopsie. Na
handmatige segmentatie werd de prostaat in kleine elementjes verdeeld. Daarna volgde
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de biomechanische modellering van de vervorming van de prostaat. De nauwkeurigheid
is bepaald door het berekenen van de registratiefout van 45 anatomische referentiepunten.
De mediane fout van de biomechanische modelleringsmethode was 1,88 mm. Deze was
significant beter dan 2,61 mm zonder biomechanische modellering. Biomechanische
modellering heeft dus de potentie om de nauwkeurigheid van multimodale prostaat
registratie te verbeteren.
In hoofdstuk 5 is de registratie methode zoals beschreven in hoofdstuk 4 verder
ontwikkeld. Voor toepassing op MR-echo registratie zijn een aantal aanpassingen noodza-
kelijk. Allereerst is een initiële rigide registratie van MR en echo beelden vereist. Verder is
de simulatie convergentie verbeterd door een betere conditionering van het model en zijn
de parameterinstellingen voor de simulatie geautomatiseerd. Handmatige interventie is
hierdoor alleen nog nodig voor de segmentatie van de prostaat. MR en echo beelden van
tien patiënten zijn verzameld. Ook hier zijn anatomische referentiepunten gebruikt om
de registratie nauwkeurigheid te bepalen. De mediaan van de biomechanische modelle-
ringsmethode was 2,76 mm. Dit was significant beter dan de mediaan van 3,47 mm voor
de reguliere registratie methode. Biomechanische modellering biedt de mogelijkheid om
de nauwkeurigheid van multimodale prostaat registratie te verbeteren en kan helpen om
de effectiviteit van MR-echo fusie biopten te verbeteren.
MR geleide echo fusie biopsie kan verbeteren indien potentiële prostaat tumoren
zichtbaar zijn op echo. Zichtbare tumoren kunnen gericht worden geprikt onder echo
geleiding, terwijl voor onzichtbare tumoren een nauwkeurige registratie is vereist. Om
meer te weten te komen over de zichtbaarheid van prostaatkanker op echo beelden met
voorkennis van MRI, hebben we het aantal tumoren dat zichtbaar is op echo onderzocht
in hoofdstuk 6. Multiparametrische MR beelden van 34 patiënten zijn verzameld en
beoordeeld volgens de PI-RADS richtlijnen. In totaal zijn 56 tumoren op MRI gedetecteerd
en beoordeeld. Vijf waarnemers zijn gevraagd om de zichtbaarheid van deze tumoren op
3D echo beelden te bepalen volgens een 5-puntsschaal. Onze resultaten laten zien dat 43%
van alle MR tumoren voor de meerderheid van de waarnemers zichtbaar was. Van de
PI-RADS 4 en 5 tumoren was 55% zichtbaar op echo en voor PI-RADS 5 zelfs 62%. Voor
klinische toepassing betekent dit dat meer dan de helft van de tumoren zichtbaar is op
echo beelden met voorkennis van multiparametrische MRI. Voor deze gevallen en in het
bijzonder de PI-RADS 5 gevallen (waarvan bijna tweederde zichtbaar was) kan MR-echo
fusie biopsie profiteren van zichtbaarheid op echo. Voor tumoren die niet zichtbaar zijn
tijdens fusie biopsie is een nauwkeurige registratie methode of MR geleide biopsie nodig
om gericht te kunnen biopteren.
In hoofdstuk 7 wordt de klinische haalbaarheid van een MR-echo fusie biopsie sys-
teem beschreven. De Smart Fusion methode van Toshiba is gebaseerd op het elektromag-
netisch volgen van de echo transducer. Het proces bestaat uit twee stappen: eerst wordt
de oriëntatie van de beelden gelijk gelegd, daarna wordt de exacte positie verbonden
door middel van anatomische referentiepunten. Omdat dit een rigide registratietech-
niek is die niet gecorrigeerd wordt voor prostaat vervormingen, wordt de registratie
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nauwkeurigheid geschat op ongeveer 5 mm. De nauwkeurigheid kan lokaal worden
geoptimaliseerd door de methode te verbeteren met lokale referentie vergroting, dat wil
zeggen dat het referentiepunt zo dicht mogelijk bij het doel wordt gekozen. De eerste
resultaten zijn gebaseerd op 23 patiënten met 25 MR verdachte gebieden. Kanker is
gedetecteerd in 64% van de verdachte gebieden. Voor tumoren groter dan 10 mm neemt
dit zelfs toe tot 73%. Biopsie was negatief in 7 patiënten en follow-up bleef negatief in
alle 7. Onze resultaten laten zien dat MR-TRUS fusie biopsie met de lokale referentie
vergroting uitvoerbaar is in de kliniek, zeker voor de grotere tumoren.

Bibliography

Bibliography 113
[1] H. Gray. Anatomy of the human body. Lea & Febiger, Philadelphia, Pennsylvania USA, 20th edition, 1918.
[2] J. E. McNeal. The zonal anatomy of the prostate. Prostate, 2:35–49, 1981.
[3] J. E. McNeal, E. A. Redwine, F. S. Freiha, and T. A. Stamey. Zonal distribution of prostatic adenocarcinoma.
correlation with histologic pattern and direction of spread. Am J Surg Pathol, 12:897–906, 1988.
[4] A. M. De Marzo, E. A. Platz, S. Sutcliffe, J. Xu, H. Grönberg, C. G. Drake, Y. Nakai, W. B. Isaacs, and W. G.
Nelson. Inflammation in prostate carcinogenesis. Nat Rev Cancer, 7:256–269, 2007.
[5] J. Ferlay, D. M. Parkin, and E. Steliarova-Foucher. Estimates of cancer incidence and mortality in Europe
in 2008. Eur J Cancer, 46:765–781, 2010.
[6] V. Nelen. Epidemiology of prostate cancer. In Prostate Cancer, volume 175 of Recent Results in Cancer
Research, chapter 1, pages 1–8. Springer Berlin Heidelberg, 2007.
[7] R. Siegel, J. Ma, Z. Zou, and A. Jemal. Cancer statistics, 2014. CA Cancer J Clin, 64:9–29, 2014.
[8] J. Ferlay, H. R. Shin, F. Bray, D. Forman, C. Mathers, and D. M. Parkin. Estimates of worldwide burden of
cancer in 2008: GLOBOCAN 2008. Int J Cancer, 127:2893–2917, 2010.
[9] E. D. Crawford. Epidemiology of prostate cancer. Urology, 62:3–12, 2003.
[10] P. T. Scardino, R. Weaver, and M. A. Hudson. Early detection of prostate cancer. Hum Pathol, 23:211–222,
1992.
[11] P. Tenke, J. Horti, P. Balint, and B. Kovacs. Prostate cancer screening. In Prostate Cancer, volume 175 of
Recent Results in Cancer Research, chapter 5, pages 65–81. Springer Berlin Heidelberg, 2007.
[12] A. M. D. Wolf, R. C. Wender, R. B. Etzioni, I. M. Thompson, A. V. D’Amico, R. J. Volk, D. D. Brooks,
C. Dash, I. Guessous, K. Andrews, C. DeSantis, R. A. Smith, and American Cancer Society Prostate Cancer
Advisory Committee. American Cancer Society guideline for the early detection of prostate cancer:
update 2010. CA Cancer J Clin, 60:70–98, 2010.
[13] Integraal Kankercentrum Nederland (IKNL). URL http://www.cijfersoverkanker.nl.
[14] N. B. Delongchamps, A. Singh, and G. P. Haas. The role of prevalence in the diagnosis of prostate cancer.
Cancer Control, 13:158–168, 2006.
[15] M. Sánchez-Chapado, G. Olmedilla, M. Cabeza, E. Donat, and A. Ruiz. Prevalence of prostate cancer
and prostatic intraepithelial neoplasia in Caucasian Mediterranean males: an autopsy study. Prostate, 54:
238–247, 2003.
[16] J. E. Johansson, O. Andrén, S. O. Andersson, P. W. Dickman, L. Holmberg, A. Magnuson, and H. O.
Adami. Natural history of early, localized prostate cancer. JAMA, 291:2713–2719, 2004.
[17] W. J. Catalona, D. S. Smith, T. L. Ratliff, K. M. Dodds, D. E. Coplen, J. J. Yuan, J. A. Petros, and G. L.
Andriole. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N
Engl J Med, 324:1156–1161, 1991.
[18] K. Lin, R. Lipsitz, T. Miller, S. Janakiraman, and U.S. Preventive Services Task Force. Benefits and harms
of prostate-specific antigen screening for prostate cancer: an evidence update for the U.S. Preventive
Services Task Force. Ann Intern Med, 149:192–199, 2008.
[19] E. D. Crawford, E. P. DeAntoni, R. Etzioni, V. C. Schaefer, R. M. Olson, C. A. Ross, and The Prostate Cancer
Education Council. Serum prostate-specific antigen and digital rectal examination for early detection of
prostate cancer in a national community-based program. Urology, 47:863–869, 1996.
114 Bibliography
[20] K. Mistry and G. Cable. Meta-analysis of prostate-specific antigen and digital rectal examination as
screening tests for prostate carcinoma. J Am Board Fam Pract, 16:95–101, 2003.
[21] H. Watanabe, H. Kato, T. Kato, M. Morita, and M. Tanaka. Diagnostic application of ultrasonotomography
to the prostate. Nihon Hinyokika Gakkai Zasshi, 59:273–279, 1968.
[22] H. Watanabe. History and applications of transrectal sonography of the prostate. Urol Clin North Am, 16:
617–622, 1989.
[23] S. W. T. P. J. Heijmink, H. van Moerkerk, L. A. L. M. Kiemeney, J. A. Witjes, F. Frauscher, and J. O. Barentsz.
A comparison of the diagnostic performance of systematic versus ultrasound-guided biopsies of prostate
cancer. Eur Radiol, 16:927–938, 2006.
[24] J. Raja, N. Ramachandran, G. Munneke, and U. Patel. Current status of transrectal ultrasound-guided
prostate biopsy in the diagnosis of prostate cancer. Clin Radiol, 61:142–153, 2006.
[25] K. K. Hodge, J. E. McNeal, M. K. Terris, and T. A. Stamey. Random systematic versus directed ultrasound
guided transrectal core biopsies of the prostate. J Urol, 142:71–75, 1989.
[26] J. C. Presti. Prostate biopsy: current status and limitations. Rev Urol, 9:93–98, 2007.
[27] T. A. Stamey. Making the most out of six systematic sextant biopsies. Urology, 45:2–12, 1995.
[28] O. Ukimura, J. A. Coleman, A. de la Taille, M. Emberton, J. I. Epstein, S. J. Freedland, G. Giannarini,
A. S. Kibel, R. Montironi, G. Ploussard, M. J. Roobol, V. Scattoni, and J. S. Jones. Contemporary role
of systematic prostate biopsies: indications, techniques, and implications for patient care. Eur Urol, 63:
214–230, 2013.
[29] M. Baumann, P. Mozer, V. Daanen, and J. Troccaz. Prostate biopsy tracking with deformation estimation.
Med Image Anal, 16:562–576, 2012.
[30] K. A. Roehl, J. A. V. Antenor, and W. J. Catalona. Serial biopsy results in prostate cancer screening study. J
Urol, 167:2435–2439, 2002.
[31] C. S. Stewart, B. C. Leibovich, A. L. Weaver, and M. M. Lieber. Prostate cancer diagnosis using a saturation
needle biopsy technique after previous negative sextant biopsies. J Urol, 166:86–92, 2001.
[32] F. Sano, H. Terao, T. Kawahara, Y. Miyoshi, T. Sasaki, K. Noguchi, Y. Kubota, and H. Uemura. Contrast-
enhanced ultrasonography of the prostate: various imaging findings that indicate prostate cancer. BJU
Int, 107:1404–1410, 2011.
[33] M. Brock, C. von Bodman, R. J. Palisaar, B. Löppenberg, F. Sommerer, T. Deix, J. Noldus, and T. Eggert.
The impact of real-time elastography guiding a systematic prostate biopsy to improve cancer detection
rate: a prospective study of 353 patients. J Urol, 187:2039–2043, 2012.
[34] D. J. Rosario, J. A. Lane, C. Metcalfe, J. L. Donovan, A. Doble, L. Goodwin, M. Davis, J. W. F. Catto,
K. Avery, D. E. Neal, and F. C. Hamdy. Short term outcomes of prostate biopsy in men tested for cancer
by prostate specific antigen: prospective evaluation within ProtecT study. BMJ, 344:d7894, 2012.
[35] D. F. Gleason. Classification of prostatic carcinomas. Cancer Chemother Rep, 50:125–128, 1966.
[36] J. I. Epstein, W. C. Allsbrook, M. B. Amin, L. L. Egevad, and ISUP Grading Committee. The 2005
International Society of Urological Pathology (ISUP) consensus conference on Gleason grading of prostatic
carcinoma. Am J Surg Pathol, 29:1228–1242, 2005.
[37] P. A. Humphrey. Gleason grading and prognostic factors in carcinoma of the prostate. Mod Pathol, 17:
292–306, 2004.
Bibliography 115
[38] P. C. Albertsen, J. A. Hanley, and J. Fine. 20-year outcomes following conservative management of
clinically localized prostate cancer. JAMA, 293:2095–2101, 2005.
[39] M. Borre, B. Nerstrøm, and J. Overgaard. The natural history of prostate carcinoma based on a Danish
population treated with no intent to cure. Cancer, 80:917–928, 1997.
[40] J. Hugosson and G. Aus. Natural course of localized prostate cancer. a personal view with a review of
published papers. Anticancer Res, 17:1441–1448, 1997.
[41] M. A. Dall’Era, P. C. Albertsen, C. Bangma, P. R. Carroll, H. B. Carter, M. R. Cooperberg, S. J. Freedland,
L. H. Klotz, C. Parker, and M. S. Soloway. Active surveillance for prostate cancer: a systematic review of
the literature. Eur Urol, 62:976–983, 2012.
[42] L. Klotz, L. Zhang, A. Lam, R. Nam, A. Mamedov, and A. Loblaw. Clinical results of long-term follow-up
of a large, active surveillance cohort with localized prostate cancer. J Clin Oncol, 28:126–131, 2010.
[43] L. Budäus, M. Bolla, A. Bossi, C. Cozzarini, J. Crook, A. Widmark, and T. Wiegel. Functional outcomes
and complications following radiation therapy for prostate cancer: a critical analysis of the literature. Eur
Urol, 61:112–127, 2012.
[44] J. D. Hall, J. C. Boyd, M. C. Lippert, and D. Theodorescu. Why patients choose prostatectomy or
brachytherapy for localized prostate cancer: results of a descriptive survey. Urology, 61:402–407, 2003.
[45] J. Hegarty, P. V. Beirne, E. Walsh, H. Comber, T. Fitzgerald, and M. Wallace Kazer. Radical prostatectomy
versus watchful waiting for prostate cancer. Cochrane Database Syst Rev, page CD006590, 2010.
[46] F. Peinemann, U. Grouven, L. G. Hemkens, C. Bartel, H. Borchers, M. Pinkawa, A. Heidenreich, and
S. Sauerland. Low-dose rate brachytherapy for men with localized prostate cancer. Cochrane Database Syst
Rev, page CD008871, 2011.
[47] R. Raaijmakers, B. G. Blijenberg, J. A. Finlay, H. G. Rittenhouse, M. F. Wildhagen, M. J. Roobol, and F. H.
Schröder. Prostate cancer detection in the prostate specific antigen range of 2.0 to 3.9 ng/ml: value of
percent free prostate specific antigen on tumor detection and tumor aggressiveness. J Urol, 171:2245–2249,
2004.
[48] I. M. Thompson, D. K. Pauler, P. J. Goodman, C. M. Tangen, M. S. Lucia, H. L. Parnes, L. M. Minasian,
L. G. Ford, S. M. Lippman, E. D. Crawford, J. J. Crowley, and C. A. Coltman. Prevalence of prostate cancer
among men with a prostate-specific antigen level ≤4.0 ng per milliliter. N Engl J Med, 350:2239–2246,
2004.
[49] A. N. Vis, R. F. Hoedemaeker, M. Roobol, T. H. van der Kwast, and F. H. Schröder. Tumor characteristics
in screening for prostate cancer with and without rectal examination as an initial screening test at low
PSA (0.0-3.9 ng/ml). Prostate, 47:252–261, 2001.
[50] I. M. Thompson, D. P. Ankerst, C. Chi, M. S. Lucia, P. J. Goodman, J. J. Crowley, H. L. Parnes, and C. A.
Coltman. Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0
ng/ml or lower. JAMA, 294:66–70, 2005.
[51] G. L. Andriole, E. D. Crawford, R. L. Grubb, S. S. Buys, D. Chia, T. R. Church, M. N. Fouad, E. P. Gelmann,
P. A. Kvale, D. J. Reding, J. L. Weissfeld, L. A. Yokochi, B. O’Brien, J. D. Clapp, J. M. Rathmell, T. L. Riley,
R. B. Hayes, B. S. Kramer, G. Izmirlian, A. B. Miller, P. F. Pinsky, P. C. Prorok, J. K. Gohagan, C. D. Berg,
and the PLCO Project Team. Mortality results from a randomized prostate-cancer screening trial. N Engl
J Med, 360:1310–1319, 2009.
116 Bibliography
[52] F. H. Schröder, J. Hugosson, M. J. Roobol, T. L. J. Tammela, S. Ciatto, V. Nelen, M. Kwiatkowski, M. Lujan,
H. Lilja, M. Zappa, L. J. Denis, F. Recker, A. Berenguer, L. Määttänen, C. H. Bangma, G. Aus, A. Villers,
X. Rebillard, T. van der Kwast, B. G. Blijenberg, S. M. Moss, H. J. de Koning, A. Auvinen, and the ERSPC
Investigators. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med,
360:1320–1328, 2009.
[53] F. H. Schröder, J. Hugosson, M. J. Roobol, T. L. J. Tammela, S. Ciatto, V. Nelen, M. Kwiatkowski, M. Lujan,
H. Lilja, M. Zappa, L. J. Denis, F. Recker, A. Páez, L. Määttänen, C. H. Bangma, G. Aus, S. Carlsson,
A. Villers, X. Rebillard, T. van der Kwast, P. M. Kujala, B. G. Blijenberg, U.-H. Stenman, A. Huber, K. Taari,
M. Hakama, S. M. Moss, H. J. de Koning, A. Auvinen, and the ERSPC Investigators. Prostate-cancer
mortality at 11 years of follow-up. N Engl J Med, 366:981–990, 2012.
[54] M. Djulbegovic, R. J. Beyth, M. M. Neuberger, T. L. Stoffs, J. Vieweg, B. Djulbegovic, and P. Dahm.
Screening for prostate cancer: systematic review and meta-analysis of randomised controlled trials. BMJ,
341:c4543, 2010.
[55] M. J. Roobol, M. Kerkhof, F. H. Schöder, J. Cuzick, P. Sasieni, M. Hakama, U. H. Stenman, S. Ciatto,
V. Nelen, M. Kwiatkowski, M. Lujan, H. Lilja, M. Zappa, L. Denis, F. Recker, A. Berenguer, M. Ruutu,
P. Kujala, C. H. Bangma, G. Aus, T. L. J. Tammela, A. Villers, X. Rebillard, S. M. Moss, H. J. de Koning,
J. Hugosson, and A. Auvinen. Prostate cancer mortality reduction by prostate-specific antigen-based
screening adjusted for nonattendance and contamination in the European Randomised Study of Screening
for Prostate Cancer (ERSPC). Eur Urol, 56:584–591, 2009.
[56] S. J. Otto, P. J. van Leeuwen, J. W. Hoekstra, J. W. Merckelbach, J. H. M. Blom, F. H. Schröder, M. J. Roobol,
and H. J. de Koning. Blinded and uniform causes of death verification in cancer screening: a major
influence on the outcome of a prostate cancer screening trial? Eur J Cancer, 46:3061–3067, 2010.
[57] F. H. Schröder, H. B. Carter, T. Wolters, R. C. N. van den Bergh, C. Gosselaar, C. H. Bangma, and M. J.
Roobol. Early detection of prostate cancer in 2007. Part 1: PSA and PSA kinetics. Eur Urol, 53:468–477,
2008.
[58] A. E. Pelzer, A. Tewari, J. Bektic, A. P. Berger, F. Frauscher, G. Bartsch, and W. Horninger. Detection
rates and biologic significance of prostate cancer with PSA less than 4.0 ng/mL: observation and clinical
implications from Tyrol screening project. Urology, 66:1029–1033, 2005.
[59] B. Spajic, H. Eupic, D. Tomas, G. Stimac, B. Kruslin, and O. Kraus. The incidence of hyperechoic prostate
cancer in transrectal ultrasound-guided biopsy specimens. Urology, 70:734–737, 2007.
[60] M. Norberg, L. Egevad, L. Holmberg, P. Sparén, B. J. Norlén, and C. Busch. The sextant protocol for
ultrasound-guided core biopsies of the prostate underestimates the presence of cancer. Urology, 50:
562–566, 1997.
[61] M. K. Terris. Sensitivity and specificity of sextant biopsies in the detection of prostate cancer: preliminary
report. Urology, 54:486–489, 1999.
[62] R. Kvåle, B. M. ller, R. Wahlqvist, S. D. Fosså, A. Berner, C. Busch, A. E. Kyrdalen, A. Svindland, T. Viset,
and O. J. Halvorsen. Concordance between Gleason scores of needle biopsies and radical prostatectomy
specimens: a population-based study. BJU Int, 103:1647–1654, 2009.
[63] M. Noguchi, T. A. Stamey, J. E. McNeal, and C. M. Yemoto. Relationship between systematic biopsies and
histological features of 222 radical prostatectomy specimens: lack of prediction of tumor significance for
men with nonpalpable prostate cancer. J Urol, 166:104–109, 2001.
[64] A. Rajinikanth, M. Manoharan, C. T. Soloway, F. J. Civantos, and M. S. Soloway. Trends in Gleason score:
Concordance between biopsy and prostatectomy over 15 years. Urology, 72:177–182, 2008.
Bibliography 117
[65] S. Tomioka, H. Nakatsu, N. Suzuki, S. Murakami, O. Matsuzaki, and J. Shimazaki. Comparison of Gleason
grade and score between preoperative biopsy and prostatectomy specimens in prostate cancer. Int J Urol,
13:555–559, 2006.
[66] H. Hricak, G. C. Dooms, J. E. McNeal, A. S. Mark, M. Marotti, A. Avallone, M. Pelzer, E. C. Proctor, and
E. A. Tanagho. MR imaging of the prostate gland: normal anatomy. AJR Am J Roentgenol, 148:51–58, 1987.
[67] N. L. Robertson, M. Emberton, and C. M. Moore. MRI-targeted prostate biopsy: a review of technique
and results. Nat Rev Urol, 10:589–597, 2013.
[68] F. V. Coakley and H. Hricak. Radiologic anotomy of the prostate: a clinical approach. Radiol Clin North
Am, 38:15–30, 2000.
[69] M. R. Engelbrecht, H. J. Huisman, R. J. F. Laheij, G. J. Jager, G. J. L. H. van Leenders, C. A. Hulsbergen-
van de Kaa, J. J. M. C. H. de la Rosette, J. G. Blickman, and J. O. Barentsz. Discrimination of prostate
cancer from normal peripheral zone and central gland tissue by using dynamic contrast-enhanced MR
imaging. Radiology, 229:248–254, 2003.
[70] R. Bammer. Basic principles of diffusion-weighted imaging. Eur J Radiol, 45:169–184, 2003.
[71] T. W. J. Scheenen, D. W. J. Klomp, S. A. Röll, J. J. Fütterer, J. O. Barentsz, and A. Heerschap. Fast
acquisition-weighted three-dimensional proton MR spectroscopic imaging of the human prostate. Magn
Reson Med, 52:80–88, 2004.
[72] A. Sciarra, J. Barentsz, A. Bjartell, J. Eastham, H. Hricak, V. Panebianco, and J. A. Witjes. Advances in
magnetic resonance imaging: How they are changing the management of prostate cancer. Eur Urol, 59:
962–977, 2011.
[73] J. J. Fütterer, S. W. T. P. J. Heijmink, T. W. J. Scheenen, J. Veltman, H. J. Huisman, P. Vos, C. A. Hulsbergen-
van de Kaa, J. A. Witjes, P. F. M. Krabbe, A. Heerschap, and J. O. Barentsz. Prostate cancer localization
with dynamic contrast-enhanced MR imaging and proton MR spectroscopic imaging. Radiology, 241:
449–458, 2006.
[74] N. B. Delongchamps, M. Rouanne, T. Flam, F. Beuvon, M. Liberatore, M. Zerbib, and F. Cornud. Multi-
parametric magnetic resonance imaging for the detection and localization of prostate cancer: combination
of T2-weighted, dynamic contrast-enhanced and diffusion-weighted imaging. BJU Int, 107:1411–1418,
2011.
[75] K. Kitajima, Y. Kaji, Y. Fukabori, K. Yoshida, N. Suganuma, and K. Sugimura. Prostate cancer detection
with 3 T MRI: Comparison of diffusion-weighted imaging and dynamic contrast-enhanced MRI in
combination with T2-weighted imaging. J Magn Reson Imaging, 31:625–631, 2010.
[76] A. Tanimoto, J. Nakashima, H. Kohno, H. Shinmoto, and S. Kuribayashi. Prostate cancer screening: The
clinical value of diffusion-weighted imaging and dynamic MR imaging in combination with T2-weighted
imaging. J Magn Reson Imaging, 25:146–152, 2007.
[77] N. M. deSouza, S. F. Riches, N. J. Vanas, V. A. Morgan, S. A. Ashley, C. Fisher, G. S. Payne, and C. Parker.
Diffusion-weighted magnetic resonance imaging: a potential non-invasive marker of tumour aggressive-
ness in localized prostate cancer. Clin Radiol, 63:774–782, 2008.
[78] T. Hambrock, D. M. Somford, H. J. Huisman, I. M. van Oort, J. A. Witjes, C. A. Hulsbergen-van de Kaa,
T. Scheenen, and J. O. Barentsz. Relationship between apparent diffusion coefficients at 3.0-T MR imaging
and Gleason grade in peripheral zone prostate cancer. Radiology, 259:453–461, 2011.
[79] Y. Itou, K. Nakanishi, Y. Narumi, Y. Nishizawa, and H. Tsukuma. Clinical utility of apparent diffusion
coefficient (ADC) values in patients with prostate cancer: can ADC values contribute to assess the
aggressiveness of prostate cancer? J Magn Reson Imaging, 33:167–172, 2011.
118 Bibliography
[80] S. Verma, A. Rajesh, H. Morales, L. Lemen, G. Bills, M. Delworth, K. Gaitonde, J. Ying, R. Samartunga, and
M. Lamba. Assessment of aggressiveness of prostate cancer: correlation of apparent diffusion coefficient
with histologic grade after radical prostatectomy. AJR Am J Roentgenol, 196:374–381, 2011.
[81] H. K. Lim, J. K. Kim, K. A. Kim, and K.-S. Cho. Prostate cancer: apparent diffusion coefficient map with
T2-weighted images for detection – a multireader study. Radiology, 250:145–151, 2009.
[82] J. J. Fütterer, M. R. Engelbrecht, H. J. Huisman, G. J. Jager, C. A. Hulsbergen-van de Kaa, J. A. Witjes, and
J. O. Barentsz. Staging prostate cancer with dynamic contrast-enhanced endorectal MR imaging prior to
radical prostatectomy: experienced versus less experienced readers. Radiology, 237:541–549, 2005.
[83] L. Dickinson, H. U. Ahmed, C. Allen, J. O. Barentsz, B. Carey, J. J. Fütterer, S. W. Heijmink, P. J. Hoskin,
A. Kirkham, A. R. Padhani, R. Persad, P. Puech, S. Punwani, A. S. Sohaib, B. Tombal, A. Villers, J. van der
Meulen, and M. Emberton. Magnetic resonance imaging for the detection, localisation, and characteri-
sation of prostate cancer: recommendations from a European consensus meeting. Eur Urol, 59:477–494,
2011.
[84] G. J. Kelloff, P. Choyke, D. S. Coffey, and P. C. I. W. G. . Challenges in clinical prostate cancer: role of
imaging. AJR Am J Roentgenol, 192:1455–1470, 2009.
[85] J. O. Barentsz, J. Richenberg, R. Clements, P. Choyke, S. Verma, G. Villeirs, O. Rouvière, V. Logager, J. J.
Fütterer, and European Society of Urogenital Radiology. ESUR prostate MR guidelines 2012. Eur Radiol,
22:746–757, 2012.
[86] J. G. R. Bomers and J. O. Barentsz. Standardization of multiparametric prostate MR imaging using
PI-RADS. Biomed Res Int, 2014:431680, 2014.
[87] L. M. Johnson, B. Turkbey, W. D. Figg, and P. L. Choyke. Multiparametric MRI in prostate cancer
management. Nat Rev Clin Oncol, 11:346–353, 2014.
[88] M. C. Roethke, T. H. Kuru, S. Schultze, D. Tichy, A. Kopp-Schneider, M. Fenchel, H.-P. Schlemmer, and
B. A. Hadaschik. Evaluation of the ESUR PI-RADS scoring system for multiparametric MRI of the prostate
with targeted MR/TRUS fusion-guided biopsy at 3.0 Tesla. Eur Radiol, 24:344–352, 2014.
[89] A. B. Rosenkrantz, S. Kim, R. P. Lim, N. Hindman, F.-M. Deng, J. S. Babb, and S. S. Taneja. Prostate cancer
localization using multiparametric MR imaging: comparison of Prostate Imaging Reporting and Data
System (PI-RADS) and Likert scales. Radiology, 269:482–492, 2013.
[90] D. Portalez, P. Mozer, F. Cornud, R. Renard-Penna, V. Misrai, M. Thoulouzan, and B. Malavaud. Valida-
tion of the European Society of Urogenital Radiology scoring system for prostate cancer diagnosis on
multiparametric magnetic resonance imaging in a cohort of repeat biopsy patients. Eur Urol, 62:986–996,
2012.
[91] L. Schimmöller, M. Quentin, C. Arsov, R. S. Lanzman, A. Hiester, R. Rabenalt, G. Antoch, P. Albers,
and D. Blondin. Inter-reader agreement of the ESUR score for prostate MRI using in-bore MRI-guided
biopsies as the reference standard. Eur Radiol, 23:3185–3190, 2013.
[92] S. D. Herman, A. C. Friedman, P. D. Radecki, and D. F. Caroline. Incidental prostatic carcinoma detected
by MRI and diagnosed by MRI/CT-guided biopsy. AJR Am J Roentgenol, 146:351–352, 1986.
[93] J. Haffner, L. Lemaitre, P. Puech, G.-P. Haber, X. Leroy, J. S. Jones, and A. Villers. Role of magnetic resonance
imaging before initial biopsy: comparison of magnetic resonance imaging-targeted and systematic biopsy
for significant prostate cancer detection. BJU Int, 108:E171–E178, 2011.
[94] T. Hambrock, D. M. Somford, C. Hoeks, S. A. W. Bouwense, H. Huisman, D. Yakar, I. M. van Oort, J. A.
Witjes, J. J. Fütterer, and J. O. Barentsz. Magnetic resonance imaging guided prostate biopsy in men with
repeat negative biopsies and increased prostate specific antigen. J Urol, 183:520–527, 2010.
Bibliography 119
[95] C. M. A. Hoeks, M. G. Schouten, J. G. R. Bomers, S. P. Hoogendoorn, C. A. Hulsbergen-van de Kaa,
T. Hambrock, H. Vergunst, J. P. M. Sedelaar, J. J. Fütterer, and J. O. Barentsz. Three-Tesla magnetic
resonance-guided prostate biopsy in men with increased prostate-specific antigen and repeated, negative,
random, systematic, transrectal ultrasound biopsies: Detection of clinically significant prostate cancers.
Eur Urol, 62:902–909, 2012.
[96] S. H. Lee, M. S. Chung, J. H. Kim, Y. T. Oh, K. H. Rha, and B. H. Chung. Magnetic resonance imaging
targeted biopsy in men with previously negative prostate biopsy results. J Endourol, 26:787–791, 2012.
[97] Y. Watanabe, A. Terai, T. Araki, M. Nagayama, A. Okumura, Y. Amoh, T. Ishimori, M. Ishibashi,
S. Nakashita, and Y. Dodo. Detection and localization of prostate cancer with the targeted biopsy
strategy based on ADC map: A prospective large-scale cohort study. J Magn Reson Imaging, 35:1414–1421,
2012.
[98] T. Hambrock, C. Hoeks, C. Hulsbergen-van de Kaa, T. Scheenen, J. Fütterer, S. Bouwense, I. van Oort,
F. Schröder, H. Huisman, and J. Barentsz. Prospective assessment of prostate cancer aggressiveness
using 3-T diffusion-weighted magnetic resonance imaging-guided biopsies versus a systematic 10-core
transrectal ultrasound prostate biopsy cohort. Eur Urol, 61:177–184, 2012.
[99] D. Beyersdorff, A. Winkel, B. Hamm, S. Lenk, S. A. Loening, and M. Taupitz. MR imaging-guided prostate
biopsy with a closed MR unit at 1.5 T: initial results. Radiology, 234:576–581, 2005.
[100] K. Engelhard, H. P. Hollenbach, B. Kiefer, A. Winkel, K. Goeb, and D. Engehausen. Prostate biopsy in the
supine position in a standard 1.5-T scanner under real time MR-imaging control using a MR-compatible
endorectal biopsy device. Eur Radiol, 16:1237–1243, 2006.
[101] T. Franiel, C. Stephan, A. Erbersdobler, E. Dietz, A. Maxeiner, N. Hell, A. Huppertz, K. Miller, R. Strecker,
and B. Hamm. Areas suspicious for prostate cancer: MR-guided biopsy in patients with at least one
transrectal US-guided biopsy with a negative finding – multiparametric MR imaging for detection and
biopsy planning. Radiology, 259:162–172, 2011.
[102] M. Roethke, A. G. Anastasiadis, M. Lichy, M. Werner, P. Wagner, S. Kruck, C. D. Claussen, A. Stenzl, H. P.
Schlemmer, and D. Schilling. MRI-guided prostate biopsy detects clinically significant cancer: analysis of
a cohort of 100 patients after previous negative TRUS biopsy. World J Urol, 30:213–218, 2012.
[103] N. Arumainayagam, H. U. Ahmed, C. M. Moore, A. Freeman, C. Allen, S. A. Sohaib, A. Kirkham,
J. van der Meulen, and M. Emberton. Multiparametric MR imaging for detection of clinically significant
prostate cancer: A validation cohort study with transperineal template prostate mapping as the reference
standard. Radiology, 268:761–769, 2013.
[104] M. R. Pokorny, M. de Rooij, E. Duncan, F. H. Schröder, R. Parkinson, J. O. Barentsz, and L. C. Thompson.
Prospective study of diagnostic accuracy comparing prostate cancer detection by transrectal ultrasound-
guided biopsy versus magnetic resonance (MR) imaging with subsequent MR-guided biopsy in men
without previous prostate biopsies. Eur Urol, 66:22–29, 2014.
[105] M. de Rooij, S. Crienen, J. A. Witjes, J. O. Barentsz, M. M. Rovers, and J. P. Grutters. Cost-effectiveness
of magnetic resonance (MR) imaging and MR-guided targeted biopsy versus systematic transrectal
ultrasound-guided biopsy in diagnosing prostate cancer: A modelling study from a health care perspec-
tive. Eur Urol, 66:430–436, 2014.
[106] T. Penzkofer and C. M. Tempany-Afdhal. Prostate cancer detection and diagnosis: the role of MR and its
comparison with other diagnostic modalities – a radiologist’s perspective. NMR Biomed, 27:3–15, 2014.
[107] I. Kaplan, N. E. Oldenburg, P. Meskell, M. Blake, P. Church, and E. J. Holupka. Real time MRI-ultrasound
image guided stereotactic prostate biopsy. Magn Reson Imaging, 20:295–299, 2002.
120 Bibliography
[108] F. Cornud, L. Brolis, N. B. Delongchamps, D. Portalez, B. Malavaud, R. Renard-Penna, and P. Mozer.
TRUS-MRI image registration: a paradigm shift in the diagnosis of significant prostate cancer. Abdom
Imaging, 38:1447–1463, 2013.
[109] J. K. Logan, S. Rais-Bahrami, B. Turkbey, A. Gomella, H. Amalou, P. L. Choyke, B. J. Wood, and P. A. Pinto.
Current status of magnetic resonance imaging (MRI) and ultrasonography fusion software platforms for
guidance of prostate biopsies. BJU Int, 114:641–652, 2014.
[110] C. M. Moore, N. L. Robertson, N. Arsanious, T. Middleton, A. Villers, L. Klotz, S. S. Taneja, and M. Em-
berton. Image-guided prostate biopsy using magnetic resonance imaging-derived targets: a systematic
review. Eur Urol, 63:125–140, 2013.
[111] P. Puech, O. Rouvière, R. Renard-Penna, A. Villers, P. Devos, M. Colombel, M.-O. Bitker, X. Leroy, F. Mège-
Lechevallier, E. Comperat, A. Ouzzane, and L. Lemaitre. Prostate cancer diagnosis: Multiparametric
MR-targeted biopsy with cognitive and transrectal US-MR fusion guidance versus systematic biopsy–
prospective multicenter study. Radiology, 268:461–469, 2013.
[112] N. B. Delongchamps, M. Peyromaure, A. Schull, F. Beuvon, N. Bouazza, T. Flam, M. Zerbib, N. Muradyan,
P. Legman, and F. Cornud. Prebiopsy magnetic resonance imaging and prostate cancer detection:
Comparison of random and targeted biopsies. J Urol, 189:493–499, 2013.
[113] S. Xu, J. Kruecker, B. Turkbey, N. Glossop, A. K. Singh, P. Choyke, P. Pinto, and B. J. Wood. Real-time
MRI-TRUS fusion for guidance of targeted prostate biopsies. Comput Aided Surg, 13:255–264, 2008.
[114] T. E. Byrne. A review of prostate motion with considerations for the treatment of prostate cancer. Med
Dosim, 30:155–161, 2005.
[115] O. Ukimura, N. Hirahara, A. Fujihara, T. Yamada, T. Iwata, K. Kamoi, K. Okihara, H. Ito, T. Nishimura,
and T. Miki. Technique for a hybrid system of real-time transrectal ultrasound with preoperative magnetic
resonance imaging in the guidance of targeted prostate biopsy. Int J Urol, 17:890–893, 2010.
[116] A. K. Singh, J. Kruecker, S. Xu, N. Glossop, P. Guion, K. Ullman, P. L. Choyke, and B. J. Wood. Initial
clinical experience with real-time transrectal ultrasonography-magnetic resonance imaging fusion-guided
prostate biopsy. BJU Int, 101:841–845, 2008.
[117] R. Narayanan, J. Kurhanewicz, K. Shinohara, E. D. Crawford, A. Simoneau, and J. S. Suri. MRI-ultrasound
registration for targeted prostate biopsy. In IEEE Int Symp Biomedical Imaging, pages 991–994, 2009.
[118] J. Mitra, Z. Kato, R. Martí, A. Oliver, X. Lladó, D. Sidibé, S. Ghose, J. C. Vilanova, J. Comet, and
F. Meriaudeau. A spline-based non-linear diffeomorphism for multimodal prostate registration. Med
Image Anal, 16:1259–1279, 2012.
[119] S. Martin, M. Baumann, V. Daanen, and J. Troccaz. MR prior based automatic segmentation of the prostate
in TRUS images for MR/TRUS data fusion. In IEEE Int Symp Biomedical Imaging, pages 640–643, 2010.
[120] A. Fedorov, K. Tuncali, F. M. Fennessy, J. Tokuda, N. Hata, W. M. Wells, R. Kikinis, and C. M. Tempany.
Image registration for targeted MRI-guided transperineal prostate biopsy. J Magn Reson Imaging, 36:
987–992, 2012.
[121] V. V. Karnik, A. Fenster, J. Bax, D. W. Cool, L. Gardi, I. Gyacskov, C. Romagnoli, and A. D. Ward.
Assessment of image registration accuracy in three-dimensional transrectal ultrasound guided prostate
biopsy. Med Phys, 37:802–813, 2010.
[122] Y. Hu, T. Carter, H. Ahmed, M. Emberton, C. Allen, D. Hawkes, and D. Barratt. Modelling prostate
motion for data fusion during image-guided interventions. IEEE Trans Med Imaging, 30:1887–1900, 2011.
Bibliography 121
[123] R. Alterovitz, K. Goldberg, J. Pouliot, I.-C. J. Hsu, Y. Kim, S. M. Noworolski, and J. Kurhanewicz.
Registration of MR prostate images with biomechanical modeling and nonlinear parameter estimation.
Med Phys, 33:446–454, 2006.
[124] A. Bharatha, M. Hirose, N. Hata, S. K. Warfield, M. Ferrant, K. H. Zou, E. Suarez-Santana, J. Ruiz-Alzola,
A. D’Amico, R. A. Cormack, R. Kikinis, F. A. Jolesz, and C. M. Tempany. Evaluation of three-dimensional
finite element-based deformable registration of pre- and intraoperative prostate imaging. Med Phys, 28:
2551–2560, 2001.
[125] Y. Hu, H. U. Ahmed, Z. Taylor, C. Allen, M. Emberton, D. Hawkes, and D. Barratt. MR to ultrasound
registration for image-guided prostate interventions. Med Image Anal, 16:687–703, 2012.
[126] B. A. Hadaschik, T. H. Kuru, C. Tulea, P. Rieker, I. V. Popeneciu, T. Simpfendörfer, J. Huber, P. Zogal,
D. Teber, S. Pahernik, M. Roethke, P. Zamecnik, W. Roth, G. Sakas, H.-P. Schlemmer, and M. Hohenfellner.
A novel stereotactic prostate biopsy system integrating pre-interventional magnetic resonance imaging
and live ultrasound fusion. J Urol, 186:2214–2220, 2011.
[127] T. Miyagawa, S. Ishikawa, T. Kimura, T. Suetomi, M. Tsutsumi, T. Irie, M. Kondoh, and T. Mitake.
Real-time virtual sonography for navigation during targeted prostate biopsy using magnetic resonance
imaging data. Int J Urol, 17:855–860, 2010.
[128] M. M. Siddiqui, S. Rais-Bahrami, H. Truong, L. Stamatakis, S. Vourganti, J. Nix, A. N. Hoang, A. Walton-
Diaz, B. Shuch, M. Weintraub, J. Kruecker, H. Amalou, B. Turkbey, M. J. Merino, P. L. Choyke, B. J. Wood,
and P. A. Pinto. Magnetic resonance imaging/ultrasound-fusion biopsy significantly upgrades prostate
cancer versus systematic 12-core transrectal ultrasound biopsy. Eur Urol, 64:713–719, 2013.
[129] G. A. Sonn, E. Chang, S. Natarajan, D. J. Margolis, M. Macairan, P. Lieu, J. Huang, F. J. Dorey, R. E. Reiter,
and L. S. Marks. Value of targeted prostate biopsy using magnetic resonance-ultrasound fusion in men
with prior negative biopsy and elevated prostate-specific antigen. Eur Urol, 65:809–815, 2013.
[130] W. J. M. van de Ven, C. A. Hulsbergen-van de Kaa, T. Hambrock, J. O. Barentsz, and H. J. Huisman.
Simulated required accuracy of image registration tools for targeting high-grade cancer components with
prostate biopsies. Eur Radiol, 23:1401–1407, 2013.
[131] A. Jemal, F. Bray, M. M. Center, J. Ferlay, E. Ward, and D. Forman. Global cancer statistics. CA Cancer J
Clin, 61:69–90, 2011.
[132] M. Aihara, T. M. Wheeler, M. Ohori, and P. T. Scardino. Heterogeneity of prostate cancer in radical
prostatectomy specimens. Urology, 43:60–67, 1994.
[133] E. T. Ruijter, C. A. van de Kaa, J. A. Schalken, F. M. Debruyne, and D. J. Ruiter. Histological grade
heterogeneity in multifocal prostate cancer. Biological and clinical implications. J Pathol, 180:295–299,
1996.
[134] S. Kadoury, P. Yan, S. Xu, N. Glossop, P. Choyke, B. Turkbey, P. Pinto, B. Wood, and J. Kruecker. Realtime
TRUS/MRI fusion targeted-biopsy for prostate cancer: A clinical demonstration of increased positive
biopsy rates. In Prostate Cancer Imaging. Computer-Aided Diagnosis, Prognosis, and Intervention, volume
6367 of Lect Notes Comput Sci, pages 52–62, 2010.
[135] H. Huisman and P. Vos. MRCAD for daily clinical analysis of prostate MR. Kitware Source, 13:14–15, 2010.
[136] J. I. Epstein. An update of the Gleason grading system. J Urol, 183:433–440, 2010.
[137] J. H. Kim, J. K. Kim, B. W. Park, N. Kim, and K. S. Cho. Apparent diffusion coefficient: prostate cancer
versus noncancerous tissue according to anatomical region. J Magn Reson Imaging, 28:1173–1179, 2008.
122 Bibliography
[138] T. Tamada, T. Sone, Y. Jo, S. Toshimitsu, T. Yamashita, A. Yamamoto, D. Tanimoto, and K. Ito. Apparent
diffusion coefficient values in peripheral and transition zones of the prostate: comparison between normal
and malignant prostatic tissues and correlation with histologic grade. J Magn Reson Imaging, 28:720–726,
2008.
[139] A. Oto, A. Kayhan, Y. Jiang, M. Tretiakova, C. Yang, T. Antic, F. Dahi, A. L. Shalhav, G. Karczmar, and
W. M. Stadler. Prostate cancer: differentiation of central gland cancer from benign prostatic hyperplasia
by using diffusion-weighted and dynamic contrast-enhanced MR imaging. Radiology, 257:715–723, 2010.
[140] C. Sato, S. Naganawa, T. Nakamura, H. Kumada, S. Miura, O. Takizawa, and T. Ishigaki. Differentiation
of noncancerous tissue and cancer lesions by apparent diffusion coefficient values in transition and
peripheral zones of the prostate. J Magn Reson Imaging, 21:258–262, 2005.
[141] X. Chai, M. van Herk, J. B. van de Kamer, M. C. C. M. Hulshof, P. Remeijer, H. T. Lotz, and A. Bel. Finite
element based bladder modeling for image-guided radiotherapy of bladder cancer. Med Phys, 38:142–150,
2011.
[142] Z. A. Taylor, M. Cheng, and S. Ourselin. High-speed nonlinear finite element analysis for surgical
simulation using graphics processing units. IEEE Trans Med Imaging, 27:650–663, 2008.
[143] M. M. Center, A. Jemal, J. Lortet-Tieulent, E. Ward, J. Ferlay, O. Brawley, and F. Bray. International
variation in prostate cancer incidence and mortality rates. Eur Urol, 61:1079–1092, 2012.
[144] R. Siegel, D. Naishadham, and A. Jemal. Cancer statistics, 2012. CA Cancer J Clin, 62:10–29, 2012.
[145] J.-L. Campos-Fernandes, L. Bastien, N. Nicolaiew, G. Robert, S. Terry, F. Vacherot, L. Salomon, Y. Allory,
D. Vordos, A. Hoznek, R. Yiou, J. J. Patard, C. C. Abbou, and A. de la Taille. Prostate cancer detection rate
in patients with repeated extended 21-sample needle biopsy. Eur Urol, 55:600–606, 2009.
[146] W. J. M. van de Ven, Y. Hu, J. O. Barentsz, N. Karssemeijer, D. Barratt, and H. J. Huisman. Surface-based
prostate registration with biomechanical regularization. In Medical Imaging, volume 8671 of Proceedings of
the SPIE, page 86711R, 2013.
[147] F. Ritter, T. Boskamp, A. Homeyer, H. Laue, M. Schwier, F. Link, and H.-O. Peitgen. Medical image
analysis: A visual approach. IEEE Pulse, 2:60–70, 2011.
[148] H. Si. Tetgen - a qualitiy tetrahedral mesh generator and three-dimensional Delaunay triangulator, 2006. URL
http://tetgen.berlios.de.
[149] F. Heckel, O. Konrad, H. Karl Hahn, and H.-O. Peitgen. Interactive 3D medical image segmentation with
energy-minimizing implicit functions. Comput Graph, 35:275–287, 2011.
[150] I. T. Young and L. J. van Vliet. Recursive implementation of the Gaussian filter. Signal Processing, 44:139 –
151, 1995.
[151] T. Boehler, D. van Straaten, S. Wirtz, and H.-O. Peitgen. A robust and extendible framework for medical
image registration focused on rapid clinical application deployment. Comput Biol Med, 41:340–349, 2011.
[152] J. R. Shewchuk. Tetrahedral mesh generation by Delaunay refinement. In Proceedings of the SCG, pages
86–95, 1998.
[153] G. L. Miller, D. Talmor, S.-H. Teng, and N. Walkington. A Delaunay based numerical method for three
dimensions: generation, formulation, and partition. In Proceedings of the STOC, pages 683–692, 1995.
[154] Z. A. Taylor, O. Comas, M. Cheng, J. Passenger, D. J. Hawkes, D. Atkinson, and S. Ourselin. On modelling
of anisotropic viscoelasticity for soft tissue simulation: numerical solution and GPU execution. Med Image
Anal, 13:234–244, 2009.
Bibliography 123
[155] R Development Core Team. R: A Language and Environment for Statistical Computing. R Foundation for
Statistical Computing, Vienna, Austria, 2011. URL http://www.R-project.org/.
[156] J. Pinheiro, D. Bates, S. DebRoy, D. Sarkar, and R Development Core Team. nlme: Linear and Nonlinear
Mixed Effects Models, 2011. R package version 3.1-101.
[157] W. J. M. van de Ven and J. O. Barentsz. Prostate cancer: MRI/US-guided biopsy – a viable alternative to
TRUS-guidance. Nat Rev Urol, 10:559–560, 2013.
[158] S. Klein, U. A. van der Heide, I. M. Lips, M. van Vulpen, M. Staring, and J. P. W. Pluim. Automatic
segmentation of the prostate in 3D MR images by atlas matching using localized mutual information.
Med Phys, 35:1407–1417, 2008.
[159] S. Ghose, A. Oliver, R. Martí, X. Lladó, J. C. Vilanova, J. Freixenet, J. Mitra, D. Sidibé, and F. Meriaudeau.
A survey of prostate segmentation methodologies in ultrasound, magnetic resonance and computed
tomography images. Comput Methods Programs Biomed, 108:262–287, 2012.
[160] G. Litjens, R. Toth, W. van de Ven, C. Hoeks, S. Kerkstra, B. van Ginneken, G. Vincent, G. Guillard,
N. Birbeck, J. Zhang, R. Strand, F. Malmberg, Y. Ou, C. Davatzikos, M. Kirschner, F. Jung, J. Yuan, W. Qiu,
Q. Gao, P. E. Edwards, B. Maan, F. van der Heijden, S. Ghose, J. Mitra, J. Dowling, D. Barratt, H. Huisman,
and A. Madabhushi. Evaluation of prostate segmentation algorithms for MRI: The PROMISE12 challenge.
Med Image Anal, 18:359–373, 2014.
[161] Y. Chi, J. Liang, and D. Yan. A material sensitivity study on the accuracy of deformable organ registration
using linear biomechanical models. Med Phys, 33:421–433, 2006.
[162] Y. Kim, B. Ahn, J. W. Lee, K. H. Rha, and J. Kim. Local property characterization of prostate glands
using inhomogeneous modeling based on tumor volume and location analysis. Med Biol Eng Comput, 51:
197–205, 2013.
[163] J. Chappelow, B. N. Bloch, N. Rofsky, E. Genega, R. Lenkinski, W. DeWolf, and A. Madabhushi. Elastic
registration of multimodal prostate MRI and histology via multiattribute combined mutual information.
Med Phys, 38:2005–2018, 2011.
[164] E. Gibson, C. Crukley, M. Gaed, J. A. Gómez, M. Moussa, J. L. Chin, G. S. Bauman, A. Fenster, and A. D.
Ward. Registration of prostate histology images to ex vivo MR images via strand-shaped fiducials. J
Magn Reson Imaging, 36:1402–1412, 2012.
[165] A. Walton Diaz, A. N. Hoang, B. Turkbey, C. W. Hong, H. Truong, T. Sterling, S. Rais-Bahrami, M. M.
Siddiqui, L. Stamatakis, S. Vourganti, J. Nix, J. Logan, C. Harris, M. Weintraub, C. Chua, M. J. Merino,
P. Choyke, B. J. Wood, and P. A. Pinto. Can magnetic resonance-ultrasound fusion biopsy improve cancer
detection in enlarged prostates? J Urol, 190:2020–2025, 2013.
[166] P. Mozer, M. Rouprêt, C. Le Cossec, B. Granger, E. Comperat, A. de Gorski, O. Cussenot, and R. Renard-
Penna. First round of targeted biopsies with magnetic resonance imaging/ultrasound-fusion images
compared to conventional ultrasound-guided trans-rectal biopsies for the diagnosis of localised prostate
cancer. BJU Int, 115:50–57, 2015.
[167] N. B. Delongchamps, A. Lefèvre, N. Bouazza, F. Beuvon, P. Legman, and F. Cornud. Detection of
significant prostate cancer with magnetic resonance targeted biopsies – should transrectal ultrasound-
magnetic resonance imaging fusion guided biopsies alone be a standard of care? J Urol, 193:1198–1204,
2015.
[168] O. Ukimura, A. Marien, S. Palmer, A. Villers, M. Aron, A. L. de Castro Abreu, S. Leslie, S. Shoji, T. Matsug-
asumi, M. Gross, P. Dasgupta, and I. S. Gill. Trans-rectal ultrasound visibility of prostate lesions identified
by magnetic resonance imaging increases accuracy of image-fusion targeted biopsies. World J Urol, 33:
1669–1676, 2015.
124 Bibliography
[169] J. C. Weinreb, J. O. Barentsz, P. L. Choyke, F. Curnud, M. A. Haider, K. J. Macura, D. Margolis, M. D.
Schnall, F. Shtern, C. M. Tempany, H. C. Thoeny, and S. Verma. PI-RADS Pirads Imaging – Reporting and
Data System: 2015, Version 2. Eur Urol, 69:16–40, 2016.
[170] J. O. Barentsz, J. C. Weinreb, S. Verma, H. C. Thoeny, C. M. Tempany, F. Shtern, A. R. Padhani, D. Margolis,
K. J. Macura, M. A. Haider, F. Curnud, and P. L. Choyke. Synopsis of the PI-RADS v2 guidelines for
multiparametric prostate magnetic resonance imaging and recommendations for use. Eur Urol, 69:41–49,
2016.
[171] N. E. Fleshner, M. O’Sullivan, C. Premdass, and W. R. Fair. Clinical significance of small (less than 0.2
cm3) hypoechoic lesions in men with normal digital rectal examinations and prostate-specific antigen
levels less than 10 ng/mL. Urology, 53:356–358, 1999.
[172] R. Onur, P. J. Littrup, J. E. Pontes, and F. J. Bianco, Jr. Contemporary impact of transrectal ultrasound
lesions for prostate cancer detection. J Urol, 172:512–514, 2004.
[173] G. Sperandeo, M. Sperandeo, M. Morcaldi, E. Caturelli, L. Dimitri, and A. Camagna. Transrectal
ultrasonography for the early diagnosis of adenocarcinoma of the prostate: a new maneuver designed to
improve the differentiation of malignant and benign lesions. J Urol, 169:607–610, 2003.
[174] B. Ehdaie, E. Vertosick, M. Spaliviero, A. Giallo-Uvino, Y. Taur, M. O’Sullivan, J. Livingston, J. Eastham,
P. Scardino, and K. Touijer. The impact of repeat biopsies on infectious complications in men with prostate
cancer on active surveillance. J Urol, 191:660–664, 2014.
[175] P. R. Martin, D. W. Cool, C. Romagnoli, A. Fenster, and A. D. Ward. Magnetic resonance imaging-targeted,
3D transrectal ultrasound-guided fusion biopsy for prostate cancer: Quantifying the impact of needle
delivery error on diagnosis. Med Phys, 41:073504, 2014.
[176] W. J. M. van de Ven, S. Rinsma, N. Karssemeijer, J. O. Barentsz, and H. J. Huisman. Electro-magnetic
tracker-based fusion for image-guided TRUS prostate biopsy. In European Congress of Radiology, 2014.
[177] W. J. M. van de Ven, J. P. M. Sedelaar, J. J. Fütterer, and H. J. Huisman. Focally targeted magnetic
resonance imaging guided transrectal ultrasound biopsy of the prostate with an ultrasound machine that
has electromagnetic tracking fusion. In Annual Meeting of the Radiological Society of North America, 2014.
Publications

Publications 127
Papers in international journals
W. J. M. van de Ven, W. Venderink, J. P. M. Sedelaar, J. Veltman, J. O. Barentsz, J. J. Fütterer,
E. B. Cornel, and H. J. Huisman. MR targeted TRUS prostate biopsy using local reference
augmentation – initial experience. International Urology and Nephrology, in press.
W. J. M. van de Ven, J. P. M. Sedelaar, M. M. G. van der Leest, C. A. Hulsbergen - van
de Kaa, J. O. Barentsz, J. J. Fütterer, and H. J. Huisman. Visibility of prostate cancer on
transrectal ultrasound during fusion with multiparametric magnetic resonance imaging
for prostate biopsy. Clinical Imaging, 40(4):745–750, 2016.
W. J. M. van de Ven, Y. Hu, J. O. Barentsz, N. Karssemeijer, D. Barratt, and H. J. Huisman.
Biomechanical modeling constrained surface-based image registration for prostate MR
guided TRUS biopsy. Medical Physics, 42(5):2470–2481, 2015.
M. R. Pokorny, W. J. M. van de Ven, J. O. Barentsz, and L. C. Thompson. Reply to Yaalini
Shanmugabavan, Stephanie Guillaumier and Hashim U. Ahmed’s Letter to Editor re:
Morgan R. Pokorny, Maarten de Rooij, Earl Duncan, et al. Prospective study of diagnostic
accuracy comparing prostate cancer detection by transrectal ultrasound-guided biopsy
versus magnetic resonance (MR) imaging with subsequent MR-guided biopsy in men
without previous prostate biopsies. Eur Urol 2014;66:22-9. European Urology, 67(3):e54–e55,
2015.
G. J. S. Litjens, R. Toth, W. J. M. van de Ven, C. M. A. Hoeks, S. Kerkstra, B. van Ginneken,
G. Vincent, G. Guillard, N. Birbeck, J. Zhang, R. Strand, F. Malmberg, Y. Ou, C. Davatzikos,
M. Kirschner, F. Jung, J. Yuan, W. Qiu, Q. Gao, P. E. Edwards, B. Maan, F. van der
Heijden, S. Ghose, J. Mitra, J. A. Dowling, D. Barratt, H. J. Huisman, and A. Madabhushi.
Evaluation of prostate segmentation algorithms for MRI: the PROMISE12 challenge.
Medical Image Analysis, 18(2):359–373, 2014.
W. J. M. van de Ven and J. O. Barentsz. Prostate cancer: MRI/US-guided biopsy – a
viable alternative to TRUS-guidance. Nature Reviews Urology, 10(10):559–560, 2013.
W. J. M. van de Ven, C. A. Hulsbergen - van de Kaa, T. Hambrock, J. O. Barentsz, and
H. J. Huisman. Simulated required accuracy of image registration tools for targeting high-
grade cancer components with prostate biopsies. European Radiology, 23(5):1401–1407,
2013.
D. F. Stegeman, W. J. M. van de Ven, G. A. van Elswijk, R. Oostenveld, and B. U. Kleine.
The α-motoneuron pool as transmitter of rhythmicities in cortical motor drive. Clinical
Neurophysiology, 121(10):1633–1642, 2010.
128 Publications
Papers in conference proceedings
W. J. M. van de Ven, Y. Hu, N. Karssemeijer, J. O. Barentsz, D. Barratt, and H. J. Huisman.
Surface-based prostate registration with biomechanical regularization. In Medical Imaging:
Image-Guided Procedures, Robotic Interventions, and Modeling, volume 8671 of Proceedings
of the SPIE, page 86711R, 2013.
G. J. S. Litjens, O. A. Debats, W. J. M. van de Ven, N. Karssemeijer, and H. J. Huisman. A
pattern recognition approach to zonal segmentation of the prostate on MRI. In Medical
Image Computing and Computer-Assisted Intervention, volume 7511 of Lecture Notes in
Computer Science, pages 413–420, 2012.
W. J. M. van de Ven, G. J. S. Litjens, J. O. Barentsz, T. Hambrock, and H. J. Huisman.
Required accuracy of MR-US registration for prostate biopsies. In MICCAI Workshop:
Prostate Cancer Imaging. Image Analysis and Image-Guided Interventions, volume 6963 of
Lecture Notes in Computer Science, pages 92–99, 2011.
Abstracts in conference proceedings
W. J. M. van de Ven, J. P. M. Sedelaar, J. J. Fütterer, and H. J. Huisman. Focally targeted
magnetic resonance imaging guided transrectal ultrasound biopsy of the prostate with an
ultrasound machine that has electromagnetic tracking fusion. In Annual Meeting of the
Radiological Society of North America, 2014.
W. J.M. van deVen, S. Rinsma, N. Karssemeijer, J. O. Barentsz, and H. J. Huisman. Electro-
magnetic tracker-based fusion for image-guided TRUS prostate biopsy. In European
Congress of Radiology, 2014.
W. J.M. van deVen, N. Karssemeijer, J. O. Barentsz, and H. J. Huisman. Image registration
for prostate MR guided biopsy using automated biomechanical modeling. In Annual
Meeting of the Radiological Society of North America, 2013.
W. J. M. van de Ven, J. -P. van Basten, B. J. de Kruif, P. Dunias, and F. P. Wieringa. In-
vivo breed spectrum diffuse spectrometrie – een verkenning naar verbeteringen voor
onderscheid van de neurovasculaire bundel tijdens robot-prostatectomie (RALP). In
Najaarsvergadering NVU, volume 18, number 6 of Nederlands Tijdschrift voor Urologie,
page 159, 2010.
W. J. M. van de Ven, B. U. Kleine, G. A. van Elswijk, R. Oostenveld, and D. F. Stegeman.
The α-motoneuron pool as transmitter of rhythmicities in cortical motor drive. In XVIII
Congress of the International Society of Electrophysiology and Kinesiology, 2010.
J. P. van Dijk, W. J. M. van de Ven, and D. F. Stegeman. Evaluating the motor unit number
index (MUNIX) as a measure for motor unit loss. In XVIII Congress of the International
Society of Electrophysiology and Kinesiology, 2010.
Publications 129
D. F. Stegeman, G. A. van Elswijk, W. J. M. van de Ven, and B. U. Kleine. The three
frequencies: the α-motoneuron pool as transmitter of rhythmicities in cortico-spinal
motor drive. In International Workshop and Conference on Human Reflexes: Wiring and Firing
of Motoneurons, 2009.

Dankwoord

Dankwoord 133
Als laatste wil ik graag iedereen bedanken die heeft geholpen bij het tot stand brengen
van dit proefschrift. Een aantal van jullie wil ik persoonlijk noemen.
Dr. Huisman, beste Henkjan, als co-promotor ben jij degene geweest die de dagelijkse
begeleiding gedurende mijn promotie op zich heeft genomen. Tijdens onze wekelijkse
besprekingen hebben we vele discussies gehad en probeerde je me weer te prikkelen als
ik even vastzat. Tussen alle ProCAD zaken en subsidie aanvragen had je gelukkig ook
nog tijd om mijn artikelen kritisch te bekijken. Dit zorgde ervoor dat het net weer wat
scherper op papier kwam. We hebben geleerd dat technici en clinici toch echt een andere
blik hebben en dat de klinische artikelen een andere aanpak vereisen. Gelukkig zijn alle
artikelen inmiddels geaccepteerd. Bedankt dat je achter me stond en in mijn promotie
bent blijven geloven.
Prof. Karssemeijer, beste Nico, als promotor was je iets minder betrokken bij de
dagelijkse begeleiding. Toch hebben we regelmatig besproken hoe het met mijn promotie
ging. Jouw kennis en ervaring heeft me zeker verder geholpen, met name bij de technische
verhalen. Jouw kritische blik liet me vaak weer kritisch nadenken over wat ik aan het
doen was. Je bent specialist op het gebied van de mammografie, maar was ook altijd
geïnteresserd in mijn onderzoek. Ook wil ik je ontzettend bedanken voor je hulp en steun
met de laatste loodjes.
Prof. Barentsz, beste Jelle, als tweede promotor heb jij ook een belangrijke rol gespeeld
tijdens mijn promotie. Zonder jouw kennis en ervaring was dit proefschrift niet geweest
zoals het nu is. Als expert op het gebied van de prostaat MRI wil jij altijd het beste voor
de patiënt. Het was niet altijd makkelijk om je te overtuigen van het nut van MR-TRUS
fusie. Ondanks dat je het vaak enorm druk had, nam je de toch de tijd om kritisch naar
met name de klinische context van mijn artikelen te kijken. Je wist er vaak toch weer een
paar details uit te pikken die nog niet helemaal klopte, waardoor het verhaal sterker werd.
Bedankt voor je inbreng.
Beste Dr. Fütterer en Dr. Sedelaar, bedankt voor jullie hulp bij het opzetten van
de klinische studie naar MR-TRUS fusie biopten. Jullie klinische ervaring was hierbij
onmisbaar. Ook waardeer ik jullie snelle reacties op de artikelen waar we samen aan
gewerkt hebben.
Beste Dr. Cornel en Dr. Veltman, jullie hebben ervoor gezorgd dat onze studie naar
MR-TRUS fusie biopten werd uitgebreid naar het ZGT. Op deze manier hebben we er
een multi-center studie van kunnen maken en hebben we de data wat sneller kunnen
verzamelen. Bedankt voor jullie hulp en medewerking.
Wulphert, bedankt dat je mijn paranimf wilt zijn. Daarnaast ook bedankt voor de
samenwerking tijdens de MR-TRUS fusie studie. Zonder jouw hulp was het voor mij
een stuk moeilijker geworden om het laatste artikel van mijn proefschrift af te ronden. Ik
wens je veel succes met de voortzetting van de fusie biopten.
Marloes, Christina en Thomas, als co-auteurs hebben jullie natuurlijk ook een be-
langrijke bijdrage geleverd aan dit proefschrift. Bedankt voor jullie medewerking en
tijd.
134 Dankwoord
Dean Barratt and Yipeng Hu, thank you for your collaboration and giving me the
opportunity to visit UCL in London. Your experience in applying biomechanical modeling
to MR-TRUS fusion helped me getting started. Thanks for your contribution to some of
the papers in this thesis.
I would like to thank Toshiba for providing us with the newest ultrasound equipment.
Special thanks to Dr. Christoph Simm, Tetsuya Yoshida, Richard Stavenuiter, Daniella de
Bok, Fred Bijvoet, and Jan Arkesteijn for all their help and contributions related to the
prostate ultrasound and fusion biopsies.
Geert en Oscar, binnen DIAG waren wij de enige promovendi op het gebied van de
prostaat. We hadden te maken met dezelfde frustaties, maar delen gelukkig ook leuke
dingen en zijn natuurlijk lange tijd kamergenoten geweest. Geert, bedankt dat je mijn
paranimf wilt zijn. Daarnaast wil ik je, samen met Michael, Sven, en Sjoerd, bedanken
voor de hulp met MeVisLab en ProCAD.
Ik wil ook graag alle andere leden van de prostaatwerkgroep bedanken voor de
discussies tijdens onze tweewekelijkse bijeenkomst.
Gisèle, Esther en Siebren, bedankt dat jullie me hebben geholpen met het opnemen
van de prostaat echo’s.
Denise, bedankt voor je hulp met de prostaat echo’s. Ook alle laboranten op de echo
bedankt voor het vrij maken van de juiste echokamer als ik jullie weer eens tijdens een
lunchpauze lastig kwam vallen.
Marijke en Manita, zonder jullie was het inplannen van de wetenschaps-echo’s een
stuk lastiger geweest.
Solange en Leonie, bedankt voor jullie hulp.
Daarnaast wil ik natuurlijk ook alle onderzoekers binnen DIAG bedanken. Het
was een gezellige omgeving waar naast onderzoek ook ruimte was voor sociale en
sportieve activiteiten. Met het DIAG team "Runtime error" hebben we meerdere malen
aan de zevenheuvelenloop meegedaan. Ook de borrels, feestjes en natuurlijk de DIAG
weekenden waren erg gezellig. De vroege vogels onder ons begonnen de dag goed
met een lekkere kop koffie. De volgende namen mogen ook zeker niet ontbreken in dit
dankwoord: Albert, Clarisa, Colin, Geert, Jan, Jan-Jurre, Leticia, Mark, Michiel, Oscar,
Pragnya, Rashindra, Rick, Rieneke, Sarah en Steven, bedankt!
Rick, bedankt voor het ontwerpen van de kaft van mijn proefschrift.
Amy, ik ben blij om jou als zus te hebben. Vorig jaar heb je netjes je master behaald,
iets waarop je heel trots kunt zijn. Inmiddels heb je ook een leuke baan als study director
gevonden. Ik wens jou en Rick een mooie toekomst samen.
Lieve pap en mam, heel erg bedankt voor alles. Jullie hebben mij en Amy altijd
gesteund en de mogelijkheid gegeven om te gaan studeren. Zonder jullie was ik nooit
geweest waar ik nu ben.
Als laatste natuurlijk Bart. De laatste loodjes waren niet altijd even makkelijk, maar
opgeven was geen optie. Het heeft wat langer geduurd dan gepland, maar nu is het
boekje dan toch eindelijk af. Bedankt voor jouw steun en liefde. Ik hou van je!
Curriculum Vitae

Curriculum Vitae 137
Wendy van de Ven was born in Oss, The Netherlands, on June
3th 1987 and grew up in Heesch. She obtained her VWO diploma
(pre-university education) from the Maaslandcollege in Oss in
2005. That same year she started studying Natural Sciences at the
Radboud University in Nijmegen. She obtained her Bachelor of
Science degree in 2008 and continued with the Master Natural
Sciences, with a specialization in Biophysics. During her studies
she performed a major research internship at the department
of Neurology, Clinical Neurophysiology unit of the Radboud
University Medical Center, Nijmegen. The project focussed on
the transmission of cortical motor drive and motor unit loss. She finished her Master with
a minor research internship at TNO Science and Industry, Medical in Eindhoven. There
she worked on in vivo differentiation of the prostate capsule from the neurovascular
bundles by diffuse reflectance spectrometry. In August 2010, she graduated cum laude
and obtained the Master of Science degree.
Wendy started her PhD project at the Diagnostic Image Analysis Group (DIAG) of
the department of Radiology and Nuclear Medicine, Radboud University Medical Center,
Nijmegen in November 2010. Her research was about MR-TRUS fusion for prostate
biopsies. Both technical and clinical requirements have been investigated. Part of the
project was in collaboration with the Centre for Medical Image Computing at University
College London, which she visited during her PhD. The results of her PhD research are
described in this thesis.
From November 2014, Wendy continued working in DIAG as a project leader on an
international multicenter clinical trial regarding MR-TRUS fusion prostate biopsies. The
project was in collaboration with Toshiba Medical Systems. The main objective was to
determine the clinical effectiveness of MR guided TRUS biopsies in comparison with
in-bore MR guided biopsies.
Wendy is employed at ASML in Eindhoven since March 2015. There she is working
as a design engineer on on-product overlay at the Applications department.

